

REFINITIV

DELTA REPORT

10-K

DOMH - DOMINARI HOLDINGS INC.
10-K - DECEMBER 31, 2023 COMPARED TO 10-K - DECEMBER 31, 2022

The following comparison report has been automatically generated

TOTAL DELTAS	3146
CHANGES	177
DELETIONS	1452
ADDITIONS	1517

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
(Mark one)
☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2022 2023
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
Commission file number 000-05576 001-41845
DOMINARI HOLDINGS INC.
(Exact name of Registrant registrant as specified in its Charter)charter

Delaware
(State or other jurisdiction of
incorporation or organization)
One Rockefeller Plaza, 11th Floor, New York, NY 10020
(Address of principal executive offices)

52-0849320
(I.R.S. Employer
Identification No.)
703-992-9325
(Registrant's telephone number, including area code)

725 5th Avenue, 22nd Floor
New York, NY 10022
(Address of principal executive offices)
(212) 393-4540
(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock (\$0.0001 par value per share)	DOMH	The NASDAQ Nasdaq Capital Market

Securities registered pursuant to Section 12(g) of the Act: None.
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒
Indicate by check mark whether the Registrant registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the Registrant registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definition of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer ☒ Smaller reporting company ☒
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒
The aggregate market value of the voting stock held by non-affiliates of the registrant as of the last business day of the registrant's most recently completed second fiscal quarter ended June 30, 2022 June 30, 2023: \$30,913,061 \$12,149,343 based upon the closing sale price of our common stock of \$5.90 \$2.91 on that date. Common stock held by each officer and director and by each person known to own in excess of 5% of outstanding shares of our common stock has been excluded in that such persons may be deemed to be affiliates. The determination of affiliate status in is not necessarily a conclusive determination for other purposes.
There were 4,840,597 5,934,917 shares of the Registrant's registrant's common stock outstanding as of March 20, 2023 March 26, 2024.

REFINITIV CORPORATE DISCLOSURES | www.refinitiv.com | Contact Us

©2024 Refinitiv. All rights reserved. Republication or redistribution of Refinitiv content, including by framing or similar means, is prohibited without the prior written consent of Refinitiv. "Refinitiv" and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.

2/130
REFINITIV

DOMINARI HOLDINGS INC.
(Formerly Alkido Pharma, Inc.)
TABLE OF CONTENTS

	Page
Special Cautionary Notice Regarding Forward Looking Statements	ii
Part I	
Item 1. Business	1
Item 1a. 1A. Risk Factors	6
Item 1b. 1B. Unresolved Staff Comments	17 19
Item 1C. Cybersecurity	20
Item 2. Properties	17 20
Item 3. Legal Proceedings	17 20
Item 4. Mine Safety Disclosures	17
	20
Part II	
Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	18 21
Item 6. [Reserved] [Reserved]	22 19
Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations	19 22
Item 7a. 7A. Quantitative and Qualitative Disclosures about Market Risk	22 26
Item 8. Consolidated Financial Statements and Supplemental Supplementary Data	23
Index to Financial Statements	23 F-1
Part III	
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure	52 27
Item 9A. Controls and Procedures	52 27
Item 9B. Other Information	53 27
Item 9C. Disclosure Regarding Foreign Jurisdictions That Prevents that Prevent Inspections	53 27
Part III	
Item 10. Directors, Executive Officers and Corporate Governance	54 28
Item 11. Executive Compensation	57 32
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholders Stockholder Matters	61 40
Item 13. Certain Relationships and Related Transactions and Director Independence	63 42
Item 14. Principal Accounting Accountant Fees and Services	63
	43
Part IV	
Item 15. Exhibits and Consolidated Financial Statements, Statement Schedules	64 44
Item 16. Form 10-K Summary	67 46
Signatures	68 47

PART I

EXPLANATORY NOTE

SPECIAL CAUTIONARY NOTICE REGARDING FORWARD LOOKING STATEMENTS

This Annual Report on Form 10-K contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward looking statements are often identified by the words “will,” “may,” “believes,” “estimates,” “expects,” “intends,” “plans,” “projects” and words of similar import. Such words and expressions are intended to identify such forward-looking statements, but are not intended to constitute the exclusive means of identifying such statements. Such forward looking statements involve known and unknown risks, uncertainties and other factors, including those described in “Risk Factors” below that may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements. Given these uncertainties, prospective investors are cautioned not to place undue reliance on such forward-looking statements.

All references in this Annual Report on Form 10-K (“Annual Report”) to “we,” “us,” “our” and the “Company” refer to Dominari Holdings Inc., a Delaware corporation, and its consolidated subsidiaries unless the context requires otherwise.

SPECIAL CAUTIONARY NOTICE REGARDING FORWARD LOOKING STATEMENTS AND RISK FACTOR SUMMARY

This Annual Report contains statements that the Company believes are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements relating to expectations for future financial performance, business strategies or expectations for the Company’s business. These statements are based on the beliefs and assumptions of the management of the Company. Although the Company believes that its plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, it cannot provide assurance that it will achieve or realize these plans, intentions or expectations. These statements constitute projections, forecasts and forward-looking statements, and are not guarantees of performance. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. When used in this in this Annual Report, words such as “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “seek,” “should,” “strive,” “target,” “will,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. You should not place undue reliance on these forward-looking statements. Should one or more of a number of known and unknown risks and uncertainties materialize, or should any of our assumptions prove incorrect, the Company’s actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ are described in greater detail in Item 1A of Part I, “Risk Factors.”

PART I

Item 1. BUSINESS. BUSINESS

OVERVIEW Overview

Dominari Holdings Inc. ("Dominari") is a holding company that, through its various subsidiaries, is engaged in financial services, investment advising and wealth management, asset management, investment banking, the acquisition of interests in high growth industries, sales and biotechnology trading and pharmaceutical research and development, asset management. In addition to capital investment, Dominari provides management support to the executive teams of its subsidiaries, helping them to operate efficiently and reduce cost under a streamlined infrastructure. Dominari and its subsidiaries are collectively referred to herein as "Company", "we", "Company," "we," "our" or "us", "us."

Dominari Financial Inc. ("Dominari Financial"), our a wholly-owned financial subsidiary is the M&A arm of Dominari and will execute Holdings Inc., executes the Company's roll-up growth strategy in the financial sector. The roll-up strategy services industry. In addition to organic growth, Dominari Financial seeks to acquire partnership opportunities and acquisitions of third-party financial assets such as registered investment advisors and businesses, broker dealers, asset management and fintech firms, and fintech firms, insurance brokers. Our first transaction in furtherance of our growth in the financial roll-up strategy, services industry, the acquisition of 100% of a registered broker-dealer dually-registered broker dealer and investment advisor from Fieldpoint Private Bank & Trust ("Fieldpoint"), was consummated on March 27, 2023. The newly acquired dually registered broker-dealer and investment adviser will be was renamed Dominari Securities LLC ("Dominari Securities") and is a wholly-owned subsidiary of Dominari Financial. Dominari Securities will provide wealth management services, asset management services, investment banking and sales and trading.

The Company is in the process of winding down its historical pipeline of biotechnology assets held by Aikido Labs, LLC. These biotechnology assets consist of patented technology from leading universities and researchers, including prospective treatments for pancreatic cancer, acute myeloid leukemia, SARS-CoV-2 and acute lymphoblastic leukemia. The Company is also developing a broad-spectrum antiviral platform, in which the lead compounds have activity in cell-based assays against multiple viruses including Influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2, the cause of COVID-19.

HISTORY History

The Company was founded in 1967 as Spherix Incorporated. In 2017, the Company changed its name to Aikido Alkido Pharma Inc. From 2017 to 2022, the Company operated as a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics in development. During the second half of 2022, in an effort to enhance shareholder stockholder value, the Company shifted its primary focus away from biotechnology to a new line of business in the financial services industry. In furtherance of this new focus, in June of 2022, the Company formed Dominari Financial Inc., with the purpose of making strategic acquisitions across the financial services industry. On December 22, 2022, the Company changed its name to Dominari Holdings Inc.

On September 9, 2022, we entered into a membership interest purchase agreement (the "FPS Purchase Agreement") with Fieldpoint, Private Bank & Trust ("Seller"), a Connecticut bank, for the purchase of its wholly owned subsidiary, Fieldpoint Private Securities, LLC, a Connecticut limited liability company ("FPS") and dually-registered broker-dealer and investment advisor registered with the Financial Industry Regulatory Authority ("FINRA") and the Securities and Exchange Commission ("SEC"). Pursuant to the terms of the FPS Purchase Agreement, we purchased from the Seller Fieldpoint 100% of the membership interests in FPS (the "Membership Interests") and, as a result thereof, will operate the newly acquired dual registered broker-dealer and investment adviser as a wholly owned subsidiary, subsidiary of Dominari Financial Inc. The FPS Purchase Agreement provided for Dominari's acquisition of FPS's Membership Interests in two closings, the first of which occurred on October 4, 2022 (the "Initial Closing"), at which Dominari paid to the Seller Fieldpoint \$2,000,000 in consideration for a transfer by the Seller Fieldpoint to Dominari of 20% of the Membership Interests. Following FINRA's approval of the Continuing Membership Application pursuant to FINRA Rule 1017 (the "Rule 1017 Application") on March 20, 2023, the second closing occurred on March 27, 2023 (the "Second Closing"), at which time Dominari paid to the Seller Fieldpoint an additional \$1.00 \$1.4 million in consideration for a transfer by the Seller Fieldpoint to Dominari of the remaining 80% of the Membership Interests.

Dominari Securities

DOMINARI SECURITIES

Dominari Securities offers, and plans to offer, a broad range of broker-dealer and registered investment adviser services. Those services commencing shortly after the completion of its acquisition of FPS, which is expected to begin in April 2023, including: are discussed below and include wealth management, investment banking, sales and trading, asset management and insurance products.

Wealth Management Services

Dominari Securities plans to provide provides a comprehensive array of financial services to high-net-worth individuals and families, corporate executives, and public and private businesses. Clients will be able to choose a variety of ways to establish a relationship and conduct business, including by establishing brokerage accounts with transaction-based pricing and/or investment advisory accounts with asset-based fee pricing. Dominari Securities also plans to provide provides the following private client services:

Full-Service Brokerage. Dominari Securities plans to offer offers full-service brokerage services covering investment alternatives, including exchange-traded and over-the-counter corporate equity and debt securities, money market instruments, exchange-traded options, municipal bonds, mutual funds, exchange-traded funds, and unit investment trusts. Dominari Securities expects its revenue to be derived from commissions from private clients through accounts with transaction-based pricing. Dominari Securities will charge brokerage commissions on investment products in accordance with a schedule which Dominari Securities plans to formulate. Discounts will be made available to and will be able to be negotiated with customers based on transaction size and volume as well as a number of other factors.

Wealth Planning. Dominari Securities also plans to offer offers financial and wealth planning services, which will include asset management, individual and corporate retirement solutions, insurance and annuity products, IRAs and 401(k) plans, U.S. stock plan services to corporate executives and businesses, education savings programs, and trust and fiduciary services to individual and corporate clients through third-party trust companies.

Margin Lending. Dominari Securities, through its clearing partnerships, also intends to extend extends credit to its customers, collateralized by securities and cash in the customer's account, for a portion of the purchase price, and to receive receives income from interest on such extensions of credit at interest rates derived from Dominari Securities' posted rate as adjusted, from time to time.

Asset Management

Dominari Securities also plans to offer discretionary and non-discretionary fee-based programs to provide tailored investment management solutions and services to high-net-worth private clients, institutions and corporations and/or plans sponsored by them. These will include, but will not be limited to, portfolio management, manager research and due diligence through third party partners, asset allocation advice and financial planning. Dominari Securities plans to offer Portfolio management strategies and third-party investment management capabilities through separately managed accounts, alternative investments and discretionary and non-discretionary portfolio management programs as well as managed portfolios of mutual funds. Platform support functions will include sales and marketing along with administrative services such as trade execution, client services, records management and client reporting and performance monitoring. Dominari Securities expects to generate revenues through the receipt of investment advisory and transactional fees for advisory services and to also generate revenue from fees earned through sharing arrangements with registered and private alternative investment vehicles. Dominari Securities also expects to earn investment advisory fees on all assets held in discretionary and non-discretionary asset-based programs. These fees will be typically billed monthly in advance, and will be calculated based on all fee-based assets under management balances at the end of the prior month. Dominari Securities also expects to receive income from revenue-sharing arrangements that are derived from management and incentive fees on alternative investments and will be calculated on a pre-determined basis with registered and private investment companies. The Company's asset management services are expected to include:

Separately Managed Accounts. The Company plans to provide clients with fee-based programs: (i) a unified managed account which allows multiple investment managers, mutual funds and exchange-traded funds to be combined in a single custodial account; and (ii) an asset review dual contract program designed for clients seeking a direct contractual relationship with investment managers.

Discretionary Advisory Accounts. Dominari Securities plans to offer client-focused discretionary fee-based investment programs managed by Dominari Securities advisors.

Non-Discretionary Advisory Accounts. Dominari plans to provide fee-based non-discretionary investment advisory services and consultation to clients.

Alternative Investments. Dominari plans to offer high net worth and institutional investors the opportunity to participate in a wide range of non-traditional investment strategies. Strategies are expected to include single manager hedge funds, fund of funds, diversified private equity funds and single investment late stage private equity funds.

Private Market Platform. Through a collaborative effort among the firm's business units, Dominari's private market platform will focus on sourcing private investments across various sectors. Transactions are expected to cover the full spectrum of private investments, including early stage, late stage, direct, co-investments, funds and secondary market transactions in debt, equity and hybrid securities.

Investment Banking

Dominari Securities' investment banking division **will provide** provides strategic advisory services and capital markets products to emerging growth and middle market businesses. The investment banking groups **will** focus on the consumer and retail, energy, financial institutions, healthcare, rental services, technology, education, and transportation and logistics sectors. Investment banking services include:

Financial Advisory. Dominari Securities **will advise** advises buyers and sellers on sales, divestitures, mergers, acquisitions, tender offers, privatizations, spin-offs, joint ventures, restructurings and liability management. **Dominari Securities intends to provide dedicated senior bankers to clients focusing throughout the financial advisory process, which combines our structuring and negotiating expertise with our industry knowledge, extensive relationships and capital markets capabilities.**

Equities Capital Markets. Dominari Securities **will provide** provides capital raising solutions for corporate clients through initial public offerings, follow-on offerings, confidentially marketed public offerings, registered directs, private investments in public equity, private placements, at-the-market offerings, and equity-linked offerings.

Debt Capital Markets. Dominari Securities plans to offer debt capital markets solutions for emerging growth and middle market companies. Dominari Securities will focus on structuring and distributing public and private debt through financing transactions, including leveraged buyouts, acquisitions, growth capital financings, recapitalizations and Chapter 11 exit financings. Dominari Securities **will expects to** also participate in high yield debt and fixed and floating-rate senior and subordinated debt **offerings, offerings in the future.**

Fund Placement. Dominari Securities **will expects to** provide alternative investment firms with a broad and deep portfolio of value-added services. Services **will may** include bespoke strategic and tactical advisory as well as primary fundraises, co-investments and direct transactions.

Debt Advisory & Restructuring. Dominari Securities **will expects to** offer creative solutions to leveraged corporate issuers and credit investors. We will evaluate a full range of strategic alternatives, identify the appropriate structure and source of funds to provide our clients the ability to pursue an optimal and value maximizing outcome.

Sales and Trading

We intend to provide Dominari Securities provides a broad range of sales and trading services to our clients. Sales and trading services will include:

Institutional Equity Sales and Trading. Dominari Securities will act as an agent in the execution of its customers' orders through our strategic clearing strategic partners.

Equity Derivatives and Index Options. Dominari Securities will offer listed equity and index options strategies for investors seeking to manage risk and optimize returns within the equities market.

Institutional Fixed Income Sales and Trading. Dominari Securities will trade and offers trading in public and private debt (including sovereign debt) securities, including investment and non-investment grade, distressed and convertible corporate securities as well as municipal securities through our clearing partners.

Securities Lending. In connection with both its trading and brokerage activities, Dominari Securities, through its clearing relationships, will expects to borrow securities to cover short sales and to complete transactions in which customers have failed to deliver securities by the required settlement date and lend securities to other brokers and dealers for similar purposes. Dominari Securities will expects to earn interest on its cash collateral provided and will pay interest on the cash collateral received less a rebate earned for lending securities.

Asset Management

Dominari Securities offers discretionary and non-discretionary fee-based programs to provide tailored investment management solutions and services to high-net-worth private clients, institutions and corporations and/or plans sponsored by them. These include, but are not limited to, portfolio management, manager research and due diligence through third party partners, asset allocation advice and financial planning. Dominari Securities offers portfolio management strategies and third-party investment management capabilities through separately managed accounts, alternative investments and discretionary and non-discretionary portfolio management programs as well as managed portfolios of mutual funds. Platform support functions can include sales and marketing along with administrative services such as trade execution, client services, records management and client reporting and performance monitoring. Dominari Securities generates revenues through the receipt of investment advisory and transactional fees for advisory services and from fees earned through sharing arrangements with registered and private alternative investment vehicles. Dominari Securities also earns investment advisory fees on assets held in discretionary and non-discretionary asset-based programs. These fees are billed monthly in advance and are calculated based on all fee-based assets under management balances at the end of the prior month. Dominari Securities also earns income from revenue-sharing arrangements that are derived from management and incentive fees on alternative investments and calculates these on a pre-determined basis with registered and private investment companies. The Company's asset management services include:

Separately Managed Accounts. Dominari Securities provides clients with fee-based programs: (i) a unified managed account which allows multiple investment managers, mutual funds and exchange-traded funds to be combined in a single custodial account; and (ii) an asset review dual contract program designed for clients seeking a direct contractual relationship with investment managers.

Discretionary Advisory Accounts. Dominari Securities offers client-focused discretionary fee-based investment programs managed by Dominari Securities advisors.

Non-Discretionary Advisory Accounts. Dominari Securities provides fee-based non-discretionary investment advisory services and consultation to clients.

Alternative Investments. Dominari Securities offers high net worth and institutional investors the opportunity to participate in a wide range of non-traditional investment strategies. Strategies include single manager hedge funds, fund of funds, diversified private equity funds and single investment late stage private equity funds.

Private Market Platform. Through a collaborative effort among the Company's business units, Dominari's private market platform focuses on sourcing private investments across various sectors. Transactions are expected to cover the full spectrum of private investments, including early stage, late stage, direct, co-investments, funds and secondary market transactions in debt, equity and hybrid securities.

Regulation

Regulation in the United States

The financial services industry in which we will operate is subject to extensive regulation. In the U.S., the SEC is the federal agency responsible for the administration of federal securities laws. In addition, the Financial Industry Regulatory Authority, Inc. ("FINRA") is a self-regulatory organization ("SRO") that is actively involved in the regulation of securities businesses. In addition to federal regulation, we are subject to state securities regulations in each state and U.S. territory in which we conduct securities or investment advisory activities. The SEC, FINRA, and state securities regulators conduct periodic examinations of broker-dealers and investment advisors. The designated examining authority under the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") for Dominari Securities' activities as a broker-dealer is FINRA. Financial services businesses are also subject to regulation and examination by state securities regulators and attorneys general in those states in which they do business. In addition, broker-dealers and investment advisors must also comply with the rules and regulation of clearing houses, exchanges, and trading platforms of which they are a member.

Broker-dealers are subject to SEC, FINRA, and state securities regulations that cover all aspects of the securities business, including sales and trading methods, trade practices among broker-dealers, use and safekeeping of customers' funds and securities, capital structure and requirements, anti-money laundering efforts, recordkeeping and the conduct of broker-dealer personnel including officers and employees (although state securities regulations are, in a number of cases, more limited). Registered investment advisors are subject to, among other requirements, SEC regulations concerning marketing, transactions with affiliates, custody of client assets, disclosures to clients, conflict of interest, insider trading and recordkeeping. Additional legislation, changes in rules promulgated by the SEC, FINRA, and other SROs of which the broker-dealer is a member, and state securities regulators, or changes in the interpretation or enforcement of existing laws or rules may directly affect the operations and profitability of broker-dealers and investment advisors. The SEC, FINRA, and state securities regulators and state attorneys general may conduct administrative proceedings or initiate civil litigation that can result in adverse consequences for Dominari Securities, its affiliates, including affiliated investment advisors, as well as its and their officers and employees (including, without limitation, injunctions, censures, fines, suspensions, directives that impact business operations (including proposed expansions), membership expulsions, or revocations of licenses and registrations).

SEC Regulation Best Interest ("Reg BI") requires that a broker-dealer and its associated persons act in a retail customer's best interest and not place their own financial or other interests ahead of a retail customer's interests when recommending securities transactions or investment strategies, including recommendations of types of accounts. To meet this best interest standard, a broker-dealer must satisfy four component obligations including a disclosure obligation, a care obligation, a conflict of interest obligation, and a compliance obligation and both broker-dealers and investment advisors are required to provide disclosures about their standard of conduct and conflicts of interest.

In addition, certain states, have proposed or adopted measures that would make broker-dealers, sales agents and investment advisors and their representatives subject to a fiduciary duty when providing products and services to customers. The SEC did not indicate an intent to pre-empt state regulation in this area, and some of the state proposals would allow for a private right of action. In the event our wealth management division makes recommendations to retail customers, it will be required to comply with the obligations imposed under Reg BI and applicable state laws.

Regulatory Capital Requirements

Dominari Securities will be is subject to financial capital requirements that are set by regulation. Dominari Securities is a registered broker-dealer and is required to maintain net capital in an amount equal to SEC minimum financial requirements. As a broker-dealer, Dominari Securities is subject to the SEC's Uniform Net Capital Rule 15c3-1 (the "Net Capital Rule"). Compliance with the Net Capital Rule could limit Dominari Securities' operations, such as underwriting and trading activities and financing customers' prime brokerage or other margin activities, in each case, that could require the use of significant amounts of capital, limit its ability to engage in certain financing transactions, such as repurchase agreements, and may also restrict its ability (i) to make payments of dividends, withdrawals or similar distributions or payments to a stockholder/parent or other affiliate, (ii) to make a redemption or repurchase of shares of stock, or (iii) to make an unsecured loan or advance to such shareholders stockholders or affiliates.

Under the Exchange Act, state securities regulators are not permitted to impose capital, margin, custody, financial responsibility, making and keeping records, bonding, or financial or operational reporting requirements on registered broker-dealers that differ from, or are in addition to, the requirements in those areas established under the Exchange Act, including the rules and regulations promulgated thereunder.

Regulation outside the United States

In the event Dominari Securities provides financial services internationally, it will be subject to extensive regulations proposed, promulgated and enforced by, among other regulatory bodies, the European Commission and European Supervisory Authorities (including the European Banking Authority and European Securities and Market Authority), U.K. Financial Conduct Authority, German Federal Financial Supervisory Authority ("BaFin"), Investment Industry Regulatory Organization of Canada, Hong Kong Securities and Futures Commission, the Japan Financial Services Agency, the Monetary Authority of Singapore, and the Australian Securities and Investments Commission. Every country in which we may do business will impose upon us laws, rules and regulations similar to those in the U.S., including with respect to some form of capital adequacy rules, customer protection rules, data protection regulations, anti-money laundering and anti-bribery rules, compliance with other applicable trading and investment banking regulations and similar regulatory reform.

Competition

All aspects of our business are, and are expected to be, intensely competitive. We will compete primarily with small to mid-size bank holding companies that engage in wealth management, investment banking and capital markets activities as one of their lines of business and that have greater capital and resources than we do. We will also compete against other broker-dealers, asset managers and boutique firms. We believe the principal factors that will drive our competitiveness in the future will include our ability to: provide differentiated insights to our clients that lead to better business outcomes; attract, retain and develop skilled professionals; deliver a competitive breadth of high-quality service offerings; and to maintain a flat, nimble and entrepreneurial culture built on immediacy and client service.

Cybersecurity Employees

Cybersecurity presents significant challenges to the business community in general, including to the financial services industry. Increasingly, bad actors, both domestic and international, attempt to steal personal data and/or interrupt the normal functioning of businesses through accessing individuals' and companies' files and equipment connected to the internet. Recent incidents have reflected the increasing sophistication of intruders and their intent to steal personally identifiable information as well as funds and securities. These intruders sometimes use instructions that are seemingly from authorized parties but in fact, are from parties intent on attempting to steal. In other instances these intruders attempt to bypass normal safeguards and disrupt or steal significant amounts of information and then either release it to the internet or hold it for ransom. Regulators are increasingly requiring companies to provide heightened levels of sophisticated defenses. Dominari Securities will maintain ongoing planning and systems to prevent any such attack from disrupting its services to clients as well as to prevent any loss of data concerning its clients, their financial affairs, as well as Company privileged information.

Employees

As of December 31, 2022 December 31, 2023, we have 7 had 26 full-time employees and 1 2 part-time employee, employees, none of which are represented by a labor union or covered by a collective bargaining agreement. The Company offers health insurance benefits to eligible employees. Additional benefits offered by the Company depend on the employee position and title, but may include a 401(k) retirement plan, short-term disability, Workers' Compensation for qualifying illness or injury, sick leave and paid vacation. The Company also provides certain training for employees, such as New York State Harassment Prevention Training, Cyber Security Awareness Training and some continuing education training.

Item 1A. RISK FACTORS,FACTORS

The Company's business and operations are subject to numerous risks. The material risks and uncertainties that management believes affect the Company are described below. The risks and uncertainties described below are not the only ones facing the Company. Additional risks and uncertainties that are presently unknown, management is not aware of or focused on or that management currently deems immaterial may also impair the Company's business operations. If any of the following risks actually occur, the Company's financial condition and results of operations may be materially and adversely affected. **We may amend or supplement these risk factors from time to time in other reports we file with the SEC.**

BUSINESS RISKSBusiness Risks

Because we have a limited operating history to evaluate our company, the likelihood of our success must be considered in light of the problems, expenses, difficulties, complications and delays frequently encountered by an early-stage financial services company.

Since we have a limited operating history in our current financial services business, it will make it difficult for investors and securities analysts to evaluate our business and prospects. You must consider our prospects in light of the risks, expenses, and difficulties we face as an early-stage financial services company with a limited operating history. Investors should evaluate an investment in our securities in light of the uncertainties encountered by early-stage companies in an intensely competitive industry. There can be no assurance that our efforts will be successful or that we will be able to become profitable.

Accordingly, you should consider the Company's prospects in light of the costs, uncertainties, delays and difficulties frequently encountered by companies in their start-up stages, particularly those in the financial services industry. **Shareholders** **Stockholders** should carefully consider the risks and uncertainties that a business with no operating history will face. In particular, **shareholders** **stockholders** should consider that there is a significant risk that we will not be able to:

- implement or execute our current business plan, or that our current business plan is sound;
- raise sufficient funds in the capital markets or otherwise to fully effectuate our business plan;
- maintain our management team; and/or
- attract clients.

Any of the foregoing risks may adversely affect the Company and result in the failure of our business. In addition, we expect to encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors.

We continue to incur operating losses and may not achieve profitability.

Our net loss for the year ended **December 31, 2022** **December 31, 2023** was **\$22.1 million** **\$22.9 million**. Our accumulated deficit was **\$185.9 million** **\$208.8 million** as of **December 31, 2022** **December 31, 2023**. Our ability to become profitable depends upon our ability to generate revenue from our financial **products**, **products** and **services**. We do not know when, or if, we will generate **any** significant revenue from such financial **services** and products. Even though our revenue may increase, we expect to incur significant additional losses while we grow and expand our business. We cannot predict if and when we will achieve profitability. Our failure to achieve and sustain profitability could negatively impact the market price of our common stock.

If we cannot meet our future capital requirements, we may be unable to develop and enhance our services, take advantage of business opportunities and respond to competitive pressures.

We may need to raise additional funds in the future to grow our business internally, invest in new businesses, expand through acquisitions, enhance our current services or respond to changes in our target markets. If we raise additional capital through the sale of equity or equity derivative securities, the issuance of these securities could result in dilution to our existing stockholders. If additional funds are raised through the issuance of debt securities, the terms of that debt could impose additional restrictions on our operations or harm our financial condition. Additional financing may be unavailable on acceptable terms.

If we fail to maintain an effective system of internal controls over financial reporting, we may not be able to accurately report our financial results or prevent fraud and our business may be harmed and our stock price may be adversely impacted.

Effective internal controls over financial reporting are necessary for us to provide reliable financial reports and to effectively prevent fraud. Any inability to provide reliable financial reports or to prevent fraud could harm our business. The Sarbanes-Oxley Act of 2002 requires management to evaluate and assess the effectiveness of our internal control over financial reporting. In order to continue to comply with the requirements of the Sarbanes-Oxley Act, we are required to continuously evaluate and, where appropriate, enhance our policies, procedures and internal controls. If we fail to maintain the adequacy of our internal controls over financial reporting, we could be subject to litigation or regulatory scrutiny and investors could lose confidence in the accuracy and completeness of our financial reports. We cannot assure you that in the future we will be able to fully comply with the requirements of the Sarbanes-Oxley Act or that management will conclude that our internal control over financial reporting is effective. If we fail to fully comply with the requirements of the Sarbanes-Oxley Act, our business may be harmed and our stock price may decline.

Our assessment, testing and evaluation of the design and operating effectiveness of our internal control over financial reporting resulted in our conclusion that, as of **December 31, 2022** **December 31, 2023**, our internal control over financial reporting was not effective, due to **our lack the design and maintenance of segregation of duties, and lack of controls in place fair value reporting relating to ensure that all material transactions and developments impacting the consolidated financial statements are reflected, certain notes receivable**. We can provide no assurance as to conclusions of management with respect to the effectiveness of our internal control over financial reporting in the future.

Developments in market and economic conditions may adversely affect the Company's business and profitability.

Performance in the financial services industry is heavily influenced by the overall strength of economic conditions and financial market activity, which generally have a direct and material impact on the Company's results of operations and financial condition. These conditions are a product of many factors, which are mostly unpredictable and beyond the Company's control, and may affect the decisions made by financial market participants.

Changes in economic and political conditions, including economic output levels, interest and inflation rates, employment levels, prices of commodities including oil and gas, exogenous market events, consumer confidence levels, and fiscal and monetary policy can affect market conditions. For example, the Federal Reserve's policies determine, in large part, the cost of funds for lending and investing and the return earned on those loans and investments. Changes in the Federal Reserve's policies are beyond our control and, consequently, the impact of these changes on our activities and results of our operations are difficult to predict. While global financial markets have shown signs of improvement in recent years, uncertainty remains. A period of sustained downturns and/or volatility in the securities markets, and/or prolonged levels of increasing interest rates, could lead to a return to increased credit market dislocations, reductions in the value of real estate, and other negative market factors which could significantly impair our revenues and profitability.

U.S. markets may also be impacted by political and civil unrest occurring in the Middle East, Eastern Europe, Russia, Venezuela and Asia. Continued uncertainties loom over the outcome of the EU's financial support programs. It is possible that other EU member states may choose to follow Britain's lead and leave the EU. Any negative impact on economic conditions and global markets from these developments could adversely affect our business, financial condition and liquidity.

Uncertain or unfavorable market or economic conditions could result in reduced transaction volumes, reduced revenue and reduced profitability in any or all of the Company's principal businesses. For example:

- A portion of the Company's revenues will be derived from fees generated from its asset management business segment. Asset management fees often are primarily comprised of base management and performance (or incentive) fees. Management fees are primarily based on assets under management. Assets under management balances are impacted by net inflow/outflow of client assets and changes in market values. Poor investment performance by the Company's portfolio managers could result in a loss of managed accounts and could result in reputational damage that might make it more difficult to attract new investors, and, thus further impact the Company's business and financial condition. If the Company experiences losses of managed accounts, fee revenue will decline. In addition, in periods of declining market values, the values of assets under management may ultimately decline, which would negatively impact fee revenues.

- In the past decade, passively managed index funds have seen greater investor interest, and this trend has become more prevalent in recent years. A continued lessening of investor interest in active investing and continued increase in passive investing may lead to a continued decline in the revenue the Company generates from commissions on the execution of trading transactions and, in respect of its market-making activities, a reduction in the value of its trading positions and commissions and spreads.
- The Company expects its investment banking revenue, in the form of underwriting, placement and financial advisory fees, to be directly related to the volume and value of transactions as well as the Company's role in these transactions and will typically only be earned upon the successful completion of a transaction. In an environment of uncertain or unfavorable market or economic conditions, the volume and size of capital-raising transactions and acquisitions and dispositions typically decreases, thereby reducing the demand for the Company's investment banking services and increasing price competition among financial services companies seeking such engagements. Accordingly, the Company's business will be highly dependent on market conditions, the decisions and actions of its clients, and interested third parties. The number of engagements the Company has at any given time will be subject to change and may not necessarily result in future revenues.

The Company may make strategic acquisitions of businesses, engage in joint ventures or divest or exit existing businesses, which could result in unforeseen expenses or disruptive effects on its business.

From time to time, the Company may consider acquisitions of other businesses or joint ventures with other businesses. Any acquisition or joint venture that the Company determines to pursue will be accompanied by a number of risks. After the announcement or completion of an acquisition or joint venture, the Company's **share stock** price could decline if investors view the transaction as too costly or unlikely to improve the Company's competitive position.

Costs or difficulties relating to such a transaction, including integration of products, employees, offices, technology systems, accounting systems and management controls, may be difficult to predict accurately and be greater than expected causing the Company's estimates to differ from actual results. The Company may be unable to retain key personnel after the transaction, and the transaction may impair relationships with customers and business partners. In addition, the Company may be unable to achieve anticipated benefits and synergies from the transaction as fully as expected or within the expected time frame. Divestitures or elimination of existing businesses or products could have similar effects, including the loss of earnings of the divested business or operation. These difficulties could disrupt the Company's ongoing business, increase its expenses, and adversely affect its operating results and financial condition. As the costs of doing business increase, the Company may not be able to continue to grow its revenues through "organic" growth (the growth attendant to hiring one employee at a time or through expanding into a new business line through a limited investment in technology and employment). In lieu of organic growth, it becomes increasingly necessary to grow through the acquisition of a business or businesses that fulfill the Company's strategic decisions for growth. However, due to competition or the cost of such acquisitions, such expansion may not be available on a profitable basis and may threaten the Company's ongoing ability to expand its business.

The ability to attract, develop and retain highly skilled and productive employees, particularly qualified financial advisors is critical to the success of the Company's business.

The Company faces intense competition for qualified employees from other businesses in the financial services industry, and the performance of its business may suffer to the extent it is unable to attract and retain employees effectively, particularly given the relatively small size of the Company and its employee base compared to some of its competitors. The primary sources of revenue in each of the Company's business lines are commissions and fees earned on advisory and underwriting transactions and customer accounts managed by its employees, who are regularly recruited by other firms and in certain cases are able to take their client relationships with them when they change firms. Experienced employees are regularly offered financial inducements by larger competitors to change employers, and thus competitors can de-stabilize the Company's relationship with valued employees. Some specialized areas of the Company's business are operated by a relatively small number of employees, the loss of any of whom could jeopardize the continuation of that business following the employee's departure.

Turnover in the financial services industry is high. The cost of retaining skilled professionals in the financial services industry has escalated considerably. Financial industry employers are increasingly offering guaranteed contracts, upfront payments, and increased compensation. These can be important factors in a current employee's decision to leave us as well as in a prospective employee's decision to join us. As competition for skilled professionals in the industry remains intense, we may have to devote significant resources to attracting and retaining qualified personnel. To the extent we have compensation targets, we may not be able to retain our employees, which could result in increased recruiting ~~expense~~ expenses or result in our recruiting additional employees at compensation levels that are not within our target range. In particular, our financial results may be adversely affected by the costs we incur in connection with any upfront loans or other incentives we may offer to newly recruited financial advisors and other key personnel. If we were to lose the services of any of our investment bankers, sales and trading professionals, asset managers, or executive officers to a competitor or otherwise, we may not be able to retain valuable relationships and some of our clients could choose to use the services of a competitor instead of our services. If we are unable to retain our senior professionals or recruit additional professionals, our reputation, business, results of operations and financial condition could be adversely affected. Further, new business initiatives and efforts to expand existing businesses generally require that we incur compensation and benefits expense before generating additional revenues. Moreover, companies in our industry whose employees accept positions with competitors frequently claim that those competitors have engaged in unfair hiring practices. We may be subject to claims in the future as we seek to hire qualified personnel, some of whom may work for our competitors. Some of these claims may result in material litigation.

We could incur substantial costs in defending against these claims, regardless of their merits. Such claims could also discourage potential employees who work for our competitors from joining us. Recent actions by some larger competitors to reject the “Recruiting Protocol”, an industry adopted set of practices permitting financial advisors to port their client relationships to a new firm under strict rules, is likely to increase the likelihood of litigation among competitors surrounding the employment of new advisors and their solicitation of their clients and may act as a new barrier to recruitment of financial advisors.

If we fail to manage our anticipated growth effectively, our business, financial condition and operating results could be harmed.

To manage our growth effectively, we must continue to implement our operational plans and strategies, improve, and expand our infrastructure of people and information systems and expand, train and manage our employee base. To support continued growth, we must effectively integrate, develop and motivate new employees. We face significant competition for personnel. Failure to manage our hiring needs effectively or successfully integrate our new hires may have a material adverse effect on our business, financial condition and operating results. Additionally, the growth of our business places significant demands on our operations, as well as our management and other employees. The growth of our business may require significant additional resources to meet these daily requirements, which may not scale in a cost-effective manner or may negatively affect the quality of our services and client experience. We are also required to manage relationships with a growing number of partners, institutions, clients and other third parties. Our information technology systems and our internal controls and procedures may not be adequate to support future growth of our operations and employee base. If we are unable to manage the growth of our operations effectively, our business, financial condition and operating results may be materially adversely affected.

The Company depends on its senior employees and the loss of their services could harm its business.

The Company’s success is dependent in large part upon the services of its senior executives and employees. Any loss of service services of the chief executive officer (“CEO”) and other senior executive officers may adversely affect the business and operations of the Company. If the Company’s senior executives or employees terminate their employment and the Company is unable to find suitable replacements in relatively short periods of time, its operations may be materially and adversely affected.

The precautions the Company takes to prevent and detect employee misconduct may not be effective and the Company could be exposed to unknown and unmanaged risks or losses.

The Company runs the risk that employee misconduct could occur. Misconduct by employees could include, employees binding the Company to transactions that exceed authorized limits or present unacceptable risks to the Company (rogue trading); employee theft and improper use of Company or client property; employees conspiring with other employees or third parties to defraud the Company; employees hiding unauthorized or unsuccessful activities from the Company, including outside business activities that are undisclosed and may result in liability to the Company; employees steering or soliciting their clients into investments which have not been sponsored by the Company and without the proper diligence; the improper use of confidential information; employee conduct outside of acceptable norms including harassment; or employees engaging in “hacking” or breaching our cybersecurity safeguards.

These types of misconduct could result in unknown and unmanaged risks or losses to the Company including regulatory sanctions and serious harm to its reputation. The precautions the Company takes to prevent and detect these activities may not be effective. If employee misconduct does occur, the Company’s business operations could be materially adversely affected.

There have been a number of highly-publicized cases involving fraud or other misconduct by employees in the financial services industry and there is a risk that our employees could engage in misconduct in the future that adversely affects our business. We are subject to a number of obligations and standards arising from our asset management business and our authority over the assets managed by our asset management business. In addition, our financial advisors may act in a fiduciary capacity, providing financial planning, investment advice and discretionary asset management. The violation of these obligations and standards by any of our employees could adversely affect our clients and us. It is not always possible to deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in all cases. If our employees engage in misconduct, our business could be materially adversely affected, including our cash position.

Employee misconduct, including harassment in the workplace, has come under increasing scrutiny in the national media. While the Company has adopted a Code of Conduct and instituted training for its employees, it is difficult to predict when an employee may deviate from acceptable practices and open the Company to liability either from actions taken by other employees or by authorities. The Company could also become liable for its actions in enforcing its rules of conduct on former employees who disagree with the Company’s actions.

FINANCIAL RISKS*Our failure to deal appropriately with conflicts of interest could damage our reputation and adversely affect our business.*

Market Risk

Market risk refersAppropriately dealing with conflicts of interest is complex and difficult and our reputation could be damaged if we fail, or appear to the risk that a change in the level of fail, to deal appropriately with one or more market prices, rates, indices, volatilities, correlations potential or other market factors, such as market liquidity, will result actual conflicts of interest. It is possible that potential or perceived conflicts could give rise to investor dissatisfaction or litigation or regulatory enforcement actions. In addition, regulatory scrutiny of, or litigation in losses for connection with, conflicts of interest would have a position or portfolio owned by us, material adverse effect on our reputation, which could materially and adversely affect our business in a number of ways, including an inability to raise additional funds, a reluctance of counterparties to do business with us and the costs of defending litigation.

Our results of operations may be materially affected by market fluctuations and by global and economic conditions and other factors, including changes in asset values.

Our results of operations may be materially affected by market fluctuations due to global financial markets, economic conditions, changes to global trade policies and tariffs and other factors, including the level and volatility of equity, fixed income and commodity prices, the level and term structure of interest rates, inflation and currency values, and the level of other market indices. The results of our Capital Markets business segment, particularly results relating to our involvement in primary and secondary markets for all types of financial products, are subject to substantial market fluctuations due to a variety of factors that we cannot control or predict with great certainty. These fluctuations impact results by causing variations in business flows and activity and in the fair value of securities and other financial products. Fluctuations also occur due to the level of global market activity, which, among other things, affects the size, number and timing of investment banking client assignments and transactions and the realization of returns from our principal investments.

During periods of unfavorable market or economic conditions, the level of individual investor participation in the global markets, as well as the level of client assets, may also decrease, which would negatively impact the results of our Private Client and Asset Management business segments. Substantial market fluctuations could also cause variations in the value of our investments in our funds, the flow of investment capital into or from Assets Under Management, ("AUM"), and the way customers allocate capital among money market, equity, fixed income or other investment alternatives, which could negatively impact our Private Client and Asset Management business segments.

The Company may incur losses and be subject to reputational harm to the extent that, for any reason, it is unable to sell securities it purchased as an underwriter at anticipated price levels. As an underwriter, the Company is subject to heightened standards regarding liability for material misstatements or omissions in prospectuses and other offering documents relating to offerings it underwrites. Any such misstatement or omission could subject the Company to enforcement action by the SEC and claims of investors, either of which could have a material adverse impact on the Company's results of operations, financial condition and reputation. As a market maker and dealer, the Company may own large positions in specific securities, and these undiversified holdings concentrate the risk of market fluctuations and may result in greater losses than would be the case if the Company's holdings were more diversified.

The value of our financial instruments may be materially affected by market fluctuations. Market volatility, illiquid market conditions and disruptions in the credit markets may make it extremely difficult to value and monetize certain of our financial instruments, particularly during periods of market displacement. Subsequent valuations in future periods, in light of factors then prevailing, may result in significant changes in the values of these instruments and may adversely impact historical or prospective fees and performance-based fees (also known as incentive fees, which include carried interest) in respect of certain businesses. In addition, at the time of any sales and settlements of these financial instruments, the price we ultimately realize will depend on the demand and liquidity in the market at that time and may be materially lower than their current fair value. Any of these factors could cause a decline in the value of our financial instruments, which may have an adverse effect on our results of operations in future periods. In addition, financial markets are susceptible to severe events evidenced by rapid depreciation in asset values accompanied by a reduction in asset liquidity. Under these extreme conditions, hedging and other risk management strategies may not be as effective at mitigating trading losses as they would be under more normal market conditions. Moreover, under these conditions, market participants are particularly exposed to trading strategies employed by many market participants simultaneously and on a large scale. Our risk management and monitoring processes seek to quantify and mitigate risk to more extreme market moves. However, severe market events have historically been difficult to predict and we could realize significant losses if extreme market events were to occur.

Holding large and concentrated positions may expose us to losses. Concentration of risk may reduce revenues or result in losses in our market-making, investing, underwriting, including block trading, and lending businesses in the event of unfavorable market movements, or when market conditions are more favorable for our competitors. Changes in interest rates (especially if such changes are rapid), sustained low or high interest rates or uncertainty regarding the future direction of interest rates, may create a less favorable environment for certain of the Company's businesses, particularly its fixed income business, resulting in reduced business volume and reduced revenue. If interest rates remain at low levels, the Company's profitability will be negatively impacted.

Credit Risk

Credit risk may expose the Company to losses caused by the inability of borrowers or other third parties to satisfy their obligations.

The Company is exposed to the risk that third parties that owe it money, securities or other assets will not perform their obligations.

The Company is exposed to credit risk related to third parties such as trading counterparties, customers, clearing agents, exchanges, clearing houses, and other financial intermediaries as well as issuers whose securities we hold. These parties may default on their obligations owed to the Company due to bankruptcy, lack of liquidity, operational failure or other reasons. This default risk may arise, for example, from holding securities of third parties, executing securities trades that fail to settle at the required time due to non-delivery by the counterparty or systems failure by clearing agents, exchanges, clearing houses or other financial intermediaries, and extending credit to clients through bridge or margin loans or other arrangements. Significant failures by third parties to perform their obligations owed to the Company could adversely affect the Company's revenue and its ability to borrow in the credit markets.

Liquidity Risk

Liquidity risk refers to the risk that we will be unable to finance our operations due to a loss of access to the capital markets or difficulty in liquidating our assets. Liquidity risk also encompasses our ability (or perceived ability) to meet our financial obligations without experiencing significant business disruption or reputational damage that may threaten our viability as a going concern as well as the associated funding risks triggered by the market or idiosyncratic stress events that may negatively affect our liquidity and may impact our ability to raise new funding.

Liquidity is essential to our businesses and we rely on external sources to finance a significant portion of our operations.

Our liquidity could be negatively affected by our inability to raise funding in the long-term or short-term debt capital markets, our inability to access the secured lending markets, or unanticipated outflows of cash or collateral by customers or clients. Factors that we cannot control, such as disruption of the financial markets or negative views about the financial services industry generally, including concerns regarding fiscal matters in the U.S. and other geographic areas, could impair our ability to raise funding. In addition, our ability to raise funding could be impaired if investors or lenders develop a negative perception of our long-term or short-term financial prospects due to factors such as an incurrence of large trading losses, a downgrade by the rating agencies, a decline in the level of our business activity, if regulatory authorities take significant action against us or our industry, or we discover significant employee misconduct or illegal activity. If we are unable to raise funding using the methods described above, we would likely need to finance or liquidate unencumbered assets, such as our investment portfolios or trading assets, to meet maturing liabilities or other obligations. We may be unable to sell some of our assets or we may have to sell assets at a discount to market value, either of which could adversely affect our results of operations, cash flows and financial condition.

Operational Risk From time to time we may invest in securities that are illiquid or subject to restrictions.

Operational risk refers From time to time we may invest in securities that are subject to restrictions which prohibit us from selling the risk securities for a period of loss, or time. Such agreements may limit our ability to generate liquidity quickly through the disposition of damage to our reputation, resulting from inadequate or failed processes or systems, from human factors or from external events (e.g., fraud, theft, legal and compliance risks, cyber-attacks or damage to physical assets). We may incur operational risk across the full scope of our business activities, including revenue-generating activities (e.g., sales and trading) and support and control groups (e.g., information technology and trade processing) underlying investment while the agreement is effective.

We are subject to operational risks, including a failure, breach or other disruption of our operations or security systems or those of our third parties (or third parties thereof), as well as human error or malfeasance, which could adversely affect our businesses or reputation.

Our businesses are highly dependent on our ability to process and report, on a daily basis, a large number of transactions across numerous markets. We may introduce new products or services or change processes or reporting, including in connection with new regulatory requirements, resulting in new operational risk that we may not fully appreciate or identify. The trend toward direct access to automated, electronic markets and the move to more automated trading platforms has resulted in the use of increasingly complex technology that relies on the continued effectiveness of the programming code and integrity of the data to process the trades. We rely on the ability of our employees, consultants, and internal systems to operate our different businesses and process a high volume of transactions. Additionally, we are subject to complex and evolving laws and regulations governing cybersecurity, privacy and data protection, which may differ and potentially conflict, in various jurisdictions. As a participant in the global capital markets, we face the risk of incorrect valuation or risk management of our trading positions due to flaws in data, models, electronic trading systems or processes or due to fraud or cyber-attack.

We also face the risk of operational failure or disruption of any of the clearing agents, exchanges, clearing houses or other financial intermediaries we use to facilitate our lending and securities transactions. In the event of a breakdown or improper operation of our or a direct or indirect third party's systems (or third parties thereof) or processes or improper or unauthorized action by third parties, including consultants and subcontractors or our employees, we could suffer financial loss, an impairment to our liquidity position, a disruption of our businesses, regulatory sanctions or damage to our reputation. In addition, the interconnectivity of multiple financial institutions with central agents, exchanges and clearing houses, and the increased importance of these entities, increases the risk that an operational failure at one institution or entity may cause an industry-wide operational failure that could materially impact our ability to conduct business. Furthermore, the concentration of Company and personal information held by a handful of third parties increases the risk that a breach at a key third party may cause an industry-wide data breach that could significantly increase the cost and risk of conducting business. There can be no assurance that our business contingency and security response plans fully mitigate all potential risks to us. Our ability to conduct business may be adversely affected by a disruption in the infrastructure that supports our businesses and the communities where we are located. This may include a disruption involving physical site access; cybersecurity incidents; terrorist activities; political unrest; disease pandemics; catastrophic events; climate-related incidents and natural disasters (such as earthquakes, tornadoes, hurricanes and wildfires); electrical outages; environmental hazards; computer servers; communications or other services we use; and our employees or third parties with whom we conduct business. Although we employ backup systems for our data, those backup systems may be unavailable following a disruption, the affected data may not have been backed up or may not be recoverable from the backup, or the backup data may be costly to recover, which could adversely affect our business.

Notwithstanding evolving technology and technology-based risk and control systems, our businesses ultimately rely on people, including our employees and those of third parties with which we conduct business. As a result of human error or engagement in violations of applicable policies, laws, rules or procedures, certain errors or violations are not always discovered immediately by our technological processes or by our controls and other procedures, which are intended to prevent and detect such errors or violations. These can include calculation errors, mistakes in addressing emails or other communications, errors in software or model development or implementation, or errors in judgment, as well as intentional efforts to disregard or circumvent applicable policies, laws, rules or procedures. Human errors and malfeasance, even if promptly discovered and remediated, can result in material losses and liabilities for us. Any theft of data, technology or intellectual property may negatively impact our operations and reputation, including disrupting the business activities of our subsidiaries, affiliates, joint ventures or clients conducting business in those jurisdictions.

The Company's information systems may experience an interruption or breach in security.

The Company relies heavily on communications and information systems to conduct its business. Any failure, interruption or breach in security of these systems could result in failures or disruptions in the Company's customer relationship management, regulatory or other reporting, general ledger, and other systems. While the Company has policies and procedures designed to prevent or limit the effect of the failure, interruption or security breach of its information systems, there can be no assurance that any such failures, interruptions or security breaches will not occur or, if they do occur, that they will be adequately addressed. Recent disclosures of such incursions by foreign and domestic unauthorized agents aimed at large financial institutions reflect higher risks for all such institutions. The occurrence of any failures, interruptions or security breaches of the Company's information systems could damage the Company's reputation, result in a loss of customer business, subject the Company to additional regulatory scrutiny, or expose the Company to civil litigation and possible financial liability, any of which could have a material adverse effect on the Company's financial condition and results of operations.

Our businesses rely extensively on data processing and communications systems. In addition to better serving clients, the effective use of technology increases efficiency and enables us to reduce costs. Adapting or developing our technology systems to meet new regulatory requirements, client needs, and competitive demands is critical for our business. Introduction of new technology presents challenges on a regular basis. There are significant technical and financial costs and risks in the development of new or enhanced applications, including the risk that we might be unable to effectively use new technologies or adapt our applications to emerging industry standards. Our continued success depends, in part, upon our ability to: (i) successfully maintain and upgrade the capability of our technology systems; (ii) address the needs of our clients by using technology to provide products and services that satisfy their demands; and (iii) retain skilled information technology employees. Failure of our technology systems, which could result from events beyond our control, or an inability to effectively upgrade those systems or implement new technology-driven products or services, could result in financial losses, liability to clients, and violations of applicable privacy and other applicable laws and regulatory sanctions.

Cybersecurity - Security and security breaches of our technology systems, or those of our clients or other third-party vendors we rely on, could subject us to significant liability and harm our reputation.

Our operational systems and infrastructure must continue to be safeguarded and monitored for potential failures, disruptions, cyber-attacks and breakdowns. Our operations rely on the secure processing, storage and transmission of confidential and other information in our computer systems and networks. Although cybersecurity incidents among financial services firms are on the rise, we have not experienced any material losses relating to cyber-attacks or other information security breaches. However, there can be no assurance that we will not suffer such losses in the future.

Despite our implementation of protective measures and endeavoring to modify them as circumstances warrant, our computer systems, software and networks may be vulnerable to human error, natural disasters, power loss, spam attacks, unauthorized access, distributed denial of service attacks, computer viruses and other malicious code and other events that could have an impact on the security and stability of our operations. Notwithstanding the precautions we take, if one or more of these events were to occur, this could jeopardize the information we confidentially maintain, including that of our clients and counterparties, which is processed, stored in and transmitted through our computer systems and networks, or otherwise cause interruptions or malfunctions in our operations or the operations of our clients and counterparties. We may be required to expend significant additional resources to modify our protective measures, to investigate and remediate vulnerabilities or other exposures or to make required notifications or disclosures. We may also be subject to litigation and financial losses that are neither insured nor covered under any of our current insurance policies.

A technological breakdown could also interfere with our ability to comply with financial reporting and other regulatory requirements, exposing us to potential disciplinary action by regulators. Our regulators have introduced programs to review our protections against such incidents which, if they determined that our systems do not reasonably protect our clients' assets and their data, could result in enforcement activity and sanctions.

In providing services to clients, we may manage, utilize and store sensitive or confidential client or employee data, including personal data. As a result, we may be subject to numerous laws and regulations designed to protect this information, such as U.S. federal and state and international laws governing the protection of personally identifiable information. These laws and regulations are increasing in complexity and number. If any person, including any of our associates, negligently disregards or intentionally breaches our established controls with respect to client or employee data, or otherwise mismanages or misappropriates such data, we could be subject to significant monetary damages, regulatory enforcement actions, fines and/or criminal prosecution. In addition, unauthorized disclosure of sensitive or confidential client or employee data, whether through system failure, employee negligence, fraud or misappropriation, could damage our reputation and cause us to lose clients and related revenue.

Potential liability in the event of a security breach of client data could be significant. Depending on the circumstances giving rise to the breach, this liability may not be subject to a contractual limit or an exclusion of consequential or indirect damages. The federally mandated Consolidated Audit Trail (“CAT”) program which requires that client personally identifiable information be submitted to a database not controlled by us may expose us to liability for breaches of that database not under our control.

As a result of the foregoing, the Company has and is likely to incur significant costs in preparing its infrastructure and maintaining it to resist any such attacks. In addition to personnel dedicated to overseeing the infrastructure and systems to defend against cybersecurity incidents, senior management is regularly briefed on issues, preparedness and any incidents requiring response. At **their its** regularly scheduled meetings, the **Audit Committee of the** Board of Directors **and the Board of Directors are** is briefed and brought up to date on **cybersecurity, cybersecurity matters.**

The Company continually encounters technological change.

The financial services industry is continually undergoing rapid technological change with frequent introductions of new technology-driven products and services, driven by the emergence of the Fintech industry. The effective use of technology increases efficiency and enables financial institutions to better serve customers and reduce costs. The Company’s future success depends, in part, upon its ability to address the needs of its customers by using technology to provide products and services that will satisfy customer demands, as well as to create additional efficiencies in the Company’s operations. Many of the Company’s competitors have substantially greater resources to invest in technological improvements. Failure to successfully keep pace with technological change affecting the financial services industry could have a material adverse impact on the Company’s business and, in turn, the Company’s financial condition and results of operations.

There is risk associated with the sufficiency of coverage under the Company’s insurance policies.

The Company’s operations and financial results are subject to risks and uncertainties related to the use of a combination of insurance, self-insured retention and self-insurance for a number of risks, including most significantly property and casualty, general liability, cyber-crime, workers’ compensation, and the portion of employee-related health care benefits plans funded by the Company, and certain errors and omissions liability, among others.

While the Company endeavors to purchase insurance coverage that is appropriate to its assessment of risk, it is unable to predict with certainty the frequency, nature or magnitude of claims for direct or consequential damages. The Company's business may be negatively affected if in the future its insurance proves to be inadequate or unavailable. In addition, insurance claims may divert management resources away from operating the business.

Climate change concerns could disrupt our businesses, adversely affect client activity levels, adversely affect the creditworthiness of our counterparties and damage our reputation.

Climate change may cause extreme weather events that, among other things, could damage our facilities and equipment, injure our employees, disrupt operations at one or more of our primary locations, negatively affect our ability to service and interact with our clients, and adversely affect the value of our investments. Any of these events may increase our costs including our costs to insure against these events.

Climate change may also have a negative impact on the financial condition of our clients, which may decrease revenues from those clients and increase the credit exposures to those clients. Additionally, our reputation and client relationships may be damaged as a result of our involvement, or our clients' involvement, in certain industries associated with causing or exacerbating, or alleged to cause or exacerbate, climate change. We also may be negatively impacted by any decisions we make to continue to conduct or change our activities in response to considerations relating to climate change. New regulations or guidance relating to climate change, as well as the perspectives of **shareholders, stockholders**, employees and other stakeholders regarding climate change, may affect whether and on what terms and conditions we engage in certain activities or offer certain products.

Environmental, Social and Governance (ESG) Risks

Increasingly our society and our business are faced with challenges associated with the implementation of policies and practices that are supportive of concerns related to environmental, social and governance (ESG) issues. We continue to explore implementing ESG considerations across our business practices and operations, a task complicated by the lack of consensus around a defining standard of ESG. We continue to focus on improving the resilience of our operations, fostering an inclusive workforce and maintaining a system of good corporate governance. However, our efforts in this regard may be insufficient and may expose the Company to reputational risk from entities purporting to "grade" ESG platforms, reductions in business with certain clients demanding greater ESG efforts or to regulatory expectation and enforcement if such practices become the subject of rule-making by regulators to whom we are subject.

LEGAL, REGULATORY AND COMPLIANCE RISKS

The Company is subject to extensive securities regulation and the failure to comply with these regulations could subject it to monetary penalties or sanctions.

The securities industry and the Company's **business businesses** are subject to extensive regulation by the SEC, state securities regulators, other governmental regulatory authorities and industry self-regulatory organizations. The Company may be adversely affected by new or revised legislation or regulations or changes in the interpretation or enforcement of existing laws and rules by these governmental authorities and self-regulatory organizations.

Dominari Securities is a broker-dealer and investment adviser registered with the SEC and is primarily regulated by FINRA. Broker-dealers are subject to regulations which cover all aspects of the securities business, including, without limitation sales methods and supervision, underwriting, trading practices among broker-dealers, emerging standards concerning fees and charges imposed on clients for fee-based programs, use and safekeeping of customers' funds and securities, anti-money laundering and the USA Patriot Act (the "Patriot Act") compliance, capital structure of securities firms, trade and regulatory reporting, cybersecurity, pricing of services, compliance with **DOL Department of Labor** rules and regulations for retirement accounts, compliance with lending practices (Regulation T), record keeping, and the conduct of directors, officers and employees.

Compliance with many of the regulations applicable to the Company involves a number of risks, particularly in areas where applicable regulations may be subject to varying interpretation. The requirements imposed by these regulations are designed to ensure the integrity of the financial markets and to protect customers and other third parties who deal with the Company. New regulations may result in enhanced standards of duty on broker-dealers in their dealings with their clients (fiduciary standards). Consequently, these regulations often serve to limit the Company's activities, including through net capital, customer protection and market conduct requirements, including those relating to principal trading. Much of the regulation of broker-dealers has been delegated to self-regulatory organizations, principally FINRA. FINRA adopts rules, subject to approval by the SEC, which govern its members and conducts periodic examinations of member firms' operations.

If the Company is found to have violated any applicable laws, rules or regulations, formal administrative or judicial proceedings may be initiated against it that may result in censure, fine, civil or criminal penalties, including treble damages in the case of insider trading violations, the issuance of cease-and-desist orders, the suspension or termination of our broker-dealer or investment advisory activities, the suspension or disqualification of our officers or employees; or other adverse consequences.

The imposition of any of the above or other penalties could have a material adverse effect on our operating results and financial condition.

Financial services firms have been subject to increased regulatory scrutiny increasing the risk of financial liability and reputational harm resulting from adverse regulatory actions.

Firms in the financial services industry have been operating in an onerous regulatory environment. The industry has experienced increased scrutiny from a variety of regulators, including the SEC, FINRA, and state regulators. Penalties and fines sought by regulatory authorities have increased substantially. We may be adversely affected by changes in the interpretation or enforcement of existing laws and rules by these governmental authorities and SROs. Each of the regulatory bodies with jurisdiction over us has regulatory powers dealing with many different aspects of financial services, including, but not limited to, the authority to fine us and to grant, cancel, restrict or otherwise impose conditions on the right to continue operating particular businesses. For example, the failure to comply with the obligations imposed by the Exchange Act on broker-dealers and the Advisers Act on investment advisers, including recordkeeping, registration, advertising and operating requirements, disclosure obligations and prohibitions on fraudulent activities, or by the Investment Company Act of 1940, as amended (the “1940 Act”), could result in investigations, sanctions and reputational damage. Increasingly, regulators have instituted a practice of “regulation by enforcement” where new interpretations of existing regulations are introduced by bringing enforcement actions against securities firms for activities that occurred in the past but were not then thought to be problematic. We also may be adversely affected as a result of new or revised legislation or regulations imposed by the SEC, other U.S. or foreign governmental regulatory authorities or SROs (e.g., FINRA) that supervise the financial markets. Substantial legal liability or significant regulatory action taken against us could have a material adverse effect on our business prospects including our cash position.

Numerous regulatory changes and enhanced regulatory and enforcement activity relating to the asset management business may increase our compliance and legal costs and otherwise adversely affect our business.

U.S. and foreign governments have taken regulatory actions impacting the investment management industry, and may continue to take further actions, including expanding current (or enacting new) standards, requirements and rules that may be applicable to us and our subsidiaries, particularly those subsidiaries that are SEC registered investment advisers. For example, the SEC and several states and municipalities in the United States have adopted “pay-to-play” rules, which could limit our ability to charge advisory fees. Such “pay-to-play” rules could affect the profitability of that portion of our business. Additionally, the use of “soft dollars,” where a portion of commissions paid to broker-dealers in connection with the execution of trades also pays for research and other services provided to advisors has been mostly prohibited in Europe and, is periodically reexamined in the U.S. and may be limited or modified in the future. Furthermore, new regulations regarding the management of hedge funds and the use of certain investment products may impact our investment management business and result in increased costs. For example, many regulators around the world adopted disclosure and reporting requirements relating to the hedge fund business.

On June 5, 2019, the SEC adopted Regulation Best Interest (“Reg BI”) as Rule 15l-1 under the Exchange Act. Reg BI imposes a new federal standard of conduct on registered broker-dealers and their associated persons when dealing with retail clients and requires that a broker-dealer and its representatives act in the best interest of such client and not place its own interests ahead of the customer’s interests. Reg BI requires enhanced documentation for recommendations of securities transactions to broker-dealer retail clients. The new rules and processes related thereto will likely limit revenue and most likely involve increased costs, including, but not limited to, compliance costs associated with new or enhanced technology as well as increased litigation costs.

It is not possible to determine the extent of the impact of any new laws, regulations or initiatives that may be imposed, or whether any existing proposals will become law. Conformance with any new laws or regulations could make compliance more difficult and expensive and affect the manner in which we conduct business.

If the Company violates the securities laws or is involved in litigation in connection with a violation, the Company's reputation and results of operations may be adversely affected.

Many aspects of the Company's business involve substantial risks of liability. An underwriter is exposed to substantial liability under federal and state securities laws, other federal and state laws, and court decisions, including decisions with respect to underwriters' liability and limitations on indemnification of underwriters by issuers. For example, a firm that acts as an underwriter may be held liable for material misstatements or omissions of fact in a prospectus used in connection with the securities being offered or for statements made by its securities analysts or other personnel. The Company's underwriting activities will usually involve offerings of the securities of smaller companies, which often involve a higher degree of risk and are more volatile than the securities of more established companies. In comparison with more established companies, smaller companies are also more likely to be the subject of securities class actions, to carry directors and officers liability insurance policies with lower limits or not at all, and to become insolvent. In addition, in market downturns, claims tend to increase. Each of these factors increases the likelihood that an underwriter may be required to contribute to an adverse judgment or settlement of a securities lawsuit.

RISK MANAGEMENT

The Company's risk management policies and procedures may leave it exposed to unidentified risks or an unanticipated level of risk.

The policies and procedures the Company employs to identify, monitor and manage risks may not be fully effective. Some methods of risk management are based on the use of observed historical market behavior. As a result, these methods may not predict future risk exposures, which could be significantly greater than historical measures indicate. Other risk management methods depend on evaluation of information regarding markets, clients or other matters that are publicly available or otherwise accessible. This information may not be accurate, complete, up-to-date or properly evaluated. Management of operational, legal and regulatory risk requires, among other things, policies and procedures to properly record and verify a large number of transactions and events. The Company cannot give assurances that its policies and procedures will effectively and accurately record and verify this information.

The Company seeks to monitor and control its risk exposure through a variety of separate but complementary financial, credit, operational, compliance and legal reporting systems. The Company believes that it effectively evaluates and manages the market, credit and other risks to which it is exposed. Nonetheless, the effectiveness of the Company's ability to manage risk exposure can never be completely or accurately predicted or fully assured, and there can be no guarantee that the Company's risk management will be successful. For example, unexpectedly large or rapid movements or disruptions in one or more markets or other unforeseen developments can have a material adverse effect on the Company's financial condition and results of operations. The consequences of these developments can include losses due to adverse changes in securities values, decreases in the liquidity of trading positions, higher volatility in earnings, and increases in general systemic risk. Certain of the Company's risk management systems are subject to regulatory review and may be found to be insufficient by the Company's regulators potentially leading to regulatory sanctions. There can be no guarantee that the operation of these systems will allow the Company to prevent or mitigate the various risks faced by its businesses. Various regulators periodically review companies' risk control practices, and, if found inadequate, bring enforcement actions and sanctions against such firms.

Risks Associated with the Company's Common Stock

RISKS ASSOCIATED WITH THE COMPANY'S COMMON STOCK

Our common stock may be delisted from The Nasdaq Capital Market if we fail to comply with continued listing standards.

Our common stock is currently traded on The Nasdaq Capital Market ("Nasdaq"), under the symbol "DOMH". "DOMH." If we fail to meet any of the continued listing standards of The Nasdaq, Capital Market, our common stock could be delisted from The Nasdaq Capital Market, Nasdaq. These continued listing standards include specifically enumerated criteria, such as:

- a \$1.00 minimum closing bid price;
- stockholders' equity of \$2.5 million;
- 500,000 shares of publicly-held publicly held common stock with a market value of at least \$1 million;
- 300 round-lot public stockholders; and
- compliance with Nasdaq's corporate governance requirements, as well as additional or more stringent criteria that may be applied in the exercise of Nasdaq's discretionary authority.

If we fail to comply with Nasdaq's continued listing standards, we may be delisted and our common stock will trade, if at all, only on the over-the-counter market, such as the OTC Bulletin Board or OTCQX market, and then only if one or more registered broker-dealer market makers comply with quotation requirements. In addition, the delisting of our common stock could depress our stock price, substantially limit liquidity of our common stock and materially adversely affect our ability to raise capital on terms acceptable to us, or at all. Further, delisting of our common stock would likely result in our common stock becoming a "penny stock" under the Exchange Act.

Our share price may be volatile and there may not be an active trading market for our common stock.

There can be no assurance that the market price of our common stock will not decline below its present market price or that there will be an active trading market for our common stock. The market prices of upstart financial services companies have been and are likely to continue to be highly volatile. Fluctuations in our operating results and general market conditions for upstart financial services stocks could have a significant impact on the volatility of our common stock price. We have experienced significant volatility in the price of our common stock. From January 1, 2022 January 1, 2023 through December 31, 2022 December 31, 2023, the closing share price of our common stock (on a split-adjusted basis) ranged from a high of \$11.56 \$4.45 to a low of \$3.02 \$1.85. The reason for the volatility in our common stock is not well understood and may continue. Factors that may have contributed to such volatility include, but are not limited to:

- developments regarding regulatory filings;
- our funding requirements and the terms of our financing arrangements;
- introduction of new technologies by us or our competitors;
- government regulations and laws;
- public sentiment relating to our industry;
- the number of shares issued and outstanding;
- the number of shares trading on an average trading day;
- block sales of our shares by stockholders to whom we have sold stock in private placements, or the cessation of transfer restrictions with respect to those shares; and
- market speculation regarding any of the foregoing.

Our shares of common stock are thinly traded and, as a result, stockholders may be unable to sell at or near ask prices, or at all, if they need to sell shares to raise money or otherwise desire to liquidate their shares.

Our common stock has been “thinly-traded” meaning that the number of persons interested in purchasing our common stock at or near ask prices at any given time may be relatively small or non-existent. This situation is attributable to a number of factors, including the fact that we are a small company that is relatively unknown to stock analysts, stock brokers, institutional investors and others in the investment community that generate or influence sales volume, and that even if we came to the attention of such persons, they tend to be risk-averse and would be reluctant to follow an unproven company such as ours or purchase or recommend the purchase of our shares until such time as we become more seasoned and viable. Our trading volumes ~~are~~ may have been further adversely affected by the ~~1-for-19~~ 17-for-1 reverse stock split that was effective as of ~~March 4, 2016~~ June 7, 2022. In addition, we believe that due to the limited number of shares of our common stock outstanding, an options market has not been established for our common stock, limiting the ability of market participants to hedge or otherwise undertake trading strategies available for larger companies with broader ~~shareholder~~ stockholder bases which prevents institutions and others from acquiring or trading in our securities. Consequently, there may be periods of several days or more when trading activity in our shares is minimal or non-existent, as compared to a seasoned issuer which has a large and steady volume of trading activity that will generally support continuous sales without an adverse effect on share price. We cannot give stockholders any assurance that a broader or more active public trading market for our common shares will develop or be sustained, or that current trading levels will be sustained.

Our stock price and trading volume could decline as a result of inaccurate or unfavorable research, or the cessation of research cover, about our business published by securities or industry analysts.

The trading market for our common stock may be affected by the research and reports that securities or industry analysts publish about us or our business. If one or more of the analysts who covers us downgrades our common stock or publishes inaccurate or unfavorable research about our business, our stock price could decline. In addition, the analysts' projections may have little or no relationship to the results we actually achieve and could cause our stock price to decline if we fail to meet their projections. If one or more of these analysts ceases coverage of us or fails to publish reports on us regularly, our stock price or trading volume could decline.

Because of the "anti-takeover" provisions in our Amended and Restated Certificate of Incorporation, Amended and Restated Bylaws and Delaware General Corporation Law, a third party may be discouraged from making a takeover offer that could be beneficial to our stockholders.

The effect of certain provisions of our Amended and Restated Certificate of Incorporation, Amended and Restated Bylaws and the anti-takeover provisions of the Delaware General Corporation Law (the "DGCL"), could delay or prevent a third party from acquiring us or replacing members of our Board of Directors, or make more costly any attempt to acquire control of the Company, even if the acquisition or the Board designees would be beneficial to our stockholders. These factors could also reduce the price that certain investors might be willing to pay for shares of the common stock and result in the market price being lower than it would be without these provisions.

We incur increased costs as a result of being a public company.

As a public company, we incur significant levels of legal, accounting, regulatory and other expenses. Sarbanes-Oxley and related rules of the SEC, together with the listing requirements of Nasdaq, impose significant requirements relating to disclosure controls and procedures and internal control over financial reporting. We have incurred costs as a result of compliance with these public company requirements, and we may need to hire additional qualified personnel in order to continue to satisfy these public company requirements. We are required to expend considerable time and resources complying with public company regulations. Furthermore, if we are unable to satisfy our obligations as a public company, we could be subject to delisting of our common stock, fines, sanctions and other regulatory action.

Because of their significant stock ownership, some of our executive officers and directors will be able to exert control over us and our significant corporate decisions.

Our executive officers, directors and their affiliates own or control, in the aggregate, beneficially own approximately 32.93% of our outstanding common stock as of December 31, 2023. These stockholders may be able to exercise influence over matters requiring stockholder approval, such as the election of directors and the approval of significant corporate transactions, including transactions involving an actual or potential change of control of the company or other transactions that non-controlling stockholders may not deem to be in their best interests. This concentration of ownership may harm the market price of our common stock by, among other things: delaying, deferring, or preventing a change in control of our company; impeding a merger, consolidation, takeover, or other business combination involving our company; causing us to enter into transactions or agreements that are not in the best interests of all stockholders; or discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control of our company.

Dividends on our common stock are not likely.

During the last five years, we have not paid cash dividends on our common stock, and we do not anticipate paying cash dividends on our common stock in the foreseeable future. Investors must look solely to the potential for appreciation in the market price of the shares of our common stock to obtain a return on their investment.

Item 1B. UNRESOLVED STAFF COMMENTS

As a smaller reporting company, we are not required to provide the information required by this item.

Item 1C. CYBERSECURITY

We maintain a comprehensive process for identifying, assessing, and managing material risks from cybersecurity threats (as such term is defined in Item 106(a) of Regulation S-K) as part of our broader risk management system and processes. The cybersecurity risk management system involves risk assessments, implementation of security measures, and ongoing monitoring of systems and networks, including networks on which we rely. We actively monitor the current threat landscape in an effort to identify material risks arising from new and evolving cybersecurity threats. We obtain input, as appropriate, for our cybersecurity risk management program on the security industry and threat trends from consultants, cybersecurity assessors, auditors and other third parties to gather certain insights designed to identify and assess material cybersecurity threat risks, their severity and potential mitigations. We depend on and engage various third parties, including suppliers, vendors, and service providers. Our risk management, legal, information technology, and compliance personnel identify and oversee risks from cybersecurity threats associated with our use of such entities. Any incident assessed as potentially being or potentially becoming material is immediately escalated for further assessment, and then reported to Mr. Blattner, our designated member of our Board of Directors.

Mr. Blattner has oversight responsibility for risks and incidents relating to cybersecurity threats, including compliance with disclosure requirements, cooperation with law enforcement, and related effects on financial and other risks, and report any findings and recommendations, as appropriate, to the full Board of Directors for consideration. Senior management regularly discusses cyber risks and trends and, should they arise, any material incidents with the designated member of the Board of Directors.

Our business strategy, results of operations and financial condition have not been materially affected by risks from cybersecurity threats, but we cannot provide assurance that they will not be materially affected in the future by such risks or any future material incidents. Further, a cyber incident impacting our systems or a third-party's systems could subject us to business, regulatory, litigation and reputational risk, which could have a negative effect on our business, results of operations and financial condition. For more information on our cybersecurity related risks, see Item 1A Risk Factors of this Annual Report.

Item 2. ~~PROPERTIES~~.PROPERTIES

We lease offices located in New York, New York and we believe that the New York offices are sufficient to meet our current needs.

Item 3. ~~LEGAL PROCEEDINGS~~.PROCEEDINGS

Many aspects of the Company's business involve substantial risks of liability. In the ordinary course of business, the Company may be named as defendant or co-defendant in various legal actions, including arbitrations, class actions and other litigation, which could create substantial exposure and periodic expenses. The Company may also be involved, from time to time, in other reviews, investigations and proceedings (both formal and informal) by governmental and self-regulatory agencies regarding the Company's business, which may result in expenses, adverse judgments, settlements, fines, penalties, injunctions or other relief. In the past in the ordinary course of business, we actively pursued legal remedies to enforce our intellectual property rights and to stop unauthorized use of our technology. ~~Other than ordinary routine litigation incidental~~ In March 2024, the Company received a notice of petition of a filed action seeking relief related to the ~~business, we know~~ March 2024 affiliates of ~~no material, active or pending~~ new registered representatives. This notice was filed against the Company's subsidiary Dominari Securities. The Company does not agree with the claim of the plaintiff and will defend itself accordingly. While the Company intends to defend itself vigorously from this claim, it is unable to predict the outcome of such legal ~~proceedings against us~~.proceeding. Any potential loss as a result of this legal proceeding cannot be reasonably estimated. As a result, the Company has not recorded a loss contingency for the aforementioned claim.

Item 4. ~~MINE SAFETY DISCLOSURES~~.

~~Not applicable~~.DISCLOSURES

Not applicable.

PART II

Item 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

Market Information

Our common stock is traded on the Nasdaq Capital Market under the symbol "DOMH". On March 20, 2023 March 26, 2024, the closing price of our common stock, as reported by the Nasdaq Capital Market, was \$3.30,\$2.35.

Holders

As of March 20, 2023 March 26, 2024, we had approximately 135 136 holders of record of our common stock.

Dividend Policy

We have never declared or paid cash dividends on our common stock. We currently do not anticipate paying any cash dividends in the foreseeable future. Any future determination to declare cash dividends will be made at the discretion of our board Board of directors,Directors, subject to applicable laws, and will depend on our financial condition, results of operations, capital requirements, general business conditions and other factors that our board Board of directorsDirectors may deem relevant.

Share Repurchases

Following are We did not purchase any of our monthly share repurchases for registered equity securities during the fourth quarter of fiscal year 2022:quarterly period covered by this Annual Report.

Period	Total Number of Shares Purchased	Average Price Paid Per Share	Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs	Approximate Dollar Value of Shares That May Yet Be Purchased Under the Plans or Programs (In thousands)
October 1, 2022 – October 31, 2022	-	-	-	\$ 2,000
November 1, 2022 – November 30, 2022	-	-	-	2,000
December 1, 2022 – December 31, 2022	18,200	\$ 3.1563	18,200	1,942

All share repurchases were made using cash resources. Our share repurchases may occur through open market purchases or pursuant to a Rule 10b5-1 trading plan. The above table excludes shares repurchased to settle employee tax withholding related to the vesting of stock awards.

Equity Compensation Plan Information

The following table provides information about our common stock that may be issued upon the exercise of options, warrants and rights under all of our existing equity compensation plans as of December 31, 2022 December 31, 2023.

Plan Category	Number of securities to be issued upon exercise of outstanding options, warrants and rights (1)	Weighted average exercise price of outstanding options, warrants and rights	Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (1))(2)	Number of securities to be issued upon exercise of outstanding options, warrants and rights (1)	Weighted average exercise price of outstanding options, warrants and rights	Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (1)) (2)
Equity compensation plans approved by security holder	479,654	\$ 32.35	4,555,144	556,477	\$ 4.94	839,686
Equity compensation plans not approved by security holder	-	-	-	-	-	-
	<u>479,654</u>		<u>4,555,144</u>	<u>556,477</u>		<u>839,686</u>

(1) Consists of options to acquire 24,840 24,454 shares of our common stock under the 2013 Equity Incentive Plan and 454,814 under the 2014 Equity Incentive Plan and 395,714 shares of common stock under the 2022 Equity Incentive Plan, and restricted stock awards to acquire 136,309 shares of common stock under the 2022 Equity Incentive Plan.

(2) Consists of shares of common stock available for future issuance under our equity incentive plan or any other individual compensation arrangement, plans.

Item 6. [RESERVED]

Item 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Forward-Looking Statements

The following Management's Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the Company's consolidated financial statements as of and for the years ended December 31, 2023 and 2022 and the related notes included in Part II, Item 8 of this Annual Report. This discussion contains forward-looking statements, within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, that involve risks and uncertainties. The Company's actual results could differ materially from such forward-looking statements. The Company does not undertake to update, revise or correct any of the forward-looking information unless required to do so under the federal securities laws. Readers are cautioned that such forward-looking statements should be read in conjunction with the Company's disclosures under the heading "Special Cautionary Notice Regarding Forward Looking Statements and Risk Factor Summary" included in this report. Additionally, the Company's historical results are not necessarily indicative of the results that may be expected in any future period. Amounts are presented in U.S. dollars.

You should not place undue reliance on these forward-looking statements. Should one or more of a number of known and unknown risks and uncertainties materialize, or should any of our assumptions prove incorrect, the Company's actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Factors that could cause actual results to differ include, but are not limited to, those identified below and those discussed in Part I, Item 1A "Risk Factors" of this Annual Report:

Forward-Looking Statements Our Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") is provided in addition to the accompanying consolidated financial statements and notes to assist readers in understanding our results of operations, financial condition, and cash flows. The MD&A is organized as follows:

- **Overview.** Discussion of our business and overall analysis of financial and other highlights affecting the Company in order to provide context for the remainder of the MD&A.

You should read this discussion together with the Consolidated Financial Statements, related Notes and other financial information included elsewhere in this Form 10-K. The following discussion contains assumptions, estimates and other forward-looking statements that involve a number of risks and uncertainties. These risks could cause our actual results to differ materially from those anticipated in these forward-looking statements.

- **Critical Accounting Estimate.** Accounting estimates we believe are most important to understanding the assumptions and judgments incorporated in our reported financial results and forecasts.
- **Recently Issued Accounting Pronouncements.** A discussion of recent accounting standards.
- **Results of Operations.** An analysis of our financial results is presented to compare 2023 to 2022. We also provide a discussion of our Liquidity and Capital Resources position and usage.

Overview

Dominari Holdings Inc. (the "Company"), formerly known as Alkido Pharma, Inc., was founded is a holding company that, through its various subsidiaries, is engaged in 1967 as Spherix Incorporated. Since 2017, wealth management, investment banking, sales and trading and asset management. In addition to capital investment, Dominari provides management support to the Company has operated as executive teams of its subsidiaries, helping them to operate efficiently and reduce cost under a biotechnology company with streamlined infrastructure.

Dominari Financial, a diverse portfolio wholly-owned subsidiary of small-molecule anticancer and antiviral therapeutics and their related patent technology. In an effort to enhance shareholder value, Dominari, executes the Company's growth strategy in June of this year, the Company formed a wholly owned financial services subsidiary, industry. In addition to organic growth, Dominari Financial Inc. ("Dominari"), with seeks partnership opportunities and acquisitions of third-party financial assets such as registered investment advisors and businesses, broker dealers, asset management and fintech firms, and insurance brokers. Our first transaction in furtherance of our growth in the intent of shifting the Company's primary operating focus away from biotechnology to the fintech and financial services industries. Through Dominari Holdings, industry, the Company plans to make strategic acquisitions across the fintech and financial services industries.

On September 9, 2022, Dominari entered into a membership interest purchase agreement (the "FPS Purchase Agreement") with Fieldpoint Private Bank & Trust ("Seller"), a Connecticut bank, for the purchase acquisition of its wholly owned subsidiary, Fieldpoint Private Securities, LLC, a Connecticut limited liability company ("FPS"), that is a broker-dealer registered with the Financial Industry Regulatory Authority ("FINRA") and an investment adviser registered with the Securities and Exchange Commission ("SEC"). Pursuant to the terms of the FPS Purchase Agreement, Dominari purchased from the Seller 100% of the membership interests in FPS (the "Membership Interests") a dually-registered broker dealer and investment advisor from Fieldpoint was consummated on March 27, 2023. FPS's The newly acquired dually registered broker-dealer and investment adviser businesses will be operated as was renamed Dominari Securities and is a wholly owned wholly-owned subsidiary of Dominari. The FPS Purchase Agreement provides for Dominari's acquisition of FPS's Membership Interests in two closings, the first of which occurred on October 4, 2022 (the "Initial Closing"), at which Dominari paid to the Seller \$2,000,000 in consideration for a transfer by the Seller to Dominari of 20% of the FPS Membership Interests. Following the Initial Closing, FPS filed a continuing membership application requesting approval for a change of ownership, control, or business operations with FINRA in accordance with FINRA Rule 1017 (the "Rule 1017 Application") which was approved on March 20, 2023. The second closing "Second Closing", occurred on March 27, 2023. Dominari paid the Seller an additional \$1.00 in consideration for the transfer by the Seller to Dominari of the remaining 80% of the Membership Interests. The Second Closing is subject to customary closing conditions, including the accuracy of the representations and warranties of the applicable parties under the FPS Purchase Agreement and compliance therewith. Financial.

Additionally, Aikido Labs, LLC ("Aikido Labs"), another wholly owned subsidiary of the Company, has explored opportunities in high growth industries. To date, Aikido Labs has made equity investments in Anduril Industries, Inc., Databricks, Inc., Discord, Inc., Epic Games, Inc., Payward, Inc. dba Kraken, Space Exploration Technologies Corp. dba SpaceX, Tevva Motors Ltd., Thrasio, LLC, and Yanka Industries, Inc. dba Masterclass. The Company is in the process of winding down its historical pipeline of biotechnology assets consisting held by Aikido Labs, LLC. These biotechnology assets consist of patented technologies technology from leading universities and researchers, including prospective treatments for pancreatic cancer, acute myeloid leukemia, SARS-CoV-2 and acute lymphoblastic leukemia. The Company is also developing a broad-spectrum antiviral platform, in which the lead compounds have activity in cell-based assays against multiple viruses including Influenza virus, Ebolavirus, the Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2, the cause of COVID-19.

Reverse Stock Split

On June 7, 2022, the Company effected a seventeen-for-one (17-for-1) reverse stock split of its class of common stock (the "Reverse Stock Split"). The Reverse Stock Split, which was approved by stockholders at an annual stockholder meeting on May 20, 2022, was consummated pursuant to a Certificate of Amendment filed with the Secretary of State of Delaware on June 2, 2022. The Reverse Stock Split was effective on June 7, 2022. All references to common stock, convertible preferred stock, warrants to purchase common stock, options to purchase common stock, restricted stock units, restricted stock awards, share data, per share data and related information contained in the consolidated financial statements have been retrospectively adjusted to reflect the effect of the Reverse Stock Split for all periods presented. Payment for fractional shares resulting from the reverse stock split amounted to \$26,000.

Critical Accounting Policies Estimates

Stock-Based Compensation

Our critical accounting policies The Company accounts for share-based payment awards exchanged for services at the estimated grant date fair value of the award. Stock options issued under the Company's long-term incentive plans are disclosed granted with an exercise price equal to no less than the market price of the Company's stock at the date of grant and expire up to ten years from the date of grant. These options generally vest over a one- to five-year period.

The Company estimates the fair value of stock option grants using the Black-Scholes ("Black-Scholes") option pricing model. The determination of fair value within Black-Scholes involves a number of significant estimates, judgements and assumptions that may affect the value of employee stock options used in Note 3 the model. These include the expected volatility of our stock and employee exercise behavior which are based on historical data as well as uncertain expectations of future developments over the term of the option. The assumptions used in calculating the fair value of stock-based awards represent management's best estimates and involve inherent uncertainties and the application of management's judgment. The uncertainty of these judgments and assumption could result in significant change in our stock-based compensation expense amounts in the future.

Expected Term - The expected term of options represents the period that the Company's stock-based awards are expected to be outstanding based on the simplified method, which is the half-life from vesting to the end of its contractual term.

Expected Volatility - The Company computes stock price volatility over expected terms based on its historical common stock trading prices.

Risk-Free Interest Rate - The Company bases the risk-free interest rate on the implied yield available on U. S. Treasury zero-coupon issues with an equivalent remaining term.

Expected Dividend - The Company has never declared or paid any cash dividends on its shares of common stock and does not plan to pay cash dividends in the foreseeable future, and, therefore, uses an expected dividend yield of zero in its valuation models.

The Company accounts for forfeitures as they occur.

Fair Value Option - Short-Term Note and Convertible Note

The guidance in ASC 825, *Financial Instruments*, provides a fair value option election that allows entities to make an irrevocable election of fair value as the initial and subsequent measurement attribute for certain eligible financial assets and liabilities. The Company has elected to measure the purchases of its notes using the fair value option at each reporting date. Under the fair value option, bifurcation of an embedded derivative is not necessary, and all related gains and losses on the host contract and derivative due to change in the fair value will be reflected in interest income and other, net in the consolidated statements of operations. Interest accrues on the unpaid principal balance on a quarterly basis and is recognized in interest income in the consolidated statements of operations.

The decision to elect the fair value option is determined on an instrument-by-instrument basis and must be applied to an entire instrument and is irrevocable once elected. Pursuant to this guidance, assets and liabilities are measured at fair value based, in part, on general economic and stock market conditions and those characteristics specific to the underlying investments. The carrying value is adjusted to estimated fair value at the end of each quarter, required to be reported separately in our consolidated balance sheets from those instruments using another accounting method.

Long-Term Investments

Effective January 1, 2018, the Company adopted Accounting Standards Update (“ASU”) 2016-01 and related ASU 2018-03 and ASU 2019-04 concerning recognition and measurement of financial assets and financial liabilities. In adopting this guidance, the Company has made an accounting policy election to adopt an adjusted cost method measurement alternative for investments in equity securities without readily determinable fair values.

For equity investments that are accounted for using the measurement alternative, the Company initially records equity investments at cost but is required to adjust the carrying value of such equity investments through earnings when there is an observable transaction involving the same or a similar investment with the same issuer or upon an impairment. Our investments are valued at \$24 million as of December 31, 2023. In valuing these investments there are judgements and assumptions that may affect the values derived for each security including the determination of a change in value and whether or not there are indicators of an impairment of value. These judgments could impact the estimation uncertainty and the impact of these estimates could have an effect on the financial condition and results of operations. Management’s estimates and assumptions include considerations of industry and market conditions and well as uncertain factors identified specific to each investment that could impact the carrying values.

Effect of new accounting pronouncements not yet adopted

In June 2022, the FASB issued ASU 2022-03, *Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions*, to clarify that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring the fair value of the equity security. ASU 2022-03 also clarifies that an entity cannot recognize and measure a contractual sale restriction as a separate unit of account. The amendments in ASU 2022-03 may be early adopted and are effective on a prospective basis for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. The Company is currently evaluating the impact of the amendments on the Company’s consolidated financial statements, statements and whether it will early adopt the amendments in ASU 2022-03.

Recently Issued Accounting Pronouncements

See Note 3 to the consolidated financial statements for a discussion of recent accounting standards.

Results of Operations

Fiscal Year Ended **December 31, 2022**, **December 31, 2023** Compared to Fiscal Year Ended **December 31, 2021** **December 31, 2022**

The Company did not recognize revenue from operations, nor do we expect to recognize any revenue until our operational transition into the financial services industry is complete.

During the year ended December 31, 2023, we recognized approximately \$2.0 million in revenue from operations, primarily driven by the underwriting revenue earned by Dominari Securities. During the years ended December 31, 2022, December 31, 2023 and 2021, 2022, we incurred a loss from operations of approximately \$14.4 million \$21.8 million and \$9.4 million \$14.3 million, respectively. The approximate \$5.0 million increase in loss in operations was primarily attributable to the following:

- i. An approximate \$4.0 million \$12.2 million increase in general and administrative expenses – driven by approximately \$1.5 million \$0.1 million and \$1.9 million of fully-vested restricted stock grants issued professional fees (legal, consulting, accounting, etc.) incurred to establish and operate Dominari Financial and Dominari Securities, respectively. In addition, the members of the board of directors and approximately \$1.5 million of discretionary bonus expense for employees. We Company also incurred increased compensation expenses of approximately \$1.6 million in legal and accounting advisory fees related \$9.5 million due to our transition into a financial services business, growing operations.
- ii. An approximate \$0.3 million increase \$2.7 million decrease in research and development expenses – attributable to an approximate \$0.3 million increase in expense related the Company's strategic business decision to our previous development of transition away from the biotechnology industry and into financial services. The result is a broad-spectrum antiviral platform, in which the lead compounds have activity in cell-based assays against multiple viruses including the Influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2, the cause of COVID-19; and,
- iii. An approximate increase of \$0.7 million decrease in research and development - license acquired – attributable to an approximate \$1.2 million payment under our license agreement with the University of Maryland ("UM") pursuant to which the UM granted us an exclusive, worldwide, royalty bearing license to certain intellectual property to, among other things, discover, develop, make, have made, use and sell certain licensed products and sell, use and practice certain licensed services with respect to the treatment of cancer. The additional license payment was partially offset related expenses by a decrease, year-over-year, of \$0.5 million related to a one-time recognition of restricted stock expense in 2021 in relation to the license arrangements, almost 100%.

During the year years ended December 31, 2022, December 31, 2023 and 2021, 2022, other (expense) income expenses was approximately \$(7.8) \$(1.1) million and \$2.3 million, \$(7.8) million, respectively. The activity for the years ended December 31, 2022, December 31, 2023 and 2021, 2022, is primarily a result of overall volatility in investment valuations due to macroeconomic uncertainty (i.e. inflation, global tensions in the Ukraine, etc.) impacting marketable securities and the change in fair value of note receivable, and short and long-term investments. Specifically:

- i. Marketable securities – we recognized a loss gain of approximately \$6.0 million \$0.6 million for the year ending December 31, 2022 ended December 31, 2023. The increase decrease of approximately \$6.6 million in losses over the prior year period is a direct result of a decrease in unrealized losses of approximately \$6.0 million, an increase in both realized and unrealized losses on marketable securities dividend income of \$1.3 million and \$1.8 million, respectively, approximately \$0.4 million and a \$1.1 million decrease in related dividend income, realized loss of approximately \$0.2 million. The decreases were driven by both market improvement and a decrease in sale activity resulting in fewer realized losses.

- ii. Note receivable – the changes over the years ended December 31, 2023 and 2022 are a function of observable market transactions which resulted in an increase in unrealized loss of approximately \$3.2 million on the adjusted fair value of the note receivable during the year ended December 31, 2023.
- iii. Short-term and long-term investments – we recognized the changes over the years ended December 31, 2023 and 2022 are a loss function of observable market transactions which resulted in an increase in unrealized gain of approximately \$3.3 million on change in the adjusted fair value of the investments for during the year ending December 31, 2022, of approximately \$2.6 million ended December 31, 2023. The change over prior year is a function of unrealized losses of approximately \$3.8 million on our investments of Kaya Holding Corp. and Nano Innovations Inc. for the year ending December 31, 2022, as compared to approximately \$3.6 million in unrecognized gains on our investments in Kaya Holding Corp. and Kerna Health, Inc. recorded for the year ending December 31, 2021. Further, we also recognized approximately \$0.5 million in net realized losses on our investments in DatChat, Inc., Hoth Therapeutics Inc., and Vicinity Motor Corp and an approximate \$0.9 million realized loss on our conversion of the Slinger Bag, Inc. convertible promissory note into common stock of Connexa Sports Technologies Inc. (formerly Slinger Bag Inc.). The aforementioned losses were driven by increased volatility in the market.

Liquidity and Capital Resources

We continue to incur ongoing administrative and other expenses, including public company expenses. While we continue to implement our business strategy, we intend to finance our activities through:

- managing current cash and cash equivalents on hand from our past debt and equity offerings;
- seeking additional funds raised through the sale of additional securities in the future; and
- seeking additional liquidity through credit facilities or other debt arrangements; and arrangements.

Our ultimate success is dependent on our ability to generate sufficient cash flow to meet our obligations on a timely basis. Our business may require significant amounts of capital to sustain operations that we need to execute our longer-term business plan to support our transition into the financial services industry. Our working capital amounted to approximately \$48.9 million \$26.5 million as of December 31, 2022 December 31, 2023. We believe our cash and cash equivalents and marketable securities, together with the anticipated cash flow from operations will be sufficient to meet our working capital and capital expenditure requirements for at least the next 12 months. In the event that cash flow from operations is not sufficient to fund our operations, as expected, or if our plans or assumptions change, including if inflation begins to have a greater impact on our business or if we decide to move forward with any activities that require more outlays of cash than originally planned, we may need to obtain raise additional capital sooner than expected. We may raise this additional capital by obtaining additional debt or equity financing, especially if we experience downturns in our business that are more severe or longer than anticipated, or if we experience significant increases in expense levels resulting from being a publicly-traded publicly traded company or from continuing operations. If we attempt

Our ability to obtain capital to implement our growth strategy over the longer term will depend on our future operating performance, financial condition and, more broadly, on the availability of equity and debt financing. Capital availability will be affected by prevailing conditions in our industry, the global economy, the global financial markets, and other factors, many of which are beyond our control. Specifically, as a result of recent volatility and weakness in the public markets, due to, among other factors, uncertainty in the global economy and financial markets, it may be much more difficult to raise additional capital, if and when it is needed, unless the public markets become less volatile and stronger at such time that we seek to raise additional capital. In addition, any additional debt or service requirements we take on could be based on higher interest rates and shorter maturities and could impose a significant burden on our results of operations and financial condition, and the issuance of additional equity financing, we cannot assume that such financing will be available securities could result in significant dilution to the Company on favorable terms, or at all, stockholders.

Cash Flows from Operating Activities

For the years ended December 31, 2022, December 31, 2023 and 2021, 2022, net cash used in operations was approximately \$10.6 million \$22.2 million and \$6.6 million \$10.6 million, respectively. The cash used in operating activities for the year ending December 31, 2023, is primarily attributable to a net loss of approximately \$22.9 million, approximately \$1.0 million of unrealized gain on marketable securities, change in fair value of long-term investment of approximately \$0.8 million and changes in operating assets and liabilities of \$5.3 million, partially offset by \$3.0 million stock-based compensation expense, approximately \$3.2 million in unrealized losses on note receivable and approximately \$1.2 million in realized losses on marketable securities. The cash used in operating activities for the year ending December 31, 2022, is primarily attributable to a net loss of approximately \$22.1 million. The net loss was slightly offset by approximately \$4.9 million in unrealized losses on marketable securities, approximately \$2.6 million relating to the change in fair value of short-term investments, approximately \$1.8 million in research and development expense related to acquired licenses, approximately \$1.5 million related to stock-based compensation, and approximately \$1.4 million of realized loss on marketable securities. The cash used in operating activities for the year ended December 31, 2021, is primarily attributable to a net loss of approximately \$7.2 million, further increased by approximately \$3.6 million for a change in fair value of short-term investments, and slightly offset by approximately \$3.1 million in unrealized losses on marketable securities and approximately \$1.1 million in research and development expense related to acquired licenses.

Cash Flows from Investing Activities

For the years ended December 31, 2022, December 31, 2023 and 2021, 2022, net cash used in investing activities was approximately \$14.6 million \$7.2 million and \$8.9 million \$14.6 million, respectively. The cash used in investing activities for the year ended December 31, 2023, primarily resulted from our purchase of marketable securities of approximately \$34.1 million and the acquisition of FPS for approximately \$1.1 million, partially offset by our sale of marketable securities of approximately \$27.6 million and collection of principal on note receivable of approximately \$1.1 million. The cash used in investing activities for the year ended December 31, 2022, primarily resulted from our purchase of marketable securities of approximately \$26.8 million, purchase of investments of approximately \$15.0 million, purchase of research and development licenses of approximately \$1.8 million, and the purchase of promissory notes of approximately \$1.6 million, partially offset by our sale of marketable securities of approximately \$28.7 million since we invest excess cash into marketable securities until additional cash is needed. The cash used in investing activities for the year ended December 31, 2021, primarily resulted from our purchase of marketable securities of approximately \$93.4 million, the purchase of promissory notes of approximately \$6.9 million, purchase of short-term and long-term investments of approximately \$5.7 million, deposits of approximately \$4.2 million and the purchase of convertible notes of approximately \$2.0 million, partially offset by our sale of marketable securities of approximately \$103.0 million.

Cash Flows from Financing Activities

For the year ended December 31, 2023, cash used in financing activities was approximately \$0.9 million, which reflects the cost for the purchase of treasury stock of approximately \$0.9 million. For the year ended December 31, 2022, cash used in financing activities was approximately \$7.2 million, which reflects the cost for redemption of Series O and Series P Redeemable Convertible Preferred Stock of approximately \$22.0 million and cost for purchase of treasury stock of approximately \$3.1 million, partially offset by net proceeds of approximately \$17.9 million from investors in exchange of issuance of Series O and Series P Redeemable Convertible Preferred Stock. For the year ended December 31, 2021, cash provided by financing activities was approximately \$78.2 million, which is primarily attributable to the approximate \$78.2 million from investors in exchange of issuance of common stock and warrants.

Contractual obligations

None.

Item 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

As a smaller reporting company, we are not required to provide the information required by this item.

Item 8. CONSOLIDATED FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

Consolidated financial statements and supplementary data required by this Item 8 follow.

Index to Consolidated Financial Statements

		Page
Report of Independent Registered Public Accounting Firms (PCAOB ID Number 688)	24	F-2
Report of Independent Registered Public Accounting Firms (PCAOB ID Number 100)	25	
Consolidated Balance Sheets as of December 31, 2022 December 31, 2023 and 2021 2022	26	F-3
Consolidated Statements of Operations for the Years Ended December 31, 2022 December 31, 2023 and 2021 2022	27	F-4
Consolidated Statements of Changes in Stockholders' Redeemable Convertible Preferred Stock and Stockholder's Equity for the Years Ended December 31, 2022 December 31, 2023 and 2021 2022	28	F-5
Consolidated Statements of Cash Flows for the Years Ended December 31, 2022 December 31, 2023 and 2021 2022	29	F-6
Notes to the Consolidated Financial Statements	30	F-7

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Shareholders and Board of Directors of
Dominari Holdings Inc.

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheet sheets of Dominari Holdings Inc. and Subsidiaries (the "Company") as of December 31, 2022, December 31, 2023 and 2022, the related consolidated statement statements of operations, changes in redeemable convertible preferred stock and stockholders' equity and cash flows for each of the year two years in the period ended December 31, 2022 December 31, 2023, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022, December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the year two years in the period ended December 31, 2022 December 31, 2023, in conformity with accounting principles generally accepted in the United States of America.

Basis for Opinion

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.

Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.

Critical Audit Matters

The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing separate opinions on the critical audit matter or on the accounts or disclosures to which they relate.

Valuation of investments and notes receivable

Description of the Matter Long-term Investments

As of December 31, 2022, the Company held \$23.1 million of investments measured using an adjusted cost method measurement alternative for investments in equity securities without readily determinable fair values, and \$8.6 million of notes receivable measured using the fair value option at each reporting date. We identified the valuation of these investments and notes receivable as a critical audit matter because of the significant judgement management uses to estimate their value. This is a challenging audit area due to the subjectivity in assessing, for the investments, whether there has been an observable transaction involving the same or a similar investment with the same issuer, or if there has been impairment, and for notes receivable, whether the general economic and stock market conditions and those characteristics specific to the underlying issuer indicate there should be a change in the measurement of fair value.

How we Addressed the Matter in our Audit

Our audit procedures addressing the matter involved (1) obtaining an understanding of management's process for accounting for their investments that do not have readily determinable fair values. (2) We evaluated the characteristics specific to the issuer of notes and general economic and stock market conditions that indicate if there should be a change in the measurement of fair value. (3) We evaluated the accounting conclusions reached by the Company as to whether any observable transactions had occurred that were identical or similar in nature through inspecting the Company's available financial and other information regarding the investments. For the investments and the notes (4) we considered the appropriateness of the Company's application of accounting policy by obtaining and reviewing the Company's analysis and confirming its compliance with accounting principles generally accepted in the United States. (5) We tested the mathematical accuracy of the Company's carrying value calculations and (6) considered whether or not any of the investments or notes should be impaired. (7) We also performed public searches for corroborating or contradictory information. (8) We evaluated the adequacy of the Company's disclosures in the notes to the consolidated financial statements in relation to this matter.

/s/ Marcum LLP

Marcum LLP

We have served as the Company's auditor since 2022.

New York NY

March 31, 2023

Report of Independent Registered Public Accounting Firm

To the Shareholders and the Board of Directors of
Dominari Holdings Inc.
Opinion on the Consolidated Financial Statements

We have audited the accompanying consolidated balance sheet of Dominari Holdings Inc. (formerly Alkido Pharma, Inc.) (the "Company") as of December 31, 2021, the related consolidated statements of operations, changes in stockholders' equity and cash flows, for the year then ended, and the related notes (collectively referred to as the "financial statements"). In our opinion, the consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Company as of December 31, 2021 and the consolidated results of its operations and its cash flows for the year ended December 31, 2021, in conformity with accounting principles generally accepted in the United States of America.

Basis for Opinion

These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's consolidated financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.

Our audit included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audit provides a reasonable basis for our opinion.

Critical Audit Matters

The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that is communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

Valuation of investments in privately-held companies

Description of the Matter

As of December 31, 2021 December 31, 2023, the Company had \$9.5 million \$24.15 million of investments in companies without readily determinable fair values. The Company typically measures these investments at cost less any impairment, adjusted for observable price changes in orderly transactions for an identical or similar investment. We identified the valuation of these investments as a critical audit matter because of the significant judgement management uses to estimate the investment value. This is a challenging audit area due to the subjectivity in assessing whether observable price changes have occurred for investments that are identical or similar to the investment the Company holds, and in assessing whether an investment is impaired.

How The following are the primary procedures we Addressed the Matter in our Audit

Addressing the matter involved obtaining performed to address this critical audit matter. We obtained an understanding of management's process for accounting for their investments that do not have readily determinable fair values. We considered the appropriateness of the Company's application of accounting policy by obtaining and reviewing the Company's analysis and confirming its compliance with accounting principles generally accepted in the United States. We tested the mathematical accuracy of the Company's carrying value calculations and considered whether or not any of the investments should be impaired. calculations. We evaluated the accounting conclusions reached by the Company as to whether any observable transactions had occurred that were identical or similar in nature through reading of the Company's available financial and other information regarding the investee and through public searches for corroborating or contradictory information. Further, we evaluated the appropriateness of the Company's impairment conclusions considering this internal and external information. For certain investments, we utilized our internal valuation group specialists to assess the appropriateness of the valuation methodologies and recompute the valuations derived. We also evaluated the adequacy of the Company's disclosures in Note 7 the notes to the consolidated financial statements in relation to this matter.

/s/WithumSmith+Brown, PC Marcum LLP

We have served as the Company's auditor since 2021. Marcum LLP

New York, New York

March 28, We have served as the Company's auditor since 2022.

PCAOB ID Number 100 New York, NY

April 1, 2024

F-2

DOMINARI HOLDINGS INC.
(Formerly Alkido Pharma, Inc.)
Consolidated Balance Sheets
(\$ in thousands except share and per share amounts)

	December 31, 2022	December 31, 2021	December 31, 2023	December 31, 2022
ASSETS				
Current assets				
Cash and cash equivalents	\$ 33,174	\$ 65,562	\$ 2,833	\$ 33,174
Marketable securities	7,130	11,427	13,547	7,130
Deposits with clearing broker			7,687	-
Prepaid expenses and other assets	564	442	898	564
Prepaid acquisition cost	301	-	-	301
Short-term investments at fair value	13	2,273	-	13
Notes receivable at fair value	7,474	6,984		
Investment deposit	-	4,201		
Investment in FieldPoint Securities	2,000	-		
Notes receivable, at fair value - current portion			3,177	7,474
Investment in Fieldpoint Securities			-	2,000
Total current assets	50,656	90,889	28,142	50,656
Convertible note receivable at fair value	-	2,147		
Notes receivable at fair value	1,100	-		
Property and equipment, net			344	-
Notes receivable, at fair value - non-current portion			1,129	1,100
Investments	23,103	9,465	24,150	23,103
Right-of-use assets	919	-	3,335	919
Security deposit	458	155	458	458
Total assets	\$ 76,236	\$ 102,656	\$ 57,558	\$ 76,236
LIABILITIES AND STOCKHOLDERS' EQUITY				
Current liabilities				
Accounts payable and accrued expenses	\$ 447	\$ 381	\$ 1,036	\$ 447
Accrued salaries and benefits	1,260	680	51	1,260
Accrued commissions			77	-
Lease liability - current	82	-	421	82
Other current liability			22	-
Total current liabilities	1,789	1,061	1,607	1,789
Lease liability	680	-	3,028	680
Total liabilities	2,469	1,061	4,635	2,469
Stockholders' equity				
Preferred stock, \$.0001 par value, 50,000,000 Authorized				
Series D: 5,000,000 shares designated; 3,825 shares issued and outstanding at December 31, 2022 and 2021; liquidation value of \$.0001 per share	-	-		
Series D-1: 5,000,000 shares designated; 834 shares issued and outstanding at December 31, 2022 and 2021; liquidation value of \$.0001 per share	-	-		
Common stock, \$.0001 par value, 100,000,000 shares authorized; 5,485,096 and 5,275,329 shares issued at December 31, 2022 and 2021, respectively; 5,017,079 and 5,275,329 shares outstanding at December 31, 2022 and 2021, respectively	-	-		
Preferred stock, \$.0001 par value, 50,000,000 authorized				
Series D: 5,000,000 shares designated; 3,825 shares issued and outstanding at December 31, 2023 and 2022; liquidation value of \$.0001 per share			-	-
Series D-1: 5,000,000 shares designated; 834 shares issued and outstanding at December 31, 2023 and 2022; liquidation value of \$.0001 per share			-	-
Common stock, \$.0001 par value, 100,000,000 shares authorized; 5,995,065 and 5,485,096 shares issued at December 31, 2023 and 2022, respectively; 5,934,917 and 5,017,079 shares outstanding at December 31, 2023 and 2022, respectively			-	-
Additional paid-in capital	262,970	265,633	262,187	262,970
Treasury stock, at cost, 468,017 and 0 shares at December 31, 2022 and 2021, respectively	(3,322)	(264)		

Treasury stock, at cost, 60,148 and 468,017 shares at December 30, 2023 and December 31, 2022, respectively			(501)	(3,322)
Accumulated deficit	(185,881)	(163,774)	(208,763)	(185,881)
Total stockholders' equity	73,767	101,595	52,923	73,767
Total liabilities and stockholders' equity	\$ 76,236	\$ 102,656	\$ 57,558	\$ 76,236

See accompanying notes to consolidated financial statements.

DOMINARI HOLDINGS INC.
(Formerly Aikido Pharma, Inc.)
Consolidated Statements of Operations
(\$ in thousands except share and per share amounts)

	Years Ended December 31,		Years Ended December 31,	
			2023	2022
			\$	\$
Revenues			2,039	-
	2022	2021		
Operating costs and expenses				
General and administrative	\$ 11,683	\$ 7,734	\$ 23,838	\$ 11,683
Research and development	830	559	3	830
Research and development - license acquired	1,833	1,148	(6)	1,833
Total operating expenses	14,346	9,441	23,835	14,346
Loss from operations	(14,346)	(9,441)	(21,796)	(14,346)
Other (expenses) income				
Other income (expenses)				
Other income	64	135	36	64
Interest income	687	252	716	687
Loss on marketable securities	(5,952)	(1,743)		
Gain (loss) on marketable securities			630	(5,952)
Unrealized loss on note receivable			(3,248)	-
Change in fair value of investments	(2,560)	3,626	780	(2,560)
Total other (expenses) income	(7,761)	2,270		
Total other expenses			(1,086)	(7,761)
Net loss	\$ (22,107)	\$ (7,171)	\$ (22,882)	\$ (22,107)
Deemed dividends related to Series O and Series P Redeemable Convertible Preferred Stock	(4,109)	-	-	(4,109)
Net Loss Attributable to Common Shareholders	\$ (26,216)	\$ (7,171)	\$ (22,882)	\$ (26,216)
Net loss per share, basic and diluted				
Basic and Diluted	\$ (4.91)	\$ (1.48)	\$ (4.38)	\$ (4.91)
Weighted average number of shares outstanding, basic and diluted				
Basic and Diluted	5,334,075	4,846,925	5,229,477	5,334,075

See accompanying notes to consolidated financial statements.

F-4

DOMINARI HOLDINGS INC.
(Formerly Aikido Pharma, Inc.)

Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders' Equity
(\$ in thousands except share and per share amounts)

	Redeemable Convertible Preferred Stock				Additional								Total							
	Series O		Series P		Common Stock		Preferred Stock		Paid-in	Treasury Stock		Accumulated	Stockholders'	Redeemable Convertible Preferred Stock				Preferred Stock		Com
														Series O		Series P				
	Shares	Amount	Shares	Amount	Shares	Amount	Shares	Amount	Capital	Shares	Amount	Deficit	Equity	Shares	Amount	Shares	Amount	Shares	Amount	Shares
Balance at December 31, 2020					2,054,096	\$ -	5,559	\$ -	\$ 186,485	-	\$ (264)	\$ (156,603)	\$ 29,618							
Issuance of common stock and warrants (net of offering costs of \$8,031)					3,170,935	-	-	-	78,219	-	-	-	78,219							
Exercise of warrants					4,705	-	-	-	84	-	-	-	84							
Issuance of common stock for research and development license acquired					36,764	-	-	-	531	-	-	-	531							
Conversion of Series D Preferred stock					112	-	(900)	-	-	-	-	-	-							
Stock-based compensation					8,823	-	-	-	314	-	-	-	314							
Fractional shares adjusted for reverse split					(106)	-	-	-	-	-	-	-	-							
Net loss					-	-	-	-	-	-	-	(7,171)	(7,171)							
Balance at December 31, 2021	-	\$ -	-	\$ -	5,275,329	\$ -	4,659	\$ -	\$ 265,633	-	\$ (264)	\$ (163,774)	\$ 101,595	-	\$ -	-	\$ -	4,659	\$ -	5,275,329
Issuance of Series O redeemable convertible preferred stock for cash	11,000	11,000	-	-	-	-	-	-	-	-	-	-	-	11,000	11,000	-	-	-	-	-
Issuance of Series P redeemable convertible preferred stock for cash	-	-	11,000	11,000	-	-	-	-	-	-	-	-	-	-	-	11,000	11,000	-	-	-
Cost on issuance of Series O and Series P Redeemable Convertible Preferred Stock	-	(1,504)	-	(1,505)	-	-	-	-	-	-	-	-	-	-	(1,504)	-	(1,505)	-	-	-

Deemed dividends related to Series O and Series P Redeemable Convertible Preferred Stock	-	1,504	-	1,505	-	-	-	-	(4,109)	-	-	-	(4,109)	-	1,504	-	1,505	-	-
Redemption of Series O Redeemable Convertible Preferred Stock	(11,000)	(11,000)	-	-	-	-	-	-	-	-	-	-	-	(11,000)	(11,000)	-	-	-	-
Redemption of Series P Redeemable Convertible Preferred Stock	-	-	(11,000)	(11,000)	-	-	-	-	-	-	-	-	-	-	-	(11,000)	(11,000)	-	-
Purchase of treasury stock	-	-	-	-	-	-	-	-	-	468,017	(3,058)	-	(3,058)	-	-	-	-	-	-
Stock-based compensation	-	-	-	-	238,244	-	-	-	1,472	-	-	-	1,472	-	-	-	-	-	238,244
Cancellation of common stock related to investment in CBM	-	-	-	-	(22,812)	-	-	-	-	-	-	-	-	-	-	-	-	-	(22,812)
Fractional shares adjusted for reverse split	-	-	-	-	(5,665)	-	-	-	(26)	-	-	-	(26)	-	-	-	-	-	(5,665)
Net loss	-	-	-	-	-	-	-	-	-	-	-	(22,107)	(22,107)	-	-	-	-	-	-
Balance at December 31, 2022	-	\$ -	-	\$ -	5,485,096	\$ -	4,659	\$ -	\$ 262,970	468,017	\$ (3,322)	\$ (185,881)	\$ 73,767	-	\$ -	-	\$ -	4,659	\$ - 5,485,096
Stock-based compensation	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,179,400
Cancellation of common stock	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	(25,000)
Purchase of treasury stock	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retirement of treasury stock	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	(644,400)
Net loss	-	-	-	-	-	-	-	-	-	-	-	(22,107)	(22,107)	-	-	-	-	-	-
Balance at December 31, 2023	-	\$ -	-	\$ -	-	-	-	-	-	-	-	-	-	-	\$ -	-	\$ -	4,659	\$ - 5,995,000

See accompanying notes to consolidated financial statements.

DOMINARI HOLDINGS INC.
(Formerly Alkido Pharma, Inc.)
Consolidated Statements of Cash Flows
(\$ in thousands)

	Years Ended December 31,		Years Ended December 31,	
	2022	2021	2023	2022
Cash flows from operating activities				
Net loss	\$ (22,107)	\$ (7,171)	\$ (22,882)	\$ (22,107)
Adjustments to reconcile net loss to net cash used in operating activities:				
Amortization of right-of-use assets	(188)	-	359	(188)
Depreciation			83	-
Change in fair value of short-term investment	2,621	(3,626)	13	2,621
Change in fair value of long-term investment	(61)	-	(793)	(61)
Research and development-acquired license, expensed	1,833	1,148	-	1,833
Stock-based compensation	1,472	314	2,977	1,472
Realized loss on marketable securities	1,405	67	1,180	1,405
Unrealized loss on marketable securities	4,867	3,115		
Unrealized (gain) loss on marketable securities			(1,049)	4,867
Unrealized loss on note receivable			3,248	-
Realized gain on receiving shares in exchange of note receivable extension			(36)	
Changes in operating assets and liabilities:				
Prepaid expenses and other assets	(215)	(227)	(406)	(215)
Prepaid acquisition cost	(301)	-	301	(301)
Clearing broker deposits			(4,137)	-
Accounts payable and accrued expenses	66	(186)	376	66
Accrued salaries and benefits	580	370	(1,209)	580
Accrued commissions			52	-
Lease liabilities	31	-	(88)	31
Interest receivable on convertible note	(600)	(252)		
Deposit	-	(155)		
Other current liabilities			(99)	-
Notes receivable, at fair value – net interest accrued			(122)	(600)
Net cash used in operating activities	(10,597)	(6,603)	(22,232)	(10,597)
Cash flows from investing activities				
Purchase of membership interest in FPS	(2,000)	-	-	(2,000)
Purchase of marketable securities	(26,798)	(93,432)	(34,125)	(26,798)
Sale of marketable securities	28,658	103,043	27,574	28,658
Proceeds from sale of digital currencies	93	-	-	93
Proceeds from sale of DatChat common shares	-	900		
Purchase of fixed assets			(427)	-
Acquisition of FPS, net of cash acquired and receivable owed from FPS			(1,112)	-
Return of deposit (funding of deposit) into a managed account, net	3,898	(4,201)	-	3,898
Collection of principal on note receivable			1,102	-
Funds to employee forgivable loan			(107)	-
Purchase of research and development licenses			-	(1,833)
Purchase of short-term and long-term investments	(15,016)	(5,666)	(75)	(15,016)
Purchase of research and development licenses	(1,833)	(617)		
Purchase of short-term and long-term promissory notes	(1,600)	(6,880)	-	(1,600)
Purchase of convertible note	-	(2,000)		
Net cash used in investing activities	(14,598)	(8,853)	(7,170)	(14,598)
Cash flows from financing activities				
Proceeds from issuance of common stock and warrants, net of offering cost	-	78,219		
Proceeds from issuance of Series O and Series P Redeemable Convertible Preferred Stock, net of discount and offering cost	17,891	-	-	17,891
Proceeds from exercise of warrants	-	84		
Payment for fractional shares	(26)	-	-	(26)
Redemption of Series O and Series P Redeemable Convertible Preferred Stock	(22,000)	-	-	(22,000)

Purchase of treasury stock	(3,058)	-	(939)	(3,058)
Net cash (used in) provided by financing activities	(7,193)	78,303		
Net cash used in financing activities			(939)	(7,193)
Net (decrease) increase in cash and cash equivalents and restricted cash	(32,388)	62,847		
Net decrease in cash and cash equivalents and restricted cash			(30,341)	(32,388)
Cash and cash equivalents, beginning of period	65,562	2,715	33,174	65,562
Cash and cash equivalents, end of period	<u>\$ 33,174</u>	<u>\$ 65,562</u>	<u>\$ 2,833</u>	<u>\$ 33,174</u>
Cash paid for interest and taxes			<u>\$ 686</u>	<u>\$ -</u>
Non-cash investing and financing activities				
Transfer from short-term investment to marketable securities	\$ 1,497	\$ -		
Transfer from long-term investment to marketable securities	\$ 1,439			
Receiving shares in exchange of note receivable extension			\$ 179	\$ -
Note receivable principal and interest receivable reduced due to receiving shares			\$ 143	
Transfer from short-term investment to marketable securities			\$ -	\$ 1,497
Reclassify from convertible note receivable to notes receivable at fair value	\$ 2,147	\$ -	\$ -	\$ 2,147
Transfer from long-term investment to marketable securities			\$ -	\$ 1,439
Promissory convertible note receivable conversion into common shares	\$ 899	\$ -	\$ -	\$ 899
On March 27, 2023, the Company acquired all assets and liabilities of FPS as disclosed in Note 4:				
Net assets acquired, net of cash acquired and receivable owed from FPS			\$ 3,112	
Less - Deposit previously transferred in October 2022 to FPS			<u>\$ (2,000)</u>	
Net cash paid			<u>\$ 1,112</u>	

See accompanying notes to consolidated financial statements.

DOMINARI HOLDINGS INC.
(Formerly Alkido Pharma, Inc.)

Notes to Consolidated Financial Statements

Note 1. Organization and Description of Business and Recent Developments

Organization and Description of Business

Dominari Holdings Inc. (the “Company”), formerly Alkido Pharma, Inc., was founded in 1967 as Spherix Incorporated. Since 2017, the Company has operated as a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics and their related patent technology. In an effort to enhance shareholder value, in June of this year, 2022, the Company formed a wholly owned financial services subsidiary, Dominari Financial Inc. (“Dominari” Dominari Financial”), with the intent of shifting the Company’s primary operating focus away from biotechnology to the fintech and financial services industries. Through Dominari Financial, the Company plans to make strategic acquisitions across acquired Dominari Securities LLC (“Dominari Securities”), an introducing broker-dealer, registered with the fintech Financial Industry Regulatory Authority (“FINRA”) and financial an investment adviser registered with the Securities and Exchange Commission (“SEC”). Dominari Securities provides investment advisory services industries, and annuity and insurance products of certain insurance carriers as an insurance agency through independent and affiliated brokers.

On September 9, 2022, Dominari entered into a membership interest purchase agreement, as amended and restated on March 27, 2023 (the “FPS Purchase Agreement”) with Fieldpoint Private Bank & Trust (“Seller”), a Connecticut bank, for the purchase of its wholly owned subsidiary, Fieldpoint Private Securities, LLC, a Connecticut limited liability company (“FPS”), that is a broker-dealer registered with the Financial Industry Regulatory Authority (“FINRA”) and an investment adviser registered with the Securities and Exchange Commission (“SEC”). Pursuant to the terms of the FPS Purchase Agreement, Dominari purchased from the Seller 100% of the membership interests in FPS (the “Membership Interests”). FPS’s registered broker-dealer and investment adviser businesses will be operated as a wholly owned subsidiary of Dominari. The FPS Purchase Agreement provides for Dominari’s acquisition of FPS’s Membership Interests in two closings, the first of which occurred on October 4, 2022 (the “Initial Closing”), at which Dominari paid to the Seller \$2.0 million in consideration for a transfer by the Seller to Dominari of 20% of the FPS Membership Interests. Following the Initial Closing, FPS filed a continuing membership application requesting approval for a change of ownership, control, or business operations with FINRA in accordance with FINRA Rule 1017 (the “Rule 1017 Application”). The Rule 1017 Application was approved by FINRA on March 20, 2023. The second closing (the “Second Closing”) occurred on March 27, 2023. Dominari paid to the Seller an additional \$1.00 \$1.4 million in consideration for a transfer by the Seller to Dominari of the remaining 80% of the Membership Interests. The Second Closing is subject to customary closing conditions, including the accuracy of the representations and warranties of the applicable parties under the FPS Purchase Agreement and compliance therewith.

Additionally, Alkido Labs, LLC (“Alkido Labs”), another wholly owned subsidiary of the Company, has and will continue to explore other opportunities in high growth industries. To date, Alkido Labs has made equity investments in Anduril Industries, Inc., Databricks, Inc., Discord, Inc., Epic Games, Inc., Payward, Inc. dba Kraken, Space Exploration Technologies Corp. dba SpaceX, Tevva Motors Ltd., Thrasio, LLC, and Yanka Industries, Inc. dba Masterclass. Finally, the Company will continue to foster and develop its historical pipeline of biotechnology assets consisting of patented technologies from leading universities and researchers, including prospective treatments for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. The Company is also developing a broad-spectrum antiviral platform, in which the lead compounds have activity in cell-based assays against multiple viruses including Influenza virus, Ebolavirus, the Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2, the cause of COVID-19.

Reverse Stock Split

On June 7, 2022, the Company effected a seventeen-for-one (17-for-1) reverse stock split of its class of common stock (the “Reverse Stock Split”). The Reverse Stock Split, which was approved by stockholders at an annual stockholder meeting on May 20, 2022, was consummated pursuant to a Certificate of Amendment filed with the Secretary of State of Delaware on June 2, 2022. The Reverse Stock Split was effective on June 7, 2022. All references to common stock, convertible preferred stock, warrants to purchase common stock, options to purchase common stock, restricted stock units, restricted stock awards, share data, per share data and related information contained in the consolidated financial statements have been retrospectively adjusted to reflect the effect of the Reverse Stock Split for all periods presented. Payment for fractional shares resulting from the reverse stock split amounted to \$26,000.

Note 2. Liquidity and Capital Resources

The Company continues to incur ongoing administrative and other expenses, including public company expenses, in excess of corresponding (non-financing related) revenue. While the Company continues to implement its business strategy, it intends to finance its activities through managing current cash on hand from the Company’s past equity offerings.

Based upon projected cash flow requirements, the Company has adequate cash and cash equivalents and marketable securities to fund its operations for at least the next twelve months from the date of the issuance of these consolidated financial statements.

DOMINARI HOLDINGS INC.
(Formerly Aikido Pharma, Inc.)

Notes to Consolidated Financial Statements

Note 3. Summary of Significant Accounting Policies

Basis of Presentation and Principles of Consolidation

The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP") for financial information.

Our The Company's policy is to consolidate all entities that we control it controls by ownership of a majority of the membership interest or outstanding voting stock. The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned wholly owned subsidiaries, Aikido Labs, Dominari Financial, and Dominari Securities. All significant intercompany balances and transactions have been eliminated in consolidation.

Use of Estimates

The accompanying consolidated financial statements have been prepared in conformity with US U.S. GAAP. This requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenue and expenses during the period. The Company's significant estimates and assumptions include stock-based compensation, the valuation of investments, the valuation of notes receivable and the valuation allowance related to the Company's deferred tax assets. Certain of the Company's estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company's estimates and could cause actual results to differ from those estimates and assumptions.

Segments

Operating segments are defined as components of an entity for which discrete financial information is available that is regularly reviewed by the Chief Operating Decision Maker ("CODM") in deciding how to allocate resources to an individual segment and in assessing performance. The CODM reviews financial information for the purposes of making operating decisions, allocating resources, and evaluating financial performance of the business of the reportable operating segments, based on discrete financial information. The Company's chief executive officer is the CODM. As The measures of December 31, 2022, segment profitability that are most relied upon by the CODM does not receive or evaluate the business lines separately are gross revenues and therefore the Company currently operates as one segment and, accordingly, no further segment disclosures have been presented herein. net loss.

Concentration of Cash

The Company maintains cash balances at two four financial institutions in checking accounts. From time to time, the Company's cash account balances exceed the balances as covered by the Federal Deposit Insurance System. The Company has never suffered a loss due to such excess balances. As of December 31, 2022 December 31, 2023 and 2021, 2022, the Company had no cash equivalents.

Marketable Securities

Marketable securities are classified as trading and are carried at fair value. The Company's marketable securities consist of highly liquid mutual funds and exchange-traded & closed-end funds which are valued at quoted market prices.

Property and Equipment

Property and equipment are stated at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, which range from three to five years. Property and equipment held under finance leases are amortized on a straight-line basis over the shorter of the lease term or estimated useful life of the asset.

F-8

DOMINARI HOLDINGS INC.
(Formerly Aikido Pharma, Inc.)

Notes to Consolidated Financial Statements

Research and Development

Research and development costs, including acquired in-process research and development expenses for which there is no alternative future use, are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made.

Accounting for Warrants

The Company accounts for the issuance of common stock purchase warrants issued in connection with the equity offerings in accordance with the provisions of Accounting Standards Codification ("ASC") 815, Derivatives and Hedging ("ASC 815"). The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) gives the Company a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement).

DOMINARI HOLDINGS INC.
(Formerly Aikido Pharma, Inc.)

Notes to Consolidated Financial Statements

Stock-based Compensation

The Company accounts for share-based payment awards exchanged for services at the estimated grant date fair value of the award. Stock options issued under the Company's long-term incentive plans are granted with an exercise price equal to no less than the market price of the Company's stock at the date of grant and expire up to ten years from the date of grant. These options generally vest over a one- to five-year period.

The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model and the assumptions used in calculating the fair value of stock-based awards represent management's best estimates and involve inherent uncertainties and the application of management's judgment.

Expected Term - The expected term of options represents the period that the Company's stock-based awards are expected to be outstanding based on the simplified method, which is the half-life from vesting to the end of its contractual term.

Expected Volatility - The Company computes stock price volatility over expected terms based on its historical common stock trading prices.

Risk-Free Interest Rate - The Company bases the risk-free interest rate on the implied yield available on U. S. Treasury zero-coupon issues with an equivalent remaining term.

Expected Dividend - The Company has never declared or paid any cash dividends on its common shares and does not plan to pay cash dividends in the foreseeable future, and, therefore, uses an expected dividend yield of zero in its valuation models.

The Company accounts for forfeitures as they occur.

Fair Value Option - Short-term Note and Convertible Note

The guidance in ASC 825, Financial Instruments, provides a fair value option election that allows entities to make an irrevocable election of fair value as the initial and subsequent measurement attribute for certain eligible financial assets and liabilities. The Company has elected to measure the purchases of its notes using the fair value option at each reporting date. Under the fair value option, bifurcation of an embedded derivative is not necessary, and all related gains and losses on the host contract and derivative due to change in the fair value will be reflected in interest income and other, net in the consolidated statements of operations. Interest accrues on the unpaid principal balance on a quarterly basis and is recognized in interest income in the consolidated statements of operations.

The decision to elect the fair value option is determined on an instrument-by-instrument basis and must be applied to an entire instrument and is irrevocable once elected. Pursuant to this guidance, assets and liabilities are measured at fair value based, in part, on general economic and stock market conditions and those characteristics specific to the underlying investments. The carrying value is adjusted to estimated fair value at the end of each quarter, required to be reported separately in our consolidated balance sheets from those instruments using another accounting **method** **method**.

Long-term investments

Effective January 1, 2018, the Company adopted Accounting Standards Update ("ASU") 2016-01 and related ASU 2018-03 and ASU 2019-04 concerning recognition and measurement of financial assets and financial liabilities. In adopting this guidance, the Company has made an accounting policy election to adopt an adjusted cost method measurement alternative for investments in equity securities without readily determinable fair values. **F-9**

For equity investments that are accounted for using the measurement alternative, the Company initially records equity investments at cost but is required to adjust the carrying value of such equity investments through earnings when there is an observable transaction involving the same or a similar investment with the same issuer or upon an impairment.

DOMINARI HOLDINGS INC.
(Formerly Alkido Pharma, Inc.)

Notes to Consolidated Financial Statements

Investment deposit Deposits with clearing broker

In April 2021, Deposits with Dominari Securities' clearing broker consisted of approximately \$6.7 million held in money market funds and liquid insured deposits maintained by the Company deposited \$5 million with a fund to identify opportunities to expand the Company's investments in Asia. The cash is held, net management expenses, in bank accounts on behalf of the Company until the fund manager identified investments. In October 2022, the Company withdrew and transferred the funds to its marketable securities account. During the period ended October 2022 and the year ended December 31, 2021, the Company incurred legal and advisory fees related to the account of approximately \$8 thousand and \$0.8 million, respectively. Investment deposit was \$0 and \$4.2 million clearing broker as of December 31, 2022 and 2021, respectively, December 31, 2023.

Investment in FPS

Leases

October 4, 2022, the Company completed the first of two closings related the FPS Purchase Agreement, wherein, the Company paid to the Seller \$2.0 million in consideration for a transfer by the Seller to the Company of 20% of the Membership Interests in FPS. The \$2.0 million is held in a bank account as collateral pending the completion of the second closing. Upon completion of the second closing, the \$2.0 million will be released back to the Company. There were no indicators of impairment from date of investment, October 4, 2022, through December 31, 2022. The Investment in FPS was \$2.0 million as of December 31, 2022.

Leases

The Company accounts for its leases under ASC 842, Leases ("ASC 842"). Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the consolidated balance sheet as both a right-of-use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company's incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term. For finance leases, interest on the lease liability and the amortization of the right-of-use asset results in front-loaded expense over the lease term. Variable lease expenses are recorded when incurred. See incurred (see Note 14.11 - Commitment and Contingencies Leases).

Revenue

The Company recognizes revenues under ASC 606 - Revenue from Contracts with Customers ("ASC 606"). Revenues are recognized when control of the promised goods or performance obligations for services is transferred to the Company's customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for the goods or services (see Note 15 - Revenue).

The following provides detailed information on the recognition of the Company's revenues from contracts with customers:

- Underwriting services include underwriting and placement agent services in both the equity and debt capital markets, including private equity placements, initial public offerings, follow-on offerings, and underwriting and distributing public and private debt. Underwriting and placement agent revenues are recognized at a point in time on trade-date, as the client obtains the control and benefit of the underwriting offering at that point. Costs associated with underwriting transactions are deferred until the related revenue is recognized or the engagement is otherwise concluded and are recorded on a gross basis within the general and administrative line item in the consolidated statements of operations as the Company is acting as a principal in the arrangement. Any expenses reimbursed by the Company's clients are recognized as other income.
- Commissions are earned by executing, transactions for clients primarily in equity, equity-related, and debt products. Commission revenues associated with trade execution are recognized at a point in time on trade-date. Commissions revenues are generally paid on settlement date and the Company records receivables to account for timing between trade-date and payment on settlement date.
- Account advisory fees are earned in connection with investment advisory services. Account advisory fees are recognized over time using the time elapsed method as the Company determined that the customer simultaneously receives and consumes the benefits of investment advisory services as they are provided. Account advisory fees are generally paid in advance of a specified service period (e.g. quarterly) and are initially deferred within in our Consolidated Balance Sheet.

Treasury Stock

Treasury stock is recorded at cost and is presented as a reduction of stockholders' equity.

DOMINARI HOLDINGS INC.
(Formerly Alkido Pharma, Inc.)

Notes to Consolidated Financial Statements

Income Taxes

The Company uses the asset and liability method of accounting for income taxes in accordance with ASC 740, "Income Taxes" ("ASC 740"). Under this method, income tax expense is recognized as the amount of: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary difference resulting from matters that have been recognized in the Company's consolidated financial statement or tax returns. Deferred tax assets and liabilities are determined based on the difference between the consolidated financial statement and tax bases of assets and liabilities measured at the enacted tax rates in effect for the year in which these items are expected to reverse. Deferred The Company assesses the likelihood that its deferred tax assets are reduced by valuation allowances if, will be recovered from future taxable income and, to the extent it believes, based on upon the consideration weight of all available evidence, that it is more likely than not that some all or a portion or all of the deferred tax asset assets will not be realized. realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.

As required by the provisions of ASC 740, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more likely than not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. Differences between tax positions taken or expected to be taken in a tax return and the net benefit recognized and measured pursuant to the interpretation are referred to as "unrecognized benefits." A liability is recognized for an unrecognized tax benefit because it represents an enterprise's potential future obligation to the taxing authority for a tax position that was not recognized as a result of applying the provisions of ASC 740. If applicable, interest costs and penalties related to unrecognized tax benefits are required to be calculated and would be classified as interest and penalties in general and administrative expense in the statement of operations.

Long-term investments

On August 16, 2022

Effective January 1, 2018, the Inflation Reduction Act Company adopted Accounting Standards Update ("ASU") 2016-01 and related ASU 2018-03 and ASU 2019-04 concerning recognition and measurement of 2022 was enacted into law financial assets and is effective for taxable years beginning after December 31, 2022, and remains subject to future financial liabilities. In adopting this guidance, releases. This legislation, among other tax law changes, imposes a Corporate Alternative Minimum Tax as well as a 1% excise tax on stock buy-backs. The the Company has not completed its analysis made an accounting policy election to adopt an adjusted cost method measurement alternative for investments in equity securities without readily determinable fair values.

For equity investments that are accounted for using the measurement alternative, the Company initially records equity investments at cost but is required to adjust the carrying value of this legislation, but it such equity investments through earnings when there is not expected to have an observable transaction involving the same or a material impact on similar investment with the Company's tax liability, same issuer or upon an impairment.

Recently adopted accounting standards

Recently Adopted Accounting Standards

In December 2019, October 2021, the Financial Accounting Standards Board ("FASB") FASB issued ASU No. 2019-12, "2021-08, Income Taxes Business Combinations (Topic 740): Simplifying the 805) Accounting for Income Taxes Contract Assets and Contract Liabilities from Contracts with Customers" ("ASU 2019-12" 2021-08"), which is intended. This update amends Topic 805 to simplify various aspects related add contract assets and contract liabilities to accounting for income taxes. ASU 2019-12 removes certain the list of exceptions to the general recognition and measurement principles that apply to business combinations and to require that an entity (acquirer) recognize and measure contract assets and contract liabilities in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, accordance with early adoption permitted. ASC 606. The Company adopted ASU No. 2019-12 effective January 1, 2021, and the adoption did not have a 2021-08 on January 1, 2023. There was no material impact on its to the Company's consolidated financial statements. statements from the implementation of ASU 2021-08.

DOMINARI HOLDINGS INC.
(Formerly Aikido Pharma, Inc.)

Notes to Consolidated Financial Statements

Effect of new accounting pronouncements not yet adopted

In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions, to clarify that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring the fair value of the equity security. ASU 2022-03 also clarifies that an entity cannot recognize and measure a contractual sale restriction as a separate unit of account. The amendments in ASU 2022-03 may be early adopted and are effective on a prospective basis for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. The Company is currently evaluating the impact of the amendments on the Company's consolidated financial statements and whether it will early adopt the amendments in ASU 2022-03.

F-11

DOMINARI HOLDINGS INC.
(Formerly Alkido Pharma, Inc.)

Notes to Consolidated Financial Statements

In March 2023, the FASB issued ASU 2023-01, Leases, to require entities to classify and account for leases with related parties on the basis of legally enforceable terms and conditions of the arrangement. The amendments are effective in periods beginning after December 15, 2023, including interim periods within those fiscal years. The Company is currently evaluating the provisions of the amendments and the impact on its future consolidated financial statements and whether it will early adopt the amendments in ASU 2023-01.

Effect of new accounting pronouncements to be adopted in future periods

WeThe Company reviewed all other recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact on our these consolidated financial statements.

Note 4. FPS Acquisition

On September 9, 2022, Dominari Financial entered into a membership interest purchase agreement, as amended and restated on March 27, 2023 (the "FPS Purchase Agreement") with Fieldpoint Private Bank & Trust ("Seller"), a Connecticut bank, for the purchase of its wholly owned subsidiary, Fieldpoint Private Securities, LLC, a Connecticut limited liability company ("FPS"), that is a broker-dealer registered with FINRA and an investment adviser registered with the SEC (the "FPS Acquisition"). Pursuant to the terms of the FPS Purchase Agreement, Dominari Financial purchased from the Seller 100% of the membership interests in FPS (the "FPS Membership Interests"). FPS's registered broker-dealer and investment adviser businesses were renamed and will operate as Dominari Securities, a wholly owned subsidiary of Dominari Financial. The FPS Purchase Agreement provided for Dominari Financial's acquisition of FPS's Membership Interests in two closings, the first of which occurred on October 4, 2022 (the "Initial Closing"), at which Dominari Financial paid to the Seller \$2.0 million in consideration for a transfer by the Seller to Dominari Financial of 20% of the FPS Membership Interests. Following the Initial Closing, FPS filed a continuing membership application requesting approval for a change of ownership, control, or business operations with FINRA in accordance with FINRA Rule 1017 (the "Rule 1017 Application"). The Rule 1017 Application was approved by FINRA on March 20, 2023. The second closing occurred on March 27, 2023. Dominari Financial paid to the Seller an additional approximate \$1.4 million consideration for a transfer by the Seller to Dominari Financial of the remaining 80% of the FPS Membership Interests.

Consideration Transferred

The FPS Acquisition was accounted for as a business combination under ASC 805.

Under the terms of the FPS Purchase Agreement and subsequent amendments and side letters to the agreement 100% of the FPS Membership Interests were acquired for cash consideration of approximately \$3.4 million, which reflected the fair value of net assets acquired, plus a \$1 purchase price.

Under the acquisition method of accounting, the assets acquired, and liabilities assumed of FPS were recorded as of the acquisition date, at their respective fair values, and consolidated with those of the Company. Acquisition-related costs are not included as a component of consideration transferred but are expensed in the periods in which costs are incurred. The Company incurred approximately \$0.3 million of transaction costs associated with the FPS Acquisition. The transaction costs are included in general and administrative expenses in the consolidated statement of operations.

F-12

Note 4. License agreements

DOMINARI HOLDINGS INC.
(Formerly Alkido Pharma, Inc.)

Notes to Consolidated Financial Statements

Silo Pharma Inc, Fair Value of Net Assets Acquired

Effective January 5, 2021, The following table summarizes the Company entered into an exclusive patent license agreement (the "License Agreement") with Silo Pharma Inc., a Delaware corporation and Silo Pharma Inc., a Florida corporation, and their affiliates/subsidiaries (collectively, "Silo Pharma"). On April 12, 2021, the Company entered into an amendment to the License Agreement, effective as of January 5, 2021, in which 500 shares fair values of the Company's Series M Convertible Preferred Stock were exchanged for 36,764 restricted shares assets acquired and liabilities assumed of FPS at the Company's common stock, par value \$0.001 per share, or approximately \$0.5 million. The Company paid a one-time nonrefundable cash payment date of \$0.5 million to Silo Pharma for the License Agreement. The restricted stock and cash payment were recorded as research and development expense when incurred. The Company paid Silo Pharma a running royalty equal to 2% of "net sales" (as such term is defined acquisition (\$ in the License Agreement). Running royalties are amounts paid to the licensor over time based on the revenue earned by the licensee from sales of products that embody the licensed IP, if any, thousands):

	March 27, 2023 (Unaudited)
ASSETS	
Cash and cash equivalents	\$ 92
Deposits with Clearing Broker-Dealer	3,550
Other receivables	53
Prepaid and other current assets	89
Total assets acquired	3,784
Liabilities	
Accrued expenses	\$ 273
Accrued commissions	25
Wealth management liabilities	62
Total liabilities assumed	360
Total net assets of FPS Acquisition	3,424

University of Maryland

On April 13, 2020, the Company entered into a license agreement with the University of Maryland ("UM") pursuant to which UM granted the Company an exclusive, worldwide, royalty bearing license to certain intellectual property to, among other things, discover, develop, make, have made, use and sell certain licensed products and sell, use and practice certain licensed services with respect to cancer.

During the year ended December 31, 2022, the Company paid approximately \$1.8 million of additional license fees to UM.

Note 5. Investments in Marketable Securities

The realized gain or loss, unrealized gain or loss, and dividend income related to marketable securities for the years ended December 31, 2022, December 31, 2023 and 2021, 2022, which are recorded as a component of gains and (losses) on marketable securities on the consolidated statements of operations, are as follows (\$ in thousands):

	Years Ended December 31,		Years Ended December 31,	
	2022	2021	2023	2022
Realized (loss) gain	\$ (1,405)	\$ (67)		
Unrealized loss	(4,867)	(3,115)		
Realized loss			\$ (1,180)	\$ (1,405)
Unrealized gain (loss)			1,049	(4,867)
Dividend income	320	1,439	762	320
Total	\$ (5,952)	\$ (1,743)	\$ 630	\$ (5,952)

Note 6. Short-term investments

The following table presents the Company's short-term investments as of December 31, 2022, December 31, 2023 and 2021, 2022 (\$ in thousands):

	December 31, 2022	December 31, 2021	December 31, 2023	December 31, 2022
Investment in Hoth Therapeutics, Inc.	-	770		
Investment in DatChat, Inc.	-	1,084		
Investment in Vicinity Motor Corp.	13	419		
Total	13	2,273		
Investment in Vicinity Motor Corp.			-	13
Total			-	13
The change in the fair value of the short-term investments for the year ended December 31, 2023, is summarized as follows: (\$ in thousands):				
Beginning balance		\$ 13		
Change in fair value of short-term investment		(13)		
Ending balance		\$ -		

DOMINARI HOLDINGS INC.
(Formerly Aikido Pharma, Inc.)

Notes to Consolidated Financial Statements

The change in the fair value of the short-term investments for the year ended December 31, 2022, is summarized as follows: (\$ in thousands):

Beginning balance	\$ 2,273
Transfer to marketable securities	(1,497)
Change in fair value of short-term investment	(763)
Ending balance	<u>\$ 13</u>

Investment in Hoth Therapeutics, Inc.

On March 11, 2022, 1,130,701 shares of Hoth common stock were transferred to the marketable securities account and were sold for net proceeds of approximately \$0.9 million.

On August 17, 2022, the remaining 35,714 shares of Hoth common stock were transferred to and subsequently sold from the marketable securities account, resulting in an investment in Hoth of \$0 as of December 31, 2022.

The following table summarizes the Company's investment in Hoth as of December 31, 2021:

Security Name	Shares Owned as of December 31, 2021	Fair value per Share as of December 31, 2021	Fair value as of December 31, 2021 (in thousands)
HOTH	1,166,415	\$ 0.66	\$ 770

Investment in DatChat, Inc.

DatChat, Inc. ("DatChat") is a communications software company that gives users the ability to communicate with privacy and protection.

On August 17, 2021, DatChat closed its initial public offering (the "IPO") at an initial offering price to the public of \$4.15 per share under the ticker DATS. The Company records this investment at fair value and records any change in fair value in the statements of operations (see Note 9).

On September 22, 2021, the Company entered into a Stock Transfer Agreement, by and between the Company and a purchaser, and sold 167,084 shares of DatChat common stock for net proceeds of approximately \$0.9 million.

On February 14, 2022, 357,916 shares of DatChat common stock were transferred to and subsequently sold from the marketable securities account, resulting in an investment in DatChat of \$0 as of December 31, 2022.

The following table summarizes the Company's investment in DatChat as of December 31, 2021:

Security Name	Shares Owned as of December 31, 2021	Fair value per Share as of December 31, 2021	Fair value as of December 31, 2021 (in thousands)
DATS	357,916	\$ 3.03	\$ 1,084

Investment in Vicinity Motor Corp.

On October 25, 2021, the Company entered into a warrant agreement with Vicinity Motor Corp. ("Vicinity") that entitles the Company to purchase up to 246,399 shares of Vicinity common stock at \$5.10 per share. The warrant expires on October 25, 2024. The fair value was determined using a Black-Scholes simulation. The Company recorded the fair value of the Vicinity warrant of approximately \$13,000\$0 and \$0.4 million \$13,000 in the consolidated balance sheet as of December 31, 2022 December 31, 2023 and 2021, 2022, respectively, reflecting the benefit received as part of its purchase of Vicinity common shares stock through its brokerage account. The initial investment in Vicinity was measured at approximately \$0.6 million. Gains or losses associated with changes in the fair value of investments in Vicinity warrants are recognized as Change change in fair value of investment on the consolidated statements of operations. During the year ended December 31, 2022 December 31, 2023, the Company recorded approximately \$0.4 million \$13,000 of change in fair value of investment for this investment.

The following table provides quantitative information regarding Level 3 fair value measurement inputs at their measurement dates:

	December 31, 2023	December 31, 2022
Option term (in years)	0.8	1.8
Volatility	67.2 %	76.90 %
Risk-free interest rate	5.43 %	4.47 %
Expected dividends	0.00 %	0.00 %
Stock price	\$ -	\$ 0.96

Note 7. Long-Term Investments

The Company holds interests in several privately held companies as long-term investments that the Company perceives as potential IPO candidates. The following table presents the Company's long-term investments as of December 31, 2023 and 2022 (\$ in thousands):

	Cost Basis	December 31, 2023	December 31, 2022
Investment in Kerna Health Inc	\$ 2,140	\$ 4,940	\$ 4,940
Investment in Kaya Now	1,500	-	-
Investment in Tevva Motors	1,972	2,794	2,794
Investment in ASP Isotopes	1,300	-	-
Investment in Unusual Machines	1,075	1,033	1,000
Investment in Qxpress*	1,000	1,000	1,000
Investment in Masterclass*	170	170	170
Investment in Kraken*	597	597	597
Investment in Epic Games*	3,500	3,500	3,500
Investment in Tesspay**	1,240	2,679	2,500
Investment in SpaceX*	3,500	4,867	3,674
Investment in Databricks*	1,200	842	1,200
Investment in Discord*	476	476	476
Investment in Thrasio*	300	300	300
Investment in Automation Anywhere*	476	476	476
Investment in Anduril*	476	476	476

Total	\$ 20,922	\$ 24,150	\$ 23,103
--------------	------------------	------------------	------------------

The change in the value of the long-term investments for the year ended December 31, 2023, is summarized as follows: (\$ in thousands):

* Investments made in these companies are through a Special Purpose Vehicle (“SPV”). The SPV is the holder of the actual stock. The Company does not hold these stock certificates directly.

** Investments made in these companies are through both an SPV and direct investments.

Beginning balance	\$ 23,103
Purchase of investments	75
Receiving shares in exchange of note receivable extension	179
Change in fair value of long-term investments	793
Ending balance	<u>\$ 24,150</u>

F-14

DOMINARI HOLDINGS INC.
(Formerly Aikido Pharma, Inc.)

Notes to Consolidated Financial Statements

The following table provides quantitative information regarding Level 3 fair value measurements inputs at their measurement dates: **Note 8. Notes Receivable**

	December 31, 2022	December 31, 2021
Option term (in years)	1.8	2.8
Volatility	76.90 %	95.52 %
Risk-free interest rate	4.47 %	0.97 %
Expected dividends	0.00 %	0.00 %
Stock price	\$ 0.96	\$ 3.50

Note 7. Long-Term Investments

The following table presents the Company's other investments notes receivable as of December 31, 2022, December 31, 2023 and 2021 2022 (\$ in thousands):

	December 31, 2022	December 31, 2021
Investment in Kerna Health Inc	\$ 4,940	\$ 3,800
Investment in Kaya Now	-	1,665
Investment in Tevva Motors	2,794	2,000
Investment in ASP Isotopes	-	1,000
Investment in AerocarveUS Corporation	1,000	1,000
Investment in Qxpress	1,000	-
Investment in Masterclass	170	-
Investment in Kraken	597	-
Investment in Epic Games	3,500	-
Investment in Tesspay	2,500	-
Investment in SpaceX	3,674	-
Investment in Databricks	1,200	-
Investment in Discord	476	-
Investment in Thrasio	300	-
Investment in Automation Anywhere	476	-
Investment in Anduril	476	-
Total	\$ 23,103	\$ 9,465

The change in the value of the long-term investments for the year ended December 31, 2022, is summarized as follows: (\$ in thousands):

Beginning balance	\$ 9,465
Purchase of investments	15,016
Change in fair value of long-term investments	61
Transfer to marketable securities	(1,439)
Ending balance	\$ 23,103

Investment in Kerna Health Inc December 31, 2023

On September 15, 2021, the Company entered into a securities purchase agreement (the "Kerna Securities Purchase Agreement") with Kerna Health Inc., ("Kerna"). Under the Kerna Securities Purchase Agreement, the Company agreed to purchase 1,333,334 shares of common stock of Kerna for \$1.0 million. Kerna, a private company, raised capital during the fourth quarter of 2021, increasing its share price value to \$2.85 per share. Therefore, the Company recorded a \$2.8 million unrealized gain on this investment during the fourth quarter of 2021. The investment in Kerna was valued at \$3.8 million as of December 31, 2021. In May 2022, the Company purchased additional 400,000 shares of common stock of Kerna Health Inc, ("Kerna") for approximately \$1.1 million. The investment in Kerna was valued at \$4.9 million as of December 31, 2022.

	Maturity Date	Stated Interest Rate	Principal Amount	Interest Receivable	Fair Value
Notes receivable, at fair value					
Convergent convertible note - current	12/2/2024	8 %	\$ 1,006	\$ 58	\$ 1,064
Raefan Industries LLC Investment	12/31/2024	8 %	\$ 1,363	\$ 751	\$ 2,114
American Innovative Robotics Investment	04/01/2027	8 %	\$ 1,106	\$ 22	\$ 1,129
Notes receivable, at fair value - current portion					\$ 3,177
Notes receivable, at fair value - non-current portion					\$ 1,129

December 31, 2022

	Maturity Date	Stated Interest Rate	Principal Amount	Interest Receivable	Fair Value
Short-term convertible notes receivable					
Convergent Investment	01/29/2023	8 %	\$ 2,000	\$ 307	\$ 2,307
Short-term notes receivable					
Raefan Industries LLC Investment	6/30/2023	8 %	\$ 4,730	\$ 437	\$ 5,167
Total					\$ 7,474
Long-term notes receivable					
American Innovative Robotics Investment	04/01/2027	8 %	\$ 1,100	-	\$ 1,100

**DOMINARI HOLDINGS INC.
(Formerly Alkido Pharma, Inc.)**

Notes to Consolidated Financial Statements

Convergent Therapeutics, Inc. Investment

The Company's 8% convertible promissory note ("Convergent Convertible Note") issued by Convergent Therapeutics, Inc. ("Convergent") in Kaya Holding Corp. (a.k.a Kaya Now Inc.)

On September 29, 2021, the Company principal amount of approximately \$1.8 million pursuant to a Note Purchase Agreement matured on January 29, 2023. Upon maturity, Convergent entered into a securities purchase agreement (the "Kaya Securities Purchase Agreement") contractual repayment schedule with Kaya Holding Corp., ("Kaya"). Under the Kaya Securities Purchase Agreement, Company. Pursuant to the Company agreed to purchase 8,325,000 shares schedule, Convergent will make a total of common stock eight payments in the amount of Kaya for \$250 thousand and accrued interest, every three months until fully satisfied.

The principal balance of the Convergent Convertible Note was approximately \$0.7 million. Kaya, a private company, raised capital during the fourth quarter \$1.0 and \$2.0 million as of 2021, increasing its share price value to \$0.20 per share. Therefore, the December 31, 2023 and 2022, respectively. The Company recorded an interest income receivable of approximately \$13,000 and \$0.2 million on the Convergent Convertible Note as of December 31, 2023 and 2022, respectively.

The Company recorded principal repayment of \$1.0 million in and \$0, interest receivable repayment of approximately \$0.3 million and \$0, and an unrealized gain on this investment during the fourth quarter note of 2021. The investment in Kaya was valued at approximately \$1.7 million as of December 31, 2021. \$6,000 and \$0 on the Convergent Convertible Note for the years ended December 31, 2023 and 2022, respectively.

Raefan Industries LLC Investment

On March 2, 2022 December 6, 2021, the Company purchased additional 3,375,000 shares an 8% promissory note ("Raefan Industries Promissory Note") issued by Raefan Industries, LLC ("Raefan Industries") in the principal amount of common stock of Kaya Now Inc. approximately \$2.0 million pursuant to a Note Purchase Agreement with Raefan Industries. On December 6, 2022, aka Kaya Holding Corp., ("Kaya" the Company, Raefan Industries and Mr. Jeffrey Cooper entered into a Consolidated, Amended and Restated Promissory Note agreement (the "Raefan Amended Note Agreement") for approximately \$0.6 million.

On July 21, 2022 October 20, 2023, in consideration for extending the maturity date of the Kaya Now Promissory Raefan Amended Note (See Note 8 – Notes Receivable) to February 1, 2023 December 31, 2024, Kaya Raefan Industries agreed to issue and had delivered to the Company 1,000,000 357,143 shares of TessPay at \$0.2 \$0.5 per share of common stock. The Company reduced approximately \$0.1 million of principal and interest receivable balance of Raefan Amended Note and recorded an income of approximately \$35,000 for receiving TessPay shares.

The Company recorded an interest income receivable of approximately \$0.4 million and \$26,000 on the Amended Note as of December 31, 2023 and 2022 and an unrealized loss on the note of approximately \$3.3 million and \$0 for the years ended December 31, 2023 and 2022, respectively.

American Innovative Robotics, LLC Investment

The Company recorded interest income of approximately \$89,000 and \$67,000, and an unrealized gain on the note of approximately \$6,000 and \$0 on the Robotics Promissory Note for the year ended December 31, 2023 and 2022, respectively.

F-16

DOMINARI HOLDINGS INC.
(Formerly Aikido Pharma, Inc.)

Notes to Consolidated Financial Statements

Kaya Now Inc. Investment

During the fourth quarter of 2022, the Company identified indicators of impairment for the Kaya investment as a result of adverse changes in Kaya's business operations, including liquidity concerns. As a result, the Company recorded an impairment charge of approximately \$3.1\$0.5 million in the fourth quarter of 2022. The impairment charge represents an unrealized impairment loss of approximately \$2.5 million in stock, \$0.5 million related to the promissory note (See Note 8 – *Notes Receivable*), and \$50,000 in Kaya warrants (See Note 9 – *Fair Value of Financial Assets and Liabilities*). The investment in Kaya was valued at \$0 as of December 31, 2022.

Investment in Tevva Motors Ltd.

On September 22, 2021, the Company entered into a securities purchase agreement (the "Tevva Motors Subscription Agreement") with Big Sky Opportunities Fund, LLC, who handled the offering for Tevva Motors. Under the Tevva Motors Subscription Agreement, the Company agreed to purchase 29,004 interests of Tevva Motors for approximately \$1.0 million. Subsequently, on September 30, 2021, the Company entered into a second securities purchase agreement with Big Sky Opportunities Fund, LLC to purchase an additional 29,004 interests of Tevva Motors for approximately \$1.0 million. The investment in Tevva was valued at approximately \$2.0 million as of December 31, 2021. Tevva Motors ("Tevva"), a private company, raised capital during the first quarter of 2022, increasing its share price value to \$58.0 per share. Subsequent to the first quarter raise, Tevva had an additional fund raise in the second quarter at a lower valuation of \$48.16 per share. Therefore, the Company recorded a first quarter unrealized gain of approximately \$1.4 million offset by a second quarter unrealized loss of approximately \$0.6 million. The investment in Tevva was valued at approximately \$2.8 million as of December 31, 2022.

Investment in ASP Isotopes Inc.

On November 18, 2021, the Company entered into a securities purchase agreement (the "ASP Securities Purchase Agreement") with ASP Isotopes Inc., ("ASP Isotopes"). Under the ASP Securities Purchase Agreement, the Company agreed to purchase 500,000 shares of common stock of ASP Isotopes for \$1.0 million. The investment in ASP Isotopes was valued at approximately \$1.0 million as of December 31, 2021. In August 2022, the Company purchased additional 100,000 shares of common stock of ASP Isotopes Inc. ("ASP") for \$0.3 million. In November 2022, the Company transferred all 600,000 shares of ASP Isotopes common stock, approximately \$1.4 million, inclusive of a \$0.1 million unrealized gain, to the marketable securities account.

Investment in AerocarveUS Corporation

On November 22, 2021, the Company entered into a securities purchase agreement (the "AerocarveUS Securities Purchase Agreement") with AerocarveUS Corporation, ("AerocarveUS"). Under the AerocarveUS Securities Purchase Agreement, the Company agreed to purchase 250,000 shares of common stock of AerocarveUS for \$1.0 million. The investment in AerocarveUS was valued at approximately \$1.0 million as of December 31, 2021. The investment in AerocarveUS Corporation was valued at \$1.0 million as of December 31, 2022.

Investment in Qxpress

On January 27, 2022, the Company entered into a securities purchase agreement (the "Qxpress Securities Purchase Agreement") with Qxpress. Under the Qxpress Securities Purchase Agreement, the Company agreed to purchase 46,780 shares of common stock of Qxpress for \$1.0 million. The investment in Qxpress was valued at \$1.0 million as of December 31, 2022.

**DOMINARI HOLDINGS INC.
(Formerly Aikido Pharma, Inc.)**

Notes to Consolidated Financial Statements

Investment in Masterclass (a.k.a. Yanka Industries Inc.)

In March of 2022, the Company entered into a securities purchase agreement (the “Masterclass Securities Purchase Agreement”) with Masterclass. Under the Masterclass Securities Purchase Agreement, the Company agreed to purchase 4,841 shares of common stock of Masterclass for approximately \$0.2 million. Although there was also a private fund raise in the second quarter, the per share amount approximated the fair value of the Company’s investment in Masterclass, resulting in no unrealized gain or loss. The investment in Masterclass was valued at approximately \$0.2 million as of December 31, 2022.

Investment in Kraken (a.k.a. Payward, Inc.)

In March of 2022, the Company entered into a securities purchase agreement (the “Kraken Securities Purchase Agreement”) with Kraken. Under the Kraken Securities Purchase Agreement, the Company agreed to purchase a total of 8,409 shares of common stock of Kraken for approximately \$0.5 million. In August 2022, the Company entered into a common stock transfer agreement with a private seller to purchase 3,723 shares of Kraken for approximately \$0.1 million. The investment in Kraken was valued at approximately \$0.6 million as of December 31, 2022.

Investment in Epic Games, Inc.

On March 22, 2022, the Company entered into a securities purchase agreement (the “Epic Games Securities Purchase Agreement”) with Epic Games. Under the Epic Games Securities Purchase Agreement, the Company agreed to purchase an aggregate of 901 shares of common stock of Epic Games for a total \$1.5 million. In April 2022, the Company invested an additional \$2 million for the purchase of additional shares of common stock of Epic Games. Although there was also a fund raise in April, the per share amount approximated the fair value of the Company’s investment in Epic Games, resulting in no unrealized gain or loss. The investment in Epic Games was valued at \$3.5 million as of December 31, 2022.

Investment in TESSPAY Inc.

On March 23, 2022, the Company entered into a securities purchase agreement (the “Tesspay Securities Purchase Agreement”) with Tesspay. Under the Tesspay Securities Purchase Agreement, the Company agreed to purchase 1,000,000 shares of common stock of Tesspay for approximately \$0.2 million. The Company also invested an additional \$1.0 million for pre-IPO. Tesspay, a private company, raised capital during the first quarter of 2022, increasing its share price value to \$0.25 per share. Therefore, the Company recorded \$10,000 in unrealized gain on this investment during the first quarter of 2022. Subsequent to the first quarter raise, Tesspay had an additional fund raise in the fourth quarter at \$0.50 per share, resulting in an additional unrealized gain of approximately \$1.3 million. The investment in Tesspay was valued at approximately \$2.5 million as of December 31, 2022.

Investment in SpaceX (a.k.a. Space Exploration Technologies Corp.)

On March 30, 2022, the Company entered into a securities purchase agreement (the “SpaceX Securities Purchase Agreement”) with SpaceX, under which the company agreed to purchase shares of common stock of SpaceX for \$1.5 million. In April 2022, the Company invested an additional \$2.0 million for the purchase of additional shares of common stock of SpaceX. The Company identified a private fund raise on January 3, 2023. Given the proximity to the December 31, 2022 valuation date, the value of the fund raise was used as a proxy for the fair valuation of the Company’s investment in SpaceX as of December 31, 2022. The per share price of SpaceX’s recent fund raise resulted in an unrealized gain of approximately \$0.6 million. The investment in SpaceX was valued at approximately \$3.7 million as of December 31, 2022.

Investment in Databricks, Inc.

On March 25, 2022, the Company entered into a securities purchase agreement (the “Databricks Securities Purchase Agreement”) with Databricks. Under the Databricks Securities Purchase Agreement, the Company agreed to purchase an aggregate of 3,830 shares of common stock of Databricks for a total \$1.2 million. The investment in Databricks was valued at \$1.2 million as of December 31, 2022.

Investment in Discord Inc.

In May 2022, the Company entered into a securities purchase agreement (the “Discord Securities Purchase Agreement”) with privately-held company Discord, Inc., a social communications platform provider that is particularly popular with gamers, as one of the Company’s pursuits of potentially high growth interests with near term monetization events. Under the Discord Securities Purchase Agreement, the Company agreed to purchase a total of 618 shares of common stock of Discord for approximately \$0.5 million. The investment in Discord was valued at \$0.5 million as of December 31, 2022.

DOMINARI HOLDINGS INC.
(Formerly Aikido Pharma, Inc.)

Notes to Consolidated Financial Statements

Investment in Thrasio Holdings, Inc.

In April 2022, the Company entered into a securities purchase agreement (the “Thrasio Securities Purchase Agreement”) with privately-held company Thrasio, LLC, an aggregator of private brands of top Amazon businesses and direct-to-consumer brands, as one of the Company’s pursuits of potentially high growth interests with near term monetization events. Under the Thrasio Securities Purchase Agreement, the Company agreed to purchase a total of 20,000 shares of common stock of Thrasio for \$0.3 million. The investment in Thrasio was valued at \$0.3 million as of December 31, 2022.

Investment in Automation Anywhere, Inc.

In April 2022, the Company entered into a securities purchase agreement (the “Automation Anywhere Securities Purchase Agreement”) with privately-held company Automation Anywhere, Inc., a provider of business automation solutions, as one of the Company’s pursuits of potentially high growth interests with near term monetization events. Under the Automation Anywhere Securities Purchase Agreement, the Company agreed to purchase a total of 18,490 shares of common stock of Automation Anywhere for approximately \$0.5 million. The investment in Automation Anywhere was valued at \$0.5 million as of December 31, 2022.

Investment in Anduril Industries, Inc.

In April 2022, the Company entered into a securities purchase agreement (the “Anduril Securities Purchase Agreement”) with privately-held company Anduril Industries, Inc., a defense products company, as one of the Company’s pursuits of potentially high growth interests with near term monetization events. Under the Anduril Securities Purchase Agreement, the Company agreed to purchase a total of 14,880 shares of common stock of Anduril for approximately \$0.5 million. The investment in Anduril was valued at \$0.5 million as of December 31, 2022.

Note 8. Notes Receivable

The following table presents the Company’s notes receivable as of December 31, 2022 and 2021 (\$ in thousands):

December 31, 2022

	<u>Maturity Date</u>	<u>Stated Interest Rate</u>	<u>Principal Amount</u>	<u>Interest Receivable</u>	<u>Fair Value</u>
Shor-term convertible notes receivable					
Convergent Investment	01/29/2023	8 %	\$ 2,000	\$ 307	\$ 2,307
Short-term notes receivable					
Raefan Industries LLC Investment	6/30/2023	8 %	\$ 4,730	\$ 437	\$ 5,167
Total					<u>\$ 7,474</u>
Long-term notes receivable					
American Innovative Robotics Investment	04/01/2027	8 %	\$ 1,100	\$ -	\$ 1,100

December 31, 2021

	<u>Maturity Date</u>	<u>Stated Interest Rate</u>	<u>Interest Receivable</u>	<u>Fair Value</u>
Shor-term convertible notes receivable				
Slinger Bag Inc Investment	08/06/2022	8 %	\$ 45	\$ 1,445
Nano Innovations Inc Investment	12/26/2022	10 %	\$ 1	\$ 751
Short-term notes receivable				
Raefan Group LLC Investment	10/13/2022	8 %	\$ 48	\$ 2,828
Raefan Industries LLC Investment	12/06/2022	8 %	\$ 11	\$ 1,961
Long-term convertible note receivable				
Convergent Investment	01/29/2023	8 %	\$ 147	\$ 2,147

Convergent Therapeutics, Inc. Investment

On January 29, 2021, the Company purchased an 8% convertible promissory note (“Convergent Convertible Note”) issued by Convergent Therapeutics, Inc. (“Convergent”) in the principal amount of \$2.0 million pursuant to a Note Purchase Agreement with Convergent. The Company paid a purchase price for the Convergent Convertible Note of \$2 million. The Company will receive interest on the Convergent Convertible Note at the rate of 8% per annum payable upon conversion or maturity of the Convergent Convertible Note. The Convergent Convertible Note shall mature on January 29, 2023.

DOMINARI HOLDINGS INC.
(Formerly Aikido Pharma, Inc.)

Notes to Consolidated Financial Statements

The Company recorded an interest income receivable of approximately \$0.2 million and \$0.1 million on the Convergent Convertible Note as of December 31, 2022 and 2021, respectively.

Mr. Jeffrey Cooper Investment

On October 13, 2021, the Company purchased an 8% promissory note ("Raefan Group Promissory Note") issued by Raefan Group, LLC ("Raefan Group") in the principal amount of approximately \$2.8 million pursuant to a Note Purchase Agreement with Raefan Group. The Company will receive interest on the Raefan Group Promissory Note at the rate of 8% per annum payable upon conversion or maturity of the Raefan Group Promissory Note. The Raefan Group Promissory Note shall mature on October 13, 2022.

Raefan Group LLC promissory note was satisfied and replaced with a personal note issued to Mr. Jeffrey Cooper, of Raefan Industries. The Mr. Jeffrey Cooper Promissory Note shall mature on March 11, 2023.

On December 6, 2022, Mr. Jeffrey Cooper agreed to amend the original promissory note. See Raefan Industries LLC Investment described below.

The Company recorded an interest income receivable of approximately \$0.2 million on the Mr. Jeffrey Cooper Promissory Note as of December 6, 2022.

The Company recorded an interest income receivable of approximately \$48,000 on the Raefan Group Promissory Note as of December 31, 2021.

Raefan Industries LLC Investment

On December 6, 2021, the Company purchased an 8% promissory note ("Raefan Industries Promissory Note") issued by Raefan Industries, LLC ("Raefan Industries") in the principal amount of approximately \$2.0 million pursuant to a Note Purchase Agreement with Raefan Industries. The Company paid a purchase price for the Raefan Industries Promissory Note of approximately \$2.0 million. The Company will receive interest on the Raefan Industries Promissory Note at the rate of 8% per annum payable upon conversion or maturity of the Raefan Industries Promissory Note. The Raefan Industries Promissory Note shall mature on December 6, 2022.

The Company recorded an interest income receivable of approximately \$0.1 million on the Raefan Industries Promissory Note as of December 6, 2022.

The Company recorded an interest income receivable of approximately \$11,000 on the Raefan Industries Promissory Note as of December 31, 2021.

On December 6, 2022, the Company, Raefan Industries and Mr. Jeffrey Cooper entered into a Consolidated, Amended and Restated Promissory Note agreement (the "Raefan Amended Note Agreement"). Pursuant to the Raefan Amended Note Agreement, Raefan Industries and Mr. Jeffrey Cooper agreed to consolidate, amend, restate and replace (i) Raefan Industries Promissory Note dated December 6, 2021 in the principal amount of approximately \$2.0 million and (ii) Mr. Jeffrey Cooper Promissory Note dated March 11, 2022 issued by Mr. Jeffrey Cooper in the principal amount of approximately \$2.8 million with Raefan Amended Note in the principal amount of approximately \$4.8 million. All accrued and unpaid interest due under the original notes prior to December 6, 2022 remain due and payable accordance with the terms of this Amended Note. The Company will receive interest on the Raefan Amended Note at the rate of 8% per annum payable upon conversion or maturity of the Raefan Amended Note. The Raefan Amended Note shall mature on September 30, 2023.

The Company recorded an interest income receivable of approximately \$26,000 on the with Raefan Amended Note as of December 31, 2022.

Slinger Bag Inc. (a.k.a, Connexa Sports Technologies Inc.) Investment

On August 6, 2021, the Company entered into a securities purchase agreement (the "Slinger Bag Securities Purchase Agreement") with Slinger Bag Inc., ("Slinger Bag"). Under the Slinger Bag Securities Purchase Agreement, the Company purchased an 8% convertible promissory note ("Slinger Bag Convertible Note") in the principal amount of \$1.4 million and a common stock purchase warrant to purchase up to 933,333 shares of common stock of Slinger Bag. The Company paid a purchase price of \$1.4 million for the Slinger Bag Convertible Note and the common stock purchase warrant. The Company will receive interest on the Slinger Bag Convertible Note at the rate of 8% per annum payable upon conversion or maturity of the Slinger Bag Convertible Note. The Slinger Bag Convertible Note shall mature on August 6, 2022.

DOMINARI HOLDINGS INC.
(Formerly Aikido Pharma, Inc.)

Notes to Consolidated Financial Statements

The Company recorded an interest income receivable of approximately \$45,000 on the Slinger Bag Convertible Note as of December 31, 2021.

The Company recorded an interest income receivable of approximately \$63,000 on the Slinger Bag Convertible Note as of June 17, 2022. On June 17, 2022, the Company received 558,659 shares of common stock of Connexa Sports Technologies Inc. as a result of conversion of principal and accrued interest on the Slinger Bag Convertible Note. All the 558,659 shares of common stock of Connexa Sports received were transferred to marketable securities account.

Nano Innovations Inc. Investment

On December 26, 2021, the Company entered into a securities purchase agreement (the "Nano Securities Purchase Agreement") with Nano Innovations Inc., ("Nano"). Under the Nano Securities Purchase Agreement, the Company purchased a 10% senior secured convertible promissory note ("Nano Convertible Note") in the principal amount of \$750,000 and warrants permitting the Company to purchase an amount of Nano's common voting shares equal to 50% of the number of common shares issuable upon the conversion of Nano Convertible Note. The Company paid a purchase price of \$750,000 for the Nano Convertible Note and the common stock purchase warrants. The Company will receive interest on the Nano Convertible Note at the rate of 10% per annum payable upon conversion or maturity of the Nano Convertible Note. The Nano Convertible Note shall mature on December 26, 2022.

During the fourth quarter of 2022, the Company identified indicators of impairment for the Nano investment as a result of adverse changes in Nano's business operations, including liquidity concerns. As a result, the Company recorded an impairment charge in the fourth quarter of 2022 of \$750,000, which represents an impairment loss on the total investment held. The investment in Nano was valued at \$0 as of December 31, 2022. The Company recorded an interest income receivable of approximately \$0 and \$1,000 on the Nano Convertible Note as of December 31, 2022, and 2021, respectively.

Kaya Now Inc. Investment

On April 5, 2022, the Company purchased an 8% promissory note ("Kaya Now Promissory Note") issued by Kaya Now Inc. ("Kaya") in the principal amount of \$0.5 million pursuant to a Note Purchase Agreement with Kaya Now. The Company paid a purchase price for the Kaya Now Promissory Note of \$0.5 million. The Company will receive interest on the Kaya Now Promissory Note at the rate of 8% per annum payable upon conversion or maturity of the Kaya Now Promissory Note. The Kaya Now Promissory Note shall mature on February 1, 2023.

On July 21, 2022, the Company and Kaya executed an amendment of the Kaya Now Promissory Note ("Kaya Amendment") such that the Kaya Now Promissory Note shall mature on February 1, 2023. In consideration of the Kaya Amendment, Kaya has agreed to issue to the Company 1,000,000 additional shares at \$0.2 per share of Kaya's common stock. Under the Kaya Amendment, interest on the Note during the extended term shall be paid on October 1, 2022 and January 1, 2023 at the rate of 8% per annum.

During the fourth quarter of 2022, the Company identified indicators of impairment for the Kaya investment as a result of adverse changes in Kaya's business operations, including liquidity concerns. As a result, the Company recorded an impairment charge of \$0.5 million in the fourth quarter of 2022. The impairment charge represents an impairment loss of the total investment held as a promissory note resulting in a \$0 balance for the Kaya Now Promissory Note as of December 31, 2022, December 31, 2023 and 2022.

The Company received and recorded interest income related to the Kaya Now Promissory Note of approximately \$20,000 \$10,000 for the year ending December 31, 2022 ended December 31, 2023.

American Innovative Robotics, LLC Investment

On April 1, 2022, the Company purchased an 8% promissory note ("Robotics Promissory Note") issued by American Innovative Robotics, LLC ("Robotics") in the principal amount of \$1.1 million pursuant to a Note Purchase Agreement with Robotics. The Company paid a purchase price for the Robotics Promissory Note of \$1.1 million. The Company will receive interest on the Robotics Promissory Note at the rate of 8% per annum payable every three months starting from July 1, 2022. The Robotics Promissory Note shall mature on April 1, 2027.

The Company recorded an interest income of approximately \$67,000 on the Robotics Promissory Note as of December 31, 2022.

DOMINARI HOLDINGS INC.
(Formerly Aikido Pharma, Inc.)

Notes to Consolidated Financial Statements

Note 9. Fair Value of Financial Assets and Liabilities

Financial instruments, including cash and cash equivalents, accounts payable and accrued liabilities are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. The Company measures the fair value of financial assets and liabilities based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value.

The Company uses three levels of inputs that may be used to measure fair value:

Level 1 - quoted prices in active markets for identical assets or liabilities

Level 2 - quoted prices for similar assets and liabilities in active markets or inputs that are observable

Level 3 - inputs that are unobservable (for example, cash flow modeling inputs based on assumptions)

Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company's market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment.

The following table presents the Company's assets and liabilities that are measured at fair value as of December 31, 2022 and 2021 (\$ in thousands):

	Fair value measured as of December 31, 2022			
	Total at December 31, 2022	Quoted prices in active markets (Level 1)	Significant other observable inputs (Level 2)	Significant unobservable inputs (Level 3)
Assets				
Marketable securities:				
Equities	\$ 7,130	\$ 7,130	\$ -	\$ -
Total marketable securities	\$ 7,130	\$ 7,130	\$ -	\$ -
Short-term investment	\$ 13	\$ -	\$ -	\$ 13
Short-term notes receivable at fair value	\$ 7,474	\$ -	\$ -	\$ 7,474
Long-term notes receivable at fair value	\$ 1,100	\$ -	\$ -	\$ 1,100

F-17

	Fair value measured as of December 31, 2021			
	Total at December 31, 2021	Quoted prices in active markets (Level 1)	Significant other observable inputs (Level 2)	Significant unobservable inputs (Level 3)
Assets				
Marketable securities:				
Equities	\$ 11,427	\$ 11,427	\$ -	\$ -
Total marketable securities	\$ 11,427	\$ 11,427	\$ -	\$ -
Short-term investment	\$ 2,273	\$ 1,854	\$ -	\$ 419
Notes receivable at fair value	\$ 6,984	\$ -	\$ -	\$ 6,984
Convertible note receivable at fair value	\$ 2,147	\$ -	\$ -	\$ 2,147

DOMINARI HOLDINGS INC.
(Formerly Aikido Pharma, Inc.)

Notes to Consolidated Financial Statements

The following table presents the Company's assets and liabilities that are measured at fair value as of December 31, 2023 and 2022 (\$ in thousands):

Fair value measured as of December 31, 2023				
	Total at December 31, 2023	Quoted prices in active markets (Level 1)	Significant other observable inputs (Level 2)	Significant unobservable inputs (Level 3)
Assets				
Marketable securities:				
Equities	\$ 13,547	\$ 13,547	\$ -	\$ -
Total marketable securities	\$ 13,547	\$ 13,547	\$ -	\$ -
Short-term investment	\$ -	\$ -	\$ -	\$ -
Notes receivable at fair value, current portion	\$ 3,177	\$ -	\$ -	\$ 3,177
Notes receivable at fair value, non-current portion	\$ 1,129	\$ -	\$ -	\$ 1,129
Fair value measured as of December 31, 2022				
	Total at December 31, 2022	Quoted prices in active markets (Level 1)	Significant other observable inputs (Level 2)	Significant unobservable inputs (Level 3)
Assets				
Marketable securities:				
Equities	\$ 7,130	\$ 7,130	\$ -	\$ -
Total marketable securities	\$ 7,130	\$ 7,130	\$ -	\$ -
Short-term investment	\$ 13	\$ -	\$ -	\$ 13
Notes receivable at fair value, current portion	\$ 7,474	\$ -	\$ -	\$ 7,474
Notes receivable at fair value, non-current portion	\$ 1,100	\$ -	\$ -	\$ 1,100

F-18

DOMINARI HOLDINGS INC.
(Formerly Aikido Pharma, Inc.)

Notes to Consolidated Financial Statements

Level 3 Measurement

The following table sets forth a summary of the changes in the fair value of the Company's Level 3 financial assets that are measured at fair value on a recurring basis (\$ in thousands):

	Fair Value of Level 3 short-term investment	
	December 31, 2022	December 31, 2021
Beginning balance	\$ 419	\$ -
Change in fair value of investment	(406)	419
Ending balance	<u>\$ 13</u>	<u>\$ 419</u>
Short-term investment at December 31, 2021		\$ 419
Change in fair value of investment		(406)
Short-term investment at December 31, 2022		<u>\$ 13</u>
Change in fair value of investment		(13)
Short-term investment at December 31, 2023		<u>\$ -</u>

	Fair Value of Level 3 Notes receivable at fair value		
	December 31, 2022	December 31, 2021	
Beginning balance	\$ 6,984	\$ -	
Notes receivable at fair value, current portion at December 31, 2021			\$ 6,984
Accrued interest receivable	600	104	600
Reclassify from convertible note receivable to notes receivable at fair value	2,147	-	2,147
Purchase of notes receivable	500	6,880	500
Change in fair value of short-term investment	(1,858)	-	(1,858)
Conversion of note receivable to marketable securities	(899)	-	(899)
Ending balance	<u>\$ 7,474</u>	<u>\$ 6,984</u>	
Notes receivable at fair value, current portion at December 31, 2022			\$ 7,474
Collection of principal outstanding			(1,000)
Unrealized loss on note receivable			(3,254)
Principle reduced due to receiving shares			(143)
Accrued interest receivable			100
Notes receivable at fair value, current portion at December 31, 2023			<u>\$ 3,177</u>

	Fair Value of Level 3 Convertible note receivable	
	December 31, 2022	December 31, 2021
Beginning balance	\$ 2,147	\$ -
Purchase of notes receivable	-	2,000
Reclassification to notes receivable at fair value	(2,147)	-
Accrued interest receivable	-	147
Ending balance	<u>\$ -</u>	<u>\$ 2,147</u>

	Fair Value of Level 3 Long-term notes receivable at fair value	
	December 31, 2022	December 31, 2021
Beginning balance	\$ -	
Purchase of notes receivable	1,100	
Ending balance	<u>\$ 1,100</u>	

Notes receivable at fair value, non-current portion at December 31, 2021	\$ -
Purchase of notes receivable	1,100
Notes receivable at fair value, non-current portion at December 31, 2022	<u>\$ 1,100</u>
Unrealized gain on note receivable	6
Accrued interest receivable	23
Notes receivable at fair value, non-current portion at December 31, 2023	<u>\$ 1,129</u>

DOMINARI HOLDINGS INC.
(Formerly Aikido Pharma, Inc.)

Notes to Consolidated Financial Statements

Short-term Note Receivable and Convertible Notes Receivable at fair value

Convergent Therapeutics, Inc. Investment

As of **December 31, 2022** **December 31, 2023**, the fair value of the **Convergent Convertible Note notes receivable** was measured **at \$2.3 million**, taking into consideration cost of the investment, market participant inputs, market conditions, liquidity, operating results and other qualitative and quantitative factors. **No change in fair value**

Note 10. Property and Equipment

Property and equipment, net, consists of the following as of December 31, 2023 and 2022:

	Estimated Useful Lives	December 31, 2023	December 31, 2022
Leasehold improvements	Shorter of the remaining lease term or estimated useful life	\$ 50	\$ -
Machinery, equipment and computer software	1 to 15 years	169	-
Furniture and fixtures	3 to 5 years	208	-
Total		<u>\$ 427</u>	<u>\$ -</u>
Less: Accumulated depreciation and amortization		(83)	-
Total property and equipment, net		<u><u>\$ 344</u></u>	<u><u>\$ -</u></u>

Depreciation expense was recorded \$83,000 and \$0 during the year years ended **December 31, 2022**.

December 31, 2023 and 2022, respectively.

DOMINARI HOLDINGS INC.
(Formerly Aikido Pharma, Inc.)

Notes to Consolidated Financial Statements

RaeFan Industries LLC Investment **Note 11. Leases**

As of December 31, 2022, the fair value of the RaeFan Industries Promissory Note was measured at approximately \$5.2 million, taking into consideration cost of the investment, market participant inputs, market conditions, liquidity, operating results and other qualitative and quantitative factors. No change in fair value was recorded during the year ended December 31, 2022.

Slinger Bag Inc. Investment

The Company recorded an interest income receivable of approximately \$63,000 on the Slinger Bag Convertible Note as of June 17, 2022. On June 17, 2022, the Company received 558,659 shares of common stock of Connexa Sports Technologies Inc (also known as Slinger Bag) as a result of conversion of principal and accrued interest on the Slinger Bag Convertible Note. All the 558,659 shares of common stock of Connexa Sports received were transferred to marketable securities account.

As of December 31, 2022, the fair value of the Slinger Bag Convertible Note was \$0.

Nano Innovations Inc. Investment

During the fourth quarter of 2022, the Company identified indicators of impairment for the Nano Convertible Note as a result of adverse changes in Nano's business operations, including liquidity concerns. As a result, the Company recorded an impairment charge in the fourth quarter of 2022 resulting in a \$0 fair value for the Nano Convertible Note as of December 31, 2022.

Kaya Now Inc. Investment

On July 21, 2022, the Company and Kaya executed an amendment of the Kaya Now Promissory Note ("Amendment") such that the Kaya Now Promissory Note shall mature on February 1, 2023. In consideration of the Amendment, Kaya has agreed to issue to the Company 1,000,000 additional shares at 20 cents per share of Kaya's common stock. Under the amendment, interest on the Note during the extended term shall be paid on October 1, 2022 and January 1, 2023 at the rate of 8% per annum.

During the fourth quarter of 2022, the Company identified indicators of impairment for the Kaya investment as a result of adverse changes in Kaya's business operations, including liquidity concerns. As a result, the Company recorded an impairment charge in the fourth quarter of 2022 of \$0.5 million, which represents an unrealized loss on the total investment held. The investment in Kaya was valued at \$0 as of December 31, 2022.

American Innovative Robotics LLC Investment

As of December 31, 2022, the fair value of the Robotics Promissory Note was measured at \$1.1 million, taking into consideration cost of the investment, market participant inputs, market conditions, liquidity, operating results and other qualitative and quantitative factors. No change in fair value for principal was recorded during the year ended December 31, 2022.

Note 10. Leases

On December 1, 2021, the Company entered into a Lease Agreement (the "Company's Lease") with Trump Tower Commercial LLC, a New York limited liability company. Under the Company's Lease, the Company will rent rents a portion of the twenty-second floor at 725 Fifth Avenue, New York, New York (the "22nd Floor Premises"). The Company plans to use currently uses the 22nd Floor Premises to run its day-to-day operations. The initial term of the Company's Lease is seven (7) years commencing on July 11, 2022 ("Commencement Date"). Under the Company's Lease, the Company will is required to pay monthly rent, commencing on January 11, 2023, equal to \$12,874. Effective for the sixth and seventh years of the Company's Lease, the rent shall increase to \$13,502. The Company took possession of the 22nd Floor Premises on the Commencement Date.

On September 23, 2022, Dominari Financial entered into a Lease Agreement ("Dominari's Dominari Financial's Lease") with Trump Tower Commercial LLC, a New York limited liability company. Under Dominari's Dominari Financial's Lease, Dominari will rent Financial rents a portion of a floor at 725 Fifth Avenue, New York, New York (the "Premises"). Dominari plans to use Financial currently uses the Premises to run its day-to-day operations. The initial term of Dominari's Dominari Financial's Lease is seven (7) years commencing on the date that possession of the Premises is delivered to Dominari. February 1, 2023. Under Dominari's Dominari Financial's Lease, Dominari will Financial is required to pay monthly rent equal to \$49,368. Effective for the sixth and seventh years of Dominari's Dominari Financial's Lease, the rent shall increase to \$51,868 per month. The Company has taken possession of the Premises in February 2023.

F-20

DOMINARI HOLDINGS INC.
(Formerly Aikido Pharma, Inc.)

Notes to Consolidated Financial Statements

The tables below represent the Company's lease assets and liabilities as of December 31, 2022:

	December 31, 2022
Assets:	
Operating lease right-of-use-assets	\$ 919
Liabilities:	
Current	
Operating	82
Long-term	
Operating	680
	<u>\$ 762</u>

The following tables summarize quantitative information about the Company's operating leases, under the adoption of ASC 842:

	December 31, 2022
Weighted-average remaining lease term - operating leases (in years)	7.1
Weighted-average discount rate - operating leases	10.0 %

During the year ended December 31, 2022, the Company recorded approximately \$0.1 million as lease expense to current period operations.

	Year Ended December 31, 2022
Operating leases	
Operating lease cost	\$ 73
Variable lease cost	-
Operating lease expense	<u>73</u>
Short-term lease rent expense	67
Net rent expense	<u>\$ 140</u>

Supplemental cash flow information related to leases were as follows:

	Year Ended December 31, 2022
Operating cash flows - operating leases	\$ 231
Right-of-use assets obtained in exchange for operating lease liabilities	\$ 960
As of December 31, 2022, future minimum payments during the next five years and thereafter are as follows:	
	Operating Leases
Remaining Period Ended December 31, 2023	\$ 154
Year Ended December 31, 2024	154
Year Ended December 31, 2025	142
Year Ended December 31, 2026	142
Year Ended December 31, 2027	142
Thereafter	337
Total	1,071
Less present value discount	(309)
Operating lease liabilities	<u>\$ 762</u>

DOMINARI HOLDINGS INC.
(Formerly Aikido Pharma, Inc.)

Notes to Consolidated Financial Statements

The tables below represent the Company's lease assets and liabilities as of December 31, 2023 and 2022:

	<u>December 31, 2023</u>	<u>December 31, 2022</u>
Assets:		
Operating lease right-of-use-assets	\$ 3,335	\$ 919
Liabilities:		
Current		
Operating	421	82
Long-term		
Operating	3,028	680
	<u>\$ 3,449</u>	<u>\$ 762</u>

The following tables summarize quantitative information about the Company's operating leases, under the adoption of ASC 842:

	<u>December 31, 2023</u>	<u>December 31, 2022</u>
Weighted-average remaining lease term – operating leases (in years)	6.5	7.1
Weighted-average discount rate – operating leases	10.0 %	10.0 %

During the years ended December 31, 2023 and 2022, the Company recorded approximately \$0.8 million and 0.1 million of lease expense to current period operations.

	<u>Year Ended December 31, 2023</u>	<u>Year Ended December 31, 2022</u>
Operating leases		
Operating lease cost	\$ 668	\$ 73
Operating lease expense	668	73
Short-term lease rent expense	105	67
Net rent expense	<u>\$ 773</u>	<u>\$ 140</u>

Supplemental cash flow information related to leases were as follows:

	<u>Year Ended December 31, 2023</u>	<u>Year Ended December 31, 2022</u>
Operating cash flows - operating leases	\$ 396	\$ 231
Right-of-use assets obtained in exchange for operating lease liabilities	\$ 2,780	\$ 960

As of December 31, 2023, future minimum payments during the next five years and thereafter are as follows:

	<u>Operating Leases</u>
	\$
Year Ended December 31, 2024	747
Year Ended December 31, 2025	685
Year Ended December 31, 2026	685
Year Ended December 31, 2027	685
Year Ended December 31, 2028	766
Thereafter	<u>1,160</u>
Total	4,728
Less present value discount	<u>(1,279)</u>
Operating lease liabilities	<u>\$ 3,449</u>

DOMINARI HOLDINGS INC.
(Formerly Aikido Pharma, Inc.)

Notes to Consolidated Financial Statements

Note 11, 12. Net Loss per Share

Basic loss per share of common share stock is computed by dividing the net loss allocable to common stockholders by the weighted-average number of shares of common stock or common stock equivalents outstanding. Diluted loss per common share is computed similar to basic loss per share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock. Securities that could potentially dilute loss per share in the future that were not included in the computation of diluted loss per share as of December 31, 2022 for the years ended December 31, 2023, and 2021 2022 are as follows:

	As of December 31,		As of December 31,	
	2022	2021	2023	2022
Convertible preferred stock	34	34	34	34
Warrants to purchase common stock	444,796	341,268	444,796	444,796
Restricted stock awards			136,309	-
Options to purchase common stock	54,722	28,203	420,168	54,722
Total	499,552	369,505	1,001,307	499,552

Note 12, 13. Redeemable Convertible Preferred Stock

Series O and Series P Redeemable Convertible Preferred Stock

On February 24, 2022, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional investors (the “Investors”), pursuant to which the Company agreed to issue and sell, in concurrent registered direct offerings (the “Offerings”), (i) 11,000 shares of the Company’s Series O Redeemable Convertible Preferred Stock, par value \$0.001 per share (the “Series O Preferred Stock”), and (ii) 11,000 shares of the Company’s Series P Redeemable Convertible Preferred Stock, par value \$0.001 per share (the “Series P Preferred Stock” and together with the Series O Preferred Stock, the “Preferred Stock”), in each case, at an offering price of \$952.38 per share, representing a 5% original issue discount to the stated value of \$1,000 per share of Preferred Stock, for gross proceeds of each Offering of \$10,476,180, or approximately \$21.0 million in the aggregate for the Offerings, before the deduction of the placement agent’s fee and offering expenses. The shares of Series O Preferred Stock will have a stated value of \$1,000 per share and will be convertible, at a conversion price of \$1.00 per share, into 11,000,000 shares of common stock (subject in certain circumstances to adjustments). The shares of Series P Preferred Stock will have a stated value of \$1,000 per share and will be convertible, at a conversion price of \$1.00 per share, into 11,000,000 shares of common stock (subject in certain circumstances to adjustments). The Series O Preferred Stock and the Series P Preferred Stock are being offered by the Company pursuant to a registration statement on Form S-3 (File No. 333-238172) (the “Registration Statement”) filed under the Securities Act of 1933, as amended (the “Securities Act”). The Purchase Agreement contains customary representations, warranties and agreements by the Company and customary conditions to closing. The closing of the Offerings occurred on March 2, 2022. In connection with this transaction, the Company received net proceeds of \$21.0 million, which was deposited in an escrow account.

In connection with the Offerings, the Company has entered into an engagement agreement (the “Engagement Agreement”) with H.C. Wainwright & Company, LLC, as placement agent (“HCW”), pursuant to which the Company agreed to pay HCW an aggregate cash fee equal to 8% of the aggregate gross proceeds raised in the offerings and issue HCW common stock purchase warrants to purchase up to 103,528 shares of common stock in the aggregate at an exercise price of \$21.25. The warrants were recorded as a component of stockholders’ equity in accordance with ASC 815.

F-22

DOMINARI HOLDINGS INC.
(Formerly Aikido Pharma, Inc.)

Notes to Consolidated Financial Statements

Redemption Rights

After (i) the earlier of (1) the receipt of stockholder approval and (2) the date that is 90 days following the Original Issue Date (the date of the first issuance of any shares of the Preferred Stock regardless of the number of transfers of any particular shares of Preferred Stock and regardless of the number of certificates which may be issued to evidence such Preferred Stock) and (ii) before the date that is 120 days after the Original Issue Date (the "Redemption Period"), each Holder shall have the right to cause the Company to redeem all or part of such Holder's shares of Preferred Stock at a price per share equal to 105% of the Stated Value.

As a result, the Preferred Stock were recorded separately from stockholders' equity because they are redeemable upon the occurrence of redemption events that are considered not solely within the Company's control.

During the second quarter of 2022, the Company redeemed for cash at a price equal to 105% of the \$1,000 stated value per share all of its 11,000 outstanding shares of Series O Preferred Stock and its 11,000 Series P Preferred Stock. The total redemption amount was \$23.1 million. As a result, all shares of the Series O Preferred Stock and Series P Preferred Stock have been retired and are no longer outstanding.

DOMINARI HOLDINGS INC.
(Formerly Aikido Pharma, Inc.)

Notes to Consolidated Financial Statements

During the year ended December 31, 2022, December 31, 2023 and 2022, the Company recognized approximately \$0 and \$4.1 million in deemed dividends related to the Preferred Stock in the consolidated statements of operations and the consolidated statements of changes in redeemable preferred stock and stockholders' equity, respectively.

Note 13, 14, Stockholders' Equity and Convertible Preferred Stock

Common Stock

Public Offering

On February 19, 2021 March 6, 2023, the Company consummated the public offering pursuant to an amended and restated underwriting agreement (the "Underwriting Agreement") with H.C. Wainwright & Co., LLC, as representative to the underwriters named therein (the "Underwriter"), pursuant to which the Company agreed to issue and sell to the Underwriter in an underwritten public offering (the "Offering") an aggregate of 2,757,352 cancelled 644,499 shares (the "Shares") of common stock \$0.0001 par value per share, as a result of retirement of 644,499 shares of treasury stock. On March 20, 2023, the Company (the "Common Stock"). The Company received gross proceeds of approximately \$75 million before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. On February 23, 2021, the Underwriter partially exercised its over-allotment option and purchased an additional 413,583 Shares, resulting in aggregate proceeds of approximately \$86.2 million, before deducting underwriting discounts and commissions and other expenses. The total net proceeds received from these two offerings were approximately \$78.2 million.

In connection with the Offering, the Company issued the Underwriter warrants (the "Underwriter's Warrants") to purchase up to 253,674 cancelled 25,000 shares of Common Stock, or 8% of the Shares sold in the Offering. The Underwriter's Warrants will be exercisable for a period of five years from February 19, 2021 at common stock owned by an exercise price of \$34.00 per share, subject to adjustment, executive.

Treasury Stock

On January 21, 2022, the Company's board of directors authorized a share buyback program (the "Share Buyback Program"), pursuant to which the Company authorized the Share Buyback Program in an amount of up to three million dollars. During the year ended December 31, 2023, the Company repurchased 236,630 shares at a cost of approximately \$0.9 million or \$3.97 per share through marketable securities account under the Share Buyback Program. During the year ended December 31, 2022, the Company repurchased 468,017 shares at a cost of approximately \$3.1 million or \$6.53 per share through marketable securities account under the Share Buyback Program. The Company records treasury stock using the cost method.

On March 6, 2023, the Company retired 644,499 shares of treasury stock with original cost of approximately \$3.8 million.

Preferred Stock

Series D Convertible Preferred Stock

In connection with the acquisition of North South's patent portfolio in September 2013, the Company issued 1,379,685 shares of its Series D Convertible Preferred Stock ("Series D Preferred Stock") to the stockholders of North South. Each share of Series D Preferred Stock has a stated value of \$0.0001 per share and is convertible into 10 over 1,373 of a share of Common Stock. Upon the liquidation, dissolution or winding up of the Company's business, each holder of Series D Preferred Stock shall be entitled to receive, for each share of Series D Preferred Stock held, a preferential amount in cash equal to the greater of (i) the stated value or (ii) the amount the holder would receive as a holder of Common Stock on an "as converted" basis. Each holder of Series D Preferred Stock shall be entitled to vote on all matters submitted to its stockholders and shall be entitled to such number of votes equal to the number of shares of Common Stock such shares of Series D Preferred Stock are convertible into at such time, taking into account the beneficial ownership limitations set forth in the governing Certificate of Designation and the conversion limitations described below. The conversion ratio of the Series D Preferred Stock is subject to adjustment in the event of stock splits, stock dividends, combination of shares and similar recapitalization transactions.

On December 21, 2021, the Company issued 112 shares of common stock upon the conversion of 900 shares of Series D Convertible Preferred stock.

As of December 31, 2022, December 31, 2023 and 2021, 2022, 5,000,000 Series D Preferred Stock was designated; 3,825 and 3,825 shares remained issued and outstanding, respectively, outstanding.

DOMINARI HOLDINGS INC.
(Formerly Aikido Pharma, Inc.)

Notes to Consolidated Financial Statements

Series D-1 Convertible Preferred Stock

The Company's Series D-1 Convertible Preferred Stock ("Series D-1 Preferred Stock") was established on November 22, 2013. Each share of Series D-1 Preferred Stock has a stated value of \$0.0001 per share and is convertible into 10 over 1,373 of a share of Common Stock. Upon the liquidation, dissolution or winding up of the Company's business, each holder of Series D-1 Preferred Stock shall be entitled to receive, for each share of Series D-1 Preferred Stock held, a preferential amount in cash equal to the greater of (i) the stated value or (ii) the amount the holder would receive as a holder of Common Stock on an "as converted" basis. Each holder of Series D-1 Preferred Stock shall be entitled to vote on all matters submitted to the Company's stockholders and shall be entitled to such number of votes equal to the number of shares of Common Stock such shares of Series D-1 Preferred Stock are convertible into at such time, taking into account the beneficial ownership limitations set forth in the governing Certificate of Designation. The conversion ratio of the Series D-1 Preferred Stock is subject to adjustment in the event of stock splits, stock dividends, combination of shares and similar recapitalization transactions. The Company commenced an exchange with holders of Series D Convertible Preferred Stock pursuant to which the holders of the Company's outstanding shares of Series D Preferred Stock acquired in the Merger could exchange such shares for shares of the Company's Series D-1 Preferred Stock on a one-for-one basis.

As of **December 31, 2022**, **December 31, 2023** and **2021, 2022**, 5,000,000 Series D-1 Preferred Stock was designated; 834 and 834 shares remained issued and outstanding.

Warrants

A summary of warrant activity for year years ended **December 31, 2022**, **December 31, 2023** and **2021, 2022** is presented below:

	Warrants	Weighted Average Exercise Price	Total Intrinsic Value	Weighted Average Remaining Contractual Life (in years)
Outstanding as of December 31, 2021	341,268	\$ 31.68	-	3.87
Issued	103,528	21.25	-	4.15
Outstanding as of December 31, 2022	444,796	\$ 29.25	-	3.20
Outstanding as of December 31, 2023	444,796	\$ 29.25	-	2.20

	Warrants	Weighted Average Exercise Price	Total Intrinsic Value	Weighted Average Remaining Contractual Life (in years)
Outstanding as of December 31, 2020	101,347	\$ 52.26	57,333	1.11
Issued	253,670	34.00	-	4.14
Exercised	(4,705)	17.85	-	-
Expired	(9,044)	334.51	-	-
Outstanding as of December 31, 2021	341,268	\$ 31.68	-	3.87
Issued	103,528	21.25	-	4.15
Outstanding as of December 31, 2022	444,796	\$ 29.25	-	3.20

Confirmation of Mutual Understanding - In March 2022, pursuant to a Confirmation of Mutual Understanding (the "Confirmation"), all parties to the Confirmation acknowledged and confirmed a scrivener's error set forth in warrants to purchase shares of the Company's common stock (the "Warrants") dated March 10, 2020, April 15, 2020 and March 2, 2021. Pursuant to the Confirmation, all parties, which were involved in the original execution of the warrants, agreed that clause (v) of the definition of Fundamental Transaction in Section 3(d) of the Warrants, is as follows: "the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than 50% of the voting power of the Company's outstanding equity securities, including with respect to the election of directors (not including any shares of Common Stock held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business combination)".

DOMINARI HOLDINGS INC.
(Formerly Aikido Pharma, Inc.)

Notes to Consolidated Financial Statements

Restricted Stock Awards

Pursuant to June 27, 2023, pursuant to Soo Yu's employment agreement and the January 5, 2021, License Agreement, Company's 2022 Equity Incentive Plan, the Company issued and delivered to Silo Pharma 36,764 shares of the Company's common stock. Upon issuance, the license shares were fully vested and nonforfeitable with a total fair value of approximately \$2.7 million. Pursuant to the Grant Agreement, the Company withheld 503,876 of the Silo Pharma patents. This restricted stock award vested immediately. shares granted to satisfy Soo Yu's tax obligation of approximately \$1.3 million and recorded as income taxes withheld within the consolidated balance sheet. See Restricted Stock roll-forward below.

On July 31, 2021 December 19, 2023, pursuant to Soo Yu's employment agreement and the Company's 2022 Equity Incentive Plan, the Company executed a Grant Agreement, through which Soo Yu was granted 1,287,129 shares of the Company's common stock. Upon issuance, the shares were fully vested and nonforfeitable with a total fair value of approximately \$2.6 million. Pursuant to the Grant Agreement, the Company withheld 657,079 of the shares granted to satisfy Soo Yu's tax obligation of approximately \$1.3 million and recorded as income taxes withheld within the consolidated balance sheet. See Restricted Stock roll-forward below.

December 19, 2023, pursuant to the Company's 2022 Equity Incentive Plan, the Company executed a Grant Agreement, through which Joshua Shipley was granted 33,003 shares of the Company's common stock. Upon issuance, the shares were fully vested and nonforfeitable with a total fair value of approximately \$67,000. Pursuant to the Grant Agreement, the Company withheld 13,300 of the shares granted to satisfy Soo Yu's tax obligation of approximately \$27,000 and recorded as income taxes withheld within the consolidated balance sheet. See Restricted Stock roll-forward below.

During the year ended December 31, 2023, the Company also issued each an aggregate of its six directors 1,470 136,309 shares of the Company's common stock pursuant to members of the Company's 2014 Equity Incentive Plan. These shares have a total fair value Board of approximately \$0.1 million. These restricted stock awards vested immediately. Directors and an employee for services rendered.

DOMINARI HOLDINGS INC.
(Formerly Aikido Pharma, Inc.)

Notes to Consolidated Financial Statements

During the year ended December 31, 2022, the Company issued an aggregate of 238,244 shares of the Company's common stock to members of the Company's Board of Directors and an employee for services rendered.

A summary of restricted stock awards activity for the year years ended December 31, 2022, December 31, 2023 and 2022, is presented below:

	Number of Restricted Stock Awards	Weighted Average Grant Day Fair Value	Number of Restricted Stock Awards	Weighted Average Grant Day Fair Value
Nonvested at December 31, 2021	-	\$ -	-	\$ -
Granted	238,244	6.13	238,244	6.13
Vested	(230,176)	6.15	(230,176)	6.14
Nonvested at December 31, 2022	8,068	\$ 5.64	8,068	\$ 5.90
Granted			1,315,777	\$ 2.27
Vested			(1,187,536)	2.30
Nonvested at December 31, 2023			136,309	\$ 2.26

As of December 31, 2022, approximately \$300 of unrecognized stock-based compensation expense was related to restricted stock awards. The weighted average remaining contractual terms of unvested restricted stock awards was approximately 0.01 year as of December 31, 2022.

Stock Options

A summary of option activity under the Company's stock option plan for year ended December 31, 2022 and 2021 is presented below:

	Number of Shares	Weighted Average Exercise Price	Total Intrinsic Value	Weighted Average Remaining Contractual Life (in years)
Outstanding as of December 31, 2020	22,591	\$ 680.79	\$ 68,996	8.9
Employee options granted	5,882	21.08	-	9.1
Employee options expired	(270)	-	-	-
Outstanding as of December 31, 2021	28,203	\$ 548.35	\$ -	8.2
Employee options granted	170,587	5.95	-	0.3
Employee options forfeited	(167,381)	41.90	-	-
Employee options expired	(216)	73.70	-	-
Outstanding as of December 31, 2022	31,193	\$ 302.97	\$ -	7.9
Options vested and exercisable	25,311	\$ 372.00	\$ -	7.6

The fair value of options granted in 2022 and 2021 was estimated using the following assumptions:

	For the Years Ended December 31,	
	2022	2021
Exercise price	\$ 5.95	\$ 21.08
Term (years)	10.00	10.00
Expected stock price volatility	117.0 %	124.1 %
Risk-free rate of interest	2.92 %	0.45 %

Stock-based compensation associated with the amortization of restricted stock option awards expense was \$13,000 approximately \$2.7 million and \$0.2 million \$1.4 million for the years ended December 31, 2022 December 31, 2023, and 2021, 2022, respectively. All stock compensation was recorded as a component of general and administrative expenses.

Estimated future As of December 31, 2023, there is approximately \$0.2 million unrecognized stock-based compensation expense relating related to unvested restricted stock options is approximately \$76,000, awards.

2014 Plan and Option Grants

On November 17, 2020, the Board of Directors approved to amend 2014 Equity Incentive Plan to increase the number of shares of common stock authorized to be issued pursuant to the 2014 Plan from 14,314 to 294,117 shares. F-25

At December 31, 2022, there were 25,537 shares available for grant under the 2014 Equity Incentive Plan.

DOMINARI HOLDINGS INC.
(Formerly Aikido Pharma, Inc.)

Notes to Consolidated Financial Statements

Stock Options

A summary of option activity under the Company's stock option plan for year ended December 31, 2023 and 2022 is presented below:

	Number of Shares	Weighted Average Exercise Price	Total Intrinsic Value	Weighted Average Remaining Contractual Life (in years)
Outstanding as of December 31, 2021	28,203	\$ 548.35	\$ -	8.2
Employee options granted	170,587	5.95	-	0.3
Employee options forfeited	(167,381)	41.90	-	-
Employee options expired	(216)	73.70	-	-
Outstanding as of December 31, 2022	31,193	\$ 302.97	\$ -	7.9
Employee options granted	395,714	3.42	-	9.4
Employee options forfeited	(5,882)	5.95	-	-
Employee options expired	(857)	\$ 9,719.07	-	-
Outstanding as of December 31, 2023	420,168	\$ 5.80	\$ -	9.3
Options vested and exercisable	84,929	\$ 15.16	\$ -	8.8

Stock-based compensation associated with the amortization of stock option expense was approximately \$0.2 million and \$13,000 for the years ended December 31, 2023, and 2022, respectively. All stock compensation was recorded as a component of general and administrative expenses.

Estimated future stock-based compensation expense relating to unvested stock options is approximately \$0.5 million.

Note 14, 15. Revenue

The following table presents our total revenues disaggregated by revenue type for the years ended December 31, 2023, and 2022 (in thousands):

	Years Ended December 31,	
	2023	2022
Underwriting	\$ 594	\$ -
Commissions	1,096	-
Advisory fees	209	-
Other	140	-
Total	\$ 2,039	\$ -

Note 16. Commitments and Contingencies

Legal Proceedings

In March 2024, the Company received a notice of petition of a filed action seeking relief related to the March 2024 affiliates of new registered representatives. This notice was filed against the Company's subsidiary Dominari Securities. The Company does not agree with the claim of the plaintiff and will defend itself accordingly. While the Company intends to defend itself vigorously from this claim, it is unable to predict the outcome of such legal proceeding. Any potential loss as a result of this legal proceeding cannot be reasonably estimated. As a result, the Company has not recorded a loss contingency for the aforementioned claim.

In the past, in the ordinary course of business, the Company actively pursued legal remedies to enforce its intellectual property rights and to stop unauthorized use of our the Company's technology. Other than as described above and ordinary routine litigation incidental to the business, we know the Company is not aware of no any material, active or pending legal proceedings brought against us. it.

DOMINARI HOLDINGS INC.
(Formerly Aikido Pharma, Inc.)

Notes to Consolidated Financial Statements

Note 15, 17. Income Taxes

The income tax provision consists of the following (\$ in thousands):

	For the years ended December 31,		For the years ended December 31,	
	2022	2021	2023	2022
Federal				
Current	\$ -	\$ -	\$ -	\$ -
Deferred	(3,618)	(1,581)	(3,820)	(3,618)
Increase in valuation allowance	3,618	1,581	3,820	3,618
State and local				
Current				
Deferred	(4,825)	2,492	(3,012)	(4,825)
Increase in valuation allowance	4,825	(2,492)	3,012	4,825
Income Tax Provision (Benefit)	\$ -	\$ -	\$ -	\$ -

The following is a reconciliation of the U.S. federal statutory rate to the effective income tax rates for the years ended December 31, 2022, December 31, 2023 and 2021: 2022:

	For the years ended December 31,		For the years ended December 31,	
	2022	2021	2023	2022
U.S. Statutory Federal Rate	21.00 %	21.00 %	21.00 %	21.00 %
State Taxes, Net of Federal Tax Benefit	13.58 %	%	15.36 %	13.58 %
Other Permanent Differences	(0.11) %	(0.87) %	(0.54) %	(0.11) %
State rate change in effect	2.95 %	(5.65) %	(4.18) %	2.95 %
AMT credit benefit	- %	- %	- %	- %
Decrease due to true up of State NOL	0.69 %	(44.95) %	(0.11) %	0.69 %
Decrease due to change in Federal NOL and other true ups	0.04 %	12.96 %	(1.67) %	0.04 %
Change in Valuation Allowance	(38.15) %	17.51 %	(29.85) %	(38.15) %
Income Tax Benefit	0.00 %	0.00 %	0.00 %	0.00 %

As of December 31, 2022, December 31, 2023 and 2021, 2022, the Company's deferred tax assets and liabilities consisted of the effects of temporary differences attributable to the following (\$ in thousands):

	As of December 31,		As of December 31,	
	2022	2021	2023	2022
Deferred tax assets:				
Net-operating loss carryforward	\$ 26,241	\$ 20,161	\$ 33,124	\$ 26,241
Stock based compensation	8,358	8,196	9,754	8,358
Patent portfolio and other	15,299	13,917		
Patents & Licenses			8,061	9,898
Transaction Costs			209	23
Research & Development			1,937	2,207
Operating lease liability			1,202	272
Investment portfolio and other			2,879	2,445
Total Deferred Tax assets	49,898	42,274	57,166	49,443
Valuation allowance	(49,115)	(39,759)	(55,946)	(49,115)
Deferred Tax Asset, Net of Allowance	\$ 783	\$ 2,516	\$ 1,220	\$ 328
Deferred tax liability:				
Fair value adjustment of investment	\$ (726)	\$ (2,516)		
Net lease liability	(56)	-		
Depreciation			(57)	-
Right of use asset			(1,163)	(328)

DOMINARI HOLDINGS INC.
(Formerly Aikido Pharma, Inc.)

Notes to Consolidated Financial Statements

In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period in which those temporary differences become deductible. Management considers the Company's history of cumulative net losses, the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. The Company has determined that, based on objective positive and negative evidence currently available, it is more likely than not that the Company will not realize the benefits of the deferred tax assets will not be realized in future periods. Accordingly, the Company has provided a full valuation allowance for the deferred tax assets as of December 31, 2022, December 31, 2023 and 2021, 2022. As of December 31, 2022, December 31, 2023, the change in valuation allowance is approximately \$9.4 million \$6.8 million.

As of December 31, 2022, December 31, 2023, the Company has approximately \$41 million \$40.7 million federal net operating loss carryovers ("NOLs"), which expire from 2033 through 2037, and \$49 million \$68.5 million of federal NOLs with indefinite utilization, which will never expire. The Company has approximately \$113 million \$152.3 million of state and city NOLs, which expire from 2024 2035 through 2041, 2043. As of December 31, 2023, the Company also had federal research and development tax credit carryforwards of \$0.2 million which may be available to offset future income tax liabilities and begin to expire in 2042.

The Utilization of the U.S. NOL carryover carryforwards and research and development tax credit carryforwards may be subject to a substantial annual limitation under Section 382 of the Internal Revenue Code section 382, should there of 1986, and corresponding provisions of state law, due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be a greater than 50% utilized annually to offset future taxable income. In general, an ownership change, as determined under defined by Section 382, results from transactions increasing the regulations. No study has been performed since ownership of certain stockholders or public groups in the last known stock of a corporation by more than 50% over a three-year period. If the Company experiences an ownership change, as defined by Section 382, at any time since inception, utilization of the NOL carryforwards or research and development tax credit carryforwards would be subject to an annual limitation under Section 382, which is determined by first multiplying the value of the Company's stock at the time of the ownership change by the applicable long-term tax-exempt rate, and then could be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the NOL carryforwards or research and development tax credit carryforwards before utilization. The Company determined an ownership change occurred on September 10, 2013, and any NOLs generated prior to this date are therefore limited by Section 382. Any carryforwards that will expire prior to utilization due to this limitation were removed from deferred tax assets, with a corresponding reduction of the valuation allowance. The Company has not yet determined if any additional ownership changes occurred after September 10, 2013. Any past or future ownership changes may limit the Company's ability to utilize remaining tax attributes. Due to the existence of the valuation allowance, limitations created by the 2013 ownership change and any potential future ownership changes will not impact the Company's effective tax rate.

As required by the provisions of ASC 740, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more likely than not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. Differences between tax positions taken or expected to be taken in a tax return December 31, 2023 and the net benefit recognized and measured pursuant to the interpretation are referred to as "unrecognized benefits." A 2022, no liability is recognized (or amount of NOL or amount of tax refundable is reduced) for an unrecognized tax benefit because it represents an enterprise's potential future obligation was required to the taxing authority for a tax position that was not recognized as a result of applying the provisions of ASC 740.

If applicable, be reported. The Company's policy is to record interest costs and penalties related to unrecognized income taxes outside of its income tax benefits are required to be calculated provision and would be classified classify as interest and penalties in general and administrative expense in the statement of operations. As of December 31, 2022 and 2021, December 31, 2023 or 2022, the Company had no liability for unrecognized tax benefit was required to be reported. No accrued interest or penalties were recorded during related to uncertain tax positions and no amounts had been recognized in the years ended December 31, 2022 and 2021. Company's statement of operations. The Company does not expect any significant changes in its unrecognized tax benefits in the next year. The Company files U.S. federal and state income tax returns. As of December 31, 2022, the Company's U.S. and state tax returns (Delaware, New (New York, New York City, Pennsylvania, Virginia, and Texas) remain subject to. As of December 31, 2023, the statute of limitations for assessment by the Internal Revenue Service and state tax authorities remains open for all years since 2020. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by tax the Internal Revenue Service or state authorities beginning with the tax return filed for the year ended December 31, 2018, however, there were extent utilized in a future period. There are no audits pending in any of the above-mentioned jurisdictions during 2022 2023 and 2021, 2022. The Company believes that its income tax positions would be sustained upon an audit and does not anticipate any adjustments that would result in material changes to its consolidated financial position.

In December, 2023, the FASB issued 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (ASU 2023-09) which establishes new income tax disclosure requirements in addition to modifying and eliminating certain existing requirements. Public business entities must apply the ASU's guidance to annual periods beginning after December 15, 2024. The Company may choose to early adopt any new or revised accounting standards whenever such early adoptions is permitted. The Company has chosen not to early adopt this standard.

Note 16, 18. Regulatory

Dominari Securities, the Company's broker-dealer subsidiary, is registered with the SEC as an introducing broker-dealer and is a member of FINRA. The Company's broker-dealer subsidiary is subject to SEC Uniform Net Capital Rule (Rule 15c3-1) which requires the maintenance of minimum net capital and requires that the ratio of aggregate indebtedness to net capital, both as defined, shall not exceed 15 to 1. As such, the subsidiary is subject to the minimum net capital requirements promulgated by the SEC and has elected to calculate minimum capital requirements using the basic method permitted by Rule 15c3-1. As of December 31, 2023, Dominari Securities had net capital of approximately \$4.9 million, which was approximately \$4.7 million in excess of required minimum net capital of \$0.2 million.

Note 19. Related Party Transaction

In 2021, the Company engaged the services of Revere Securities, LLC ("Revere") to strategically manage and build out the Company's investment processes. Kyle Wool, Board Member, is was previously a member of the president board of directors of Revere. The Company incurred fees of approximately \$1.0 million \$75,000 and \$1.2 million \$1.0 million during the years ending December 31, 2022, December 31, 2023, and 2021, 2022, respectively. These fees were included in general and administrative expense expenses in the consolidated statements of operations.

Note 17. Subsequent Events

Amendment to Christopher Devall's Employment Agreement

Effective as of January 1, 2023, Dominari Holdings Inc. (the "Company") and Christopher Devall amended his employment agreement with the Company, dated as of July 1, 2022 (the "Employment Agreement"). In accordance with the terms of Mr. Devall's Employment Agreement, which is for a term of five (5) years, Mr. Devall was employed by the Company as the Vice President of Operations. Under the provisions of the Employment Agreement, Mr. Devall was to become Chief Operating Officer of the Company on July 1, 2024, but the Company and Mr. Devall entered into an Amendment to the Employment Agreement, dated as of January 1, 2023 (the "Amendment" and collectively with the Employment Agreement, the "Amended Employment Agreement"), pursuant to which his appointment as Chief Operating Officer of the Company was accelerated to January 1, 2023, and his base salary was increased to \$350,000 per year, as of January 1, 2023.

In addition to the payment of base salary, Mr. Devall received a signing bonus in the form of a restricted stock grant of 8,068 shares of the Company's common stock, which was fully vested on January 1, 2023. The Amended Employment Agreement also provides for a grant of restricted stock to Mr. Devall with a value of \$1,000,000, on the later of July 1, 2022, or such date as there are a sufficient number of shares of common stock reserved under any of the Company's equity incentive plans for the awarding of such shares of restricted stock. This restricted stock award has not yet been granted. Upon grant, the award will vest in equal amounts over a period of twelve (12) consecutive calendar quarters, subject to certain rights of acceleration upon a change of control and as otherwise provided in the Amended Employment Agreement. Mr. Devall is also entitled to an annual bonus, as determined by the Company's Compensation Committee, based on certain performance criteria, provided that such annual bonus will not be less than \$50,000. Annual bonuses and all stock-based compensation are subject to certain clawback rights as provided in the Amended Employment Agreement.

Company Stock Repurchases

During the period January 1, 2023 through March 20, 2023, the Company spent approximately \$865,000 to repurchase 223,909 shares of its common stock at an average price per share of \$3.86 per share.

Closing of FPS Acquisition DOMINARI HOLDINGS INC.
(Formerly Aikido Pharma, Inc.)

Notes to Consolidated Financial Statements

On September 9, 2022, Note 20. Segment Reporting

The Company operates in two reportable business segments: (1) Dominari Financial and (2) Legacy Aikido. The Dominari Financial reportable business segment represents the Company's broker-dealer business, which is composed of mostly underwriting and transactional service activities. The Legacy Aikido reportable business segment includes Aikido Labs, which manages the investments holdings of the legacy entity. Prior to the FPS Acquisition, the Company operated as a single operating segment comprised of Legacy Aikido.

The chief operating decision-maker ("CODM") has access to and regularly reviews internal financial reporting for each business and uses that information to make operational decisions and allocate resources. Accounting policies applied by the reportable segments are the same as those used by the Company and described in the "Summary of Significant Accounting Policies." While assets are primarily held within the Legacy Aikido reportable business segment, total assets by segment is not disclosed as the CODM does not assess performance, make strategic decisions, or allocate resources based on assets.

The measures of segment profitability that are most relied upon by the CODM are gross revenues and net loss, as presented within the table below and reconciled to the statement of operations.

Year Ended December 31, 2023			
	Dominari Financial	Legacy Aikido Pharma	Consolidated
Revenue	2,039	-	2,039
Operating Costs			
General and administrative	15,750	8,088	23,839
Research and development	-	(3)	(3)
Loss from operations	<u>(13,711)</u>	<u>(8,085)</u>	<u>(21,797)</u>
Other (expenses) income			
Other income	-	36	36
Interest income	229	487	716
Gain on marketable securities	-	630	630
Unrealized loss on note receivable	-	(3,248)	(3,248)
Change in fair value of investments	-	780	780
Total other (expenses) income	<u>229</u>	<u>(1,315)</u>	<u>(1,086)</u>
Net loss	<u>(13,482)</u>	<u>(9,400)</u>	<u>(22,882)</u>
Year Ended December 31, 2022			
	Dominari Financial	Legacy Aikido Pharma	Consolidated
Revenue	-	-	-
Operating Costs			
General and administrative	157	11,526	11,683
Research and development	-	2,663	2,663
Loss from operations	<u>(157)</u>	<u>(14,189)</u>	<u>(14,346)</u>
Other (expenses) income			
Other income	-	64	64
Interest income	-	687	687
Gain on marketable securities	-	(5,952)	(5,952)
Unrealized loss on note receivable	-	-	-
Change in fair value of investments	-	(2,560)	(2,560)
Total other (expenses) income	<u>-</u>	<u>(7,761)</u>	<u>(7,761)</u>
Net loss	<u>(157)</u>	<u>(21,950)</u>	<u>(22,107)</u>

Note 21. Subsequent Events

Litigation

In March 2024 the Company received a notice of petition of a filed action seeking relief related to the March 2024 affiliates of new registered representatives. This notice was filed against the Company's subsidiary Dominari Securities LLC ("Dominari Securities"), a wholly owned subsidiary of Dominari Holdings Inc., entered into a membership interest purchase agreement, as amended and restated on March 27, 2023, (the "FPS Purchase Agreement") with Fieldpoint Private Bank & Trust (the "Seller"), a Connecticut bank, for the purchase of its wholly owned subsidiary, Fieldpoint Private Securities, LLC, a Connecticut limited liability company ("FPS") and broker-dealer registered LLC. The Company does not agree with the Financial Industry Regulatory Authority ("FINRA"). Pursuant to the terms claim of the FPS Purchase Agreement, we purchased from plaintiff and will defend itself accordingly. At this time the Seller 100% of the membership interests in FPS (the "Membership Interests") Company has no reasonable basis to assess or record any potential income statement impact related to this petition. See Note 16 Commitment and as a result thereof, will operate the newly acquired dual registered broker-dealer and investment adviser as a wholly owned subsidiary. The FPS Purchase Agreement provided Contingencies for Dominari's acquisition of FPS's Membership Interests in two closings, the first of which occurred on October 4, 2022 (the "Initial Closing"), at which Dominari paid to the Seller \$2,000,000 in consideration for a transfer by the Seller to Dominari of 20% of the Membership Interests. Following FINRA's approval of the Continuing Membership Application pursuant to FINRA Rule 1017 on March 20, 2023, the second closing occurred on March 27, 2023, at which time Dominari Holdings paid to the Seller an additional \$1.00 in consideration for a transfer by the Seller to Dominari Securities of the remaining 80% of the Membership Interests. In connection with the Second Closing, Dominari Securities received approximately \$2,000,000 of marketable securities from FPS, further information.

Item 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.

Dismissal of independent registered accounting firm

On July 5, 2022, the Company dismissed WithumSmith+Brown, PC ("Withum") as the Company's independent registered public accounting firm, effective immediately. The decision to dismiss Withum was approved by the Company's Audit Committee.

The reports of Withum on the Company's consolidated financial statement as of and for the year ended December 31, 2021 contained no adverse opinion or disclaimer of opinion nor were any such reports qualified or modified as to uncertainty, audit scope or accounting principle.

During the fiscal year ending December 31, 2021 and through the date of this Annual Report, there have been no (i) disagreements with Withum on any matter or accounting principles or practices, consolidated financial statement disclosure, or auditing scope or procedure, which connects with its reports; or (ii) "reportable events" as defined in Item 304(a)(1)(v) of Regulation S-K. Withum did not act as the Company's independent registered public accounting firm during the fiscal year ending December 31, 2020. DISCLOSURE

New independent registered public accounting firm

On July 5, 2022, the Company engaged Marcum LLP ("Marcum"), as the Company's new independent registered public accounting firm. The decision to engage Marcum was approved by the Company's Audit Committee.

During the fiscal year ending December 31, 2021, and through July 5, 2022, the Company has had not consulted Marcum regarding (i) application of accounting principles to any specified transaction, either completed or proposed, (ii) the type of audit opinion that might be rendered on the Company's consolidated financial statements, or (iii) any matter that was either the subject of a disagreement (as defined in Item 304(a)(1)(iv)) or a reportable event (as defined in Item 304(a)(1)(v)). During the fiscal year ending December 31, 2020, Marcum acted as the Company's independent registered public accounting firm.

Item 9A. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

We maintain "disclosure controls and procedures," as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, that are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in Securities and Exchange Commission rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and our Chief Financial Officer, to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognized that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures.

The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. With respect to the annual period ended December 31, 2022, December 31, 2023, under the supervision and with the participation of our management, we conducted an evaluation of the effectiveness of the design and operations of our disclosure controls and procedures. Based upon this evaluation, our management has concluded that as of December 31, 2023, our disclosure controls and procedures were not effective as of December 31, 2022, due to the material weakness in our internal controls.

Remediation A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company's financial statements will not be prevented or detected on a timely basis.

We previously identified and disclosed in our Form 10-K filed for the year ended December 31, 2021, as well as, in our subsequent quarterly reports, a deficiency deficiencies, in internal control over financial reporting, such that existed relating to there is a lack reasonable possibility that a material misstatement of segregation of duties within the Company's annual or interim financial statements will not be prevented or detected on a timely basis.

Material Weaknesses in Internal Controls

The Company's management has concluded that our control around the accounting function as for certain notes receivable accounted for at fair value was not effectively designed or maintained, and therefore initially were not accounted for correctly. As a result, our management performed additional analysis as deemed necessary to ensure that our financial statements were prepared in accordance with accounting principles generally accepted in the United States of our limited financial resources to support hiring of personnel and an internal control deficiency in our ability to implement adequate system and manual controls. To respond to the material weaknesses, we have devoted significant effort and resources to the remediation and improvement of our internal control over financial reporting America. Management understands that led to the material weakness, including obtaining advisory services from professional consultants with U.S. GAAP and SEC reporting experience to supplement the accounting standards applicable to our financial statements are complex and finance function, hiring additional resources will seek to improve management oversight of internal controls, and designing and maintaining formal accounting policies, procedures, and enhance controls over significant accounts its experienced third-party professionals with whom management can consult with respect to accounting issues and disclosures to achieve complete, accurate and timely financial accounting, reporting and disclosure. These new measures have resulted in an improved internal control environment that has been in place to have operated effectively for a sufficient period of time for management to conclude that the remediate this material weaknesses previously identified have been remediated as of December 31, 2022. weakness.

Management's Annual Report on Internal Control over Financial Reporting

Management is responsible for establishing and maintaining adequate internal controls over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act. Our management, including our Chief Executive Officer and Interim Chief Financial Officer assessed the effectiveness of our internal control over financial reporting as of December 31, 2022 December 31, 2023 and concluded that our internal controls over financial reporting were effective. not effective, due to the material weakness in our internal control over financial reporting as described above. In making this assessment, our management used the 2013 framework established in "Internal Control-Integrated Framework" promulgated by the Committee of Sponsoring Organizations of the Treadway Commission, commonly referred to as the "COSO" criteria.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. All internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to the preparation and presentation of the consolidated financial statements.

This Annual Report does not contain an attestation report of our independent registered public accounting firm regarding internal control over financial reporting since the rules for smaller reporting companies provide for this exemption.

Changes in Internal Control over Financial Reporting

There Other than the material weakness described above, there were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the year ended December 31, 2022 December 31, 2023 which have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Item 9B. OTHER INFORMATION. INFORMATION

None.

Item 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS. INSPECTIONS

None.

PART III

Item 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE ~~GOVERNANCE~~ **GOVERNANCE**

Directors and Executive Officers

The following table sets forth the name, age and position of each current director and executive officer of the Company.

Name	Age	Position	Director Since
Robert J. Vander Zanden (1)(2)(5)	77	Director and Chairman of the Board	2004
Anthony Hayes(6)	54	Chief Executive Officer, Principal Accounting Officer, Principal Financial Officer and Director	2013
Tim S. Ledwick (1)(5)	65	Director	2015
Gregory James Blattner(1)(3)(4)(7)	44	Director	2018
Paul LeMire(2)(3)(4)(7)	67	Director	2020
Robert Dudley(2)(3)(6)	67	Director	2020
Kyle Wool(2)(4)(7)	44	Director	2021
Soo Yu(6)	52	Director	2022
Carlos Aldavero	52	President, Dominari Financial Inc.	-
Christopher Devall	40	Vice President of Operations	-

Name	Age	Position	Director Since
Anthony Hayes(4)(6)	56	Chief Executive Officer and Chairman of the Board	2013
Tim S. Ledwick (1)(5)	66	Director	2015
Gregory James Blattner(3)(4)(7)	46	Director	2018
Robert Dudley(1)(2)(3)(6)	68	Director	2020
Kyle Wool(4)(7)	46	President and Director	2021
Soo Yu(6)	53	Director	2022
Kyle Haug(1)(2)(4)(5)	41	Director	2023
George Way	57	Chief Financial Officer	-
Christopher Devall	42	Chief Operating Officer	-

- (1) Member of our Audit Committee.
- (2) Member of our Compensation Committee.
- (3) Member of our Nominating Committee.
- (4) Member of our Investment Committee.
- (5) Class I Director whose directorship will be voted on by ~~shareholders~~ **stockholders** at the 2024 Annual ~~Shareholder~~ **Stockholder** Meeting.
- (6) Class II Director whose directorship will be voted on by ~~shareholders~~ **stockholders** at the 2025 Annual ~~Shareholder~~ **Stockholder** Meeting.
- (7) Class III Director whose directorship will be voted on by ~~shareholders~~ **stockholders** at the ~~2023~~ **2026** Annual ~~Shareholder~~ **Stockholder** Meeting.

The biographies of our current directors and significant employees are as follows:

Dr. Robert J. Vander Zanden

Dr. Robert J. Vander Zanden, a member of the Board of Directors since 2004, having served as a Vice President of R&D at Kraft Foods International, brings a long and distinguished career in applied technology, product commercialization, and business knowledge of the food science industry to us. Additionally, Mr. Vander Zanden has specific experience in developing organizations designed to deliver against corporate objectives. Dr. Vander Zanden holds a Ph.D. in Food Science and an M.S. in Inorganic Chemistry from Kansas State University, and a B.S. in Chemistry from the University of Wisconsin - Platteville, where he was named a Distinguished Alumnus in 2002. In his 30-year career, he has been with ITT Continental Baking Company as a Product Development Scientist; with Ralston Purina's Protein Technology Division as Manager Dietary Foods R&D; with Keebler as Group Director, Product and Process Development (with responsibility for all corporate R&D and quality); with Group Gamesa, a Frito-Lay Company, as Vice President, Technology; and with Nabisco as Vice President of R&D for their International Division. With the acquisition of Nabisco by Kraft Foods, he became the Vice President of R&D for Kraft's Latin American Division. Dr. Vander Zanden retired from Kraft Foods in 2004. He currently holds the title of Adjunct Professor and Lecturer in the Department of Food, Nutrition and Packaging Sciences at Clemson University, where he also is a member of their Industry Advisory Board. His focus on achieving product and process innovation through training, team building and creating positive working environments has resulted in his being recognized with many awards for product and packaging innovation. Mr. Vander Zanden executive experience provides him with valuable business expertise, which the Board believes qualifies him to serve as a director of the Company.

Anthony Hayes

Mr. Anthony Hayes, a director and Chief Executive Officer since 2013, has served as the Chief Executive Officer of North South since March 2013 and since June 2013, as a consultant to our Company. Mr. Hayes was the fund manager of JaNSOME IP Management LLC and JaNSOME Patent Fund LP from August 2012 to August 2013, both of which he co-founded. Mr. Hayes was the founder and Managing Member of Atwater Partners of Texas LLC from March 2010 to August 2012 and a partner at Nelson Mullins Riley & Scarborough LLP from May 1999 to March 2010. Mr. Hayes received his Juris Doctorate from Tulane University School of Law and his B.A. in economics from Mary Washington College. The Board of **Directors** believes Mr. Hayes is qualified to serve as a director of the Company based on his intimate knowledge of the Company through his service as Chief Executive Officer. On March 10, 2017, as a result of Mr. Frank Reiner's resignation as Chief Financial Officer, Mr. Hayes began serving as the Company's Principal Accounting Officer.

Tim S. Ledwick

Mr. Tim S. Ledwick, who joined as a director in 2015, was most recently the Chief Financial Officer of SYFT, a private equity-backed company that provides software solutions and services to hospitals focused on reducing costs through superior inventory management practices which was successfully sold to GHX in 2022. In addition, since 2012 he has served on the board and Chair of the Audit Committee of Telkonet, Inc. (TKOI) a smart energy management technology company. From 2007 to 2011, Mr. Ledwick provided CFO consulting services to a \$150 million services firm and, in addition, from 2007-2008 also acted as special advisor to The Dellacorte Group, a middle market financial advisory firm focused on transactions between \$100 million and \$1 billion. From 2002 through 2006, **Tim Mr. Ledwick** was a member of the Board of Directors and Executive Vice President-CFO of Dictaphone Corporation playing a lead role in developing a business plan which revitalized the company, resulting in the successful sale of the firm and delivering seven times return to **shareholders, stockholders**. From 2001-2002, **Mr.** Ledwick was brought on as CFO to lead the restructuring efforts of Lernout & Hauspie Speech Products, a Belgium-based **NASDAQ Nasdaq** listed speech technology company, whose market cap had at one point reached a high of \$9 billion. From 1999 through 2001, he was CFO of Cross Media Marketing Corp, an \$80 million public company headquartered in New York City, playing a lead role in the firm's acquisition activity, tax analysis and capital raising. Mr. Ledwick is a member of the Connecticut Society of Certified Public Accountants and received his BBA in Accounting from The George Washington University and his MS in Finance from Fairfield University.

Paul LeMire

Mr. LeMire, who joined as a member of our Board of Directors in 2020, is a high-performing investment sales manager and product specialist with 25 years of verifiable success in positioning investment management solutions across multiple channels. Mr. LeMire currently serves as the Managing Director of National Sales at Day Hagan Asset Management where he is responsible for managing the firm's asset management business. Before joining Day Hagan Asset Management, Mr. LeMire was a Senior Regional Vice President for State Street Global Advisors and served in various other Vice President positions at Invesco, Old Mutual Investment Partners, Oppenheimer Funds and CitiGroup. Mr. LeMire holds a Master of Science degree in Mechanical Engineering from Polytechnic University, a Master of Business Administration from Adelphia University and a Bachelor of Science degree from Manhattan College. The Board of Directors believes that Mr. **LeMire's Ledwick's** executive experience and financial expertise qualifies him to serve as a director of the Company.

Robert Dudley

Mr. Robert Dudley, who joined as a member of our Board of Directors in 2020, currently serves as the Eastern Division National and Metropolitan New York City Regional Sales Manager for Select Sector Standard & Poor's Depositary Receipts ("SPDRs"). Prior to joining Select Sector SPDRs in 2008, Mr. Dudley held several managerial positions at Merrill Lynch within from 1981 through 2007. Mr. Dudley began his career in the Merrill Lynch White Weld Capital Markets in Corporate Bond Syndicate, later moving to Sales Manager for Taxable Fixed Income and Equity Marketing. Later, Mr. Dudley managed Merrill Lynch Consults for the New York City District and ended his career as a Financial Advisor and Sales Manager at the Merrill Lynch Rockefeller Center Branch office. Office. The Board of Directors believes that Mr. Dudley's executive experience and financial expertise qualifies him to serve as a director of the Company.

Kyle Wool

Mr. Kyle Wool, who joined as a member of our Board of Directors in 2021, has been currently serves as the president President of Revere Dominari Holdings, CEO of Dominari Financial, and the CEO of Dominari Securities. He boasts over 20 years in various aspects of global finance previously as a Managing Director of Oppenheimer & Co., Head of Wealth Management where he provides integrated strategies designed to help build, manage and preserve wealth for wealthy families, endowments and foundations, since January 2021. Prior to his employment at Revere Wealth Management, Mr. Wool was an their Asian branch, Executive Director at Morgan Stanley, (NYSE: MS) from May 2013 and President of Revere Securities LLC. His extensive knowledge allows him to January 2021, where provide strategic guidance while advising those on the team managing all facets related to financial services categories with senior level insights within an organizing whose growth strategies, he where he where he provided strategic wealth management and investing guidance to his clients. Prior to his employment at Morgan Stanley and The Wool Group, actively contributes towards cultivating. Mr. Wool was employed at Oppenheimer is also active in various philanthropic endeavors both domestically and Co., Inc. in a number of roles, where he strategic wealth management and investing guidance to his clients, from 2005 to 2013. Specifically, from 2010 until 2013, Mr. Wool served as a Managing Director of the Professional Investors Group for Oppenheimer Asia Ltd. Mr. Wool abroad. He currently serves as a board member of LifeLine NY, a charity foundation focused on attain medical equipment for the underprivileged children of Serbia and a board member of the CIRSD (Center for International Relations and Sustainable Development), whose mission is to empower youth in communities with the greatest need to reach their full potential a board member of Project Rousseau and pursue higher education, also a board member of Lang Lang International Music Foundation. Mr. Wool is also a Partner at Merakia, a Greek steakhouse in the Flatiron district holds Series 7, 63, & 24 Securities licenses. The Board of NYC and a Partner at Isouvlaki, which is a Quick Service Restaurant in the Tristan area. In 2009, Directors believes that Mr. Wool was involved in an arbitration proceeding with FINRA, which was settled in 2011. We believe Mr. Wool is well qualified to serve as a director due to his Wool's extensive experience in banking and wealth management. management qualifies him to serve as a director of the Company.

Soo Yu

Ms. Soo Yu, who joined as a member of our Board of Directors in 2022, has been is the Managing managing Director of International Private Client Services for Revere Dominari Securities since January 2018, where she leads the top performing Wool Group. With more than a decade of experience working in financial services, she focuses on international business development and the cultivation of overseas client banking relationships. A naturalized U.S. citizen originally from South Korea, Soo Ms. Yu brings significant expertise in Asian markets and expansive global reach through her connectivity with international contacts. Soo Before joining Dominari, Ms. Yu was Managing Director of Revere Securities. Ms. Yu earned her B.A. in Fine Arts from the Fashion Institute of Technology and studied at the University of Nottingham and the Paris Fashion Institute. She holds Series 7, 66, 24 Securities licenses, New York Life, Accident and Series 66 designations Health Insurance Agent/Broker, New York Property and her real estate license, Casualty Insurance Agent/Broker and Real Estate License. Previously, she maintained her Series 79 and 24. Soo Securities license. Ms. Yu actively supports several nonprofit organizations, including philanthropies committed to improving the lives of children and the elderly as well as sustainability. She is currently a board member of The Korean Community Services of Metropolitan New York, Inc. The Board of Directors believes that Ms. Yu's wealth management experience qualifies her to serve as a director of the Company.

Gregory James Blattner

Mr. Gregory James Blattner, who joined as a member of our Board of Directors in 2018, has nearly ten years of experience in the technology industry specializing in financial services. Since January 2022, he has served as the Vice President of CDI's Modern IT Operations Business. CDI AHEAD's Managed Services business. AHEAD is technology services business integrator that helps it its clients architect, deploy and manage all of their multiplatform hybrid IT technology solutions. Prior to CDI AHEAD, Mr. Blattner spent 7 years at Agio, a progressive managed information technology and cybersecurity services provider, where he was responsible for sales and account management of enterprise accounts. Prior to Agio, from May 2013 to December 2013, Mr. Blattner was a business development manager for the Eikon platform at Thomson Reuters. From 2010 to 2013, Mr. Blattner was a sales manager at American Express for its foreign exchange business. From 2005 to 2009, Mr. Blattner held various positions at JPMorgan, first in the operational risk management arm of the investment bank and later in Foreign Exchange product sales for its treasury services business. From 2000 to 2004, Mr. Blattner was an Associate associate at Morgan Stanley's corporate treasury funding desk. He earned a bachelor's degree from Iona College. The Company Board of Directors believes Mr. Blattner's extensive experience in technology and operations solutions make qualifies him to serve as a qualified appointee as director, director of the Company.

Carlos Aldavero Kyle Haug

Mr. Aldavero Kyle Haug, a member of the Board of Directors since 2023, currently serves as the Chief Operating Officer, Chief Technology Officer and Chief Marketing Officer for Haug Partners LLP. Haug Partners is an intellectual property law firm with offices in New York, Washington D.C. and West Palm Beach. The firm specializes in protecting innovator portfolios in the life science, automobile and technology sectors. Mr. Haug graduated with a B.S. in Administration of Justice from Penn State University where he was a collegiate swimmer. Mr. Haug served on the Junior Council for the American Museum of Natural History for over a decade and is a current committee member at the Metropolitan Club, Plandome Country Club and Haug Family Foundation. The Board of Directors believes Mr. Haug's extensive experience and skill in aiding the growth of company operations qualifies him to serve as a director of the Company.

George Way

Mr. George Way has served as the Chief Financial Officer of the Company since April 3, 2023. Mr. Way has had a distinguished career as a senior executive with expertise in financial leadership, operations management, and acquisition due diligence. He has been a trusted business advisor to members of senior management with experience in solving complex business challenges, improving productivity, and reducing expenses. Prior to joining Dominari, Mr. Way served as the first Chief Financial Officer of Steward Partners, a wealth advisory firm responsible for financial reporting and analysis, tax strategy and reporting. Mr. Way also served as Chief Operating Officer of Ridgeworth Capital Management, a multi-boutique asset management firm with a broad range of responsibility encompassing operations, technology and infrastructure while leading the effort to consolidate all central service platforms. He was also a Vice President of Dominari Financial Inc. since July 22, 2022. Mr. Aldavero has over 25 years Equities Controlling & Head of experience in the financial sector, launching, growing and managing domestic and international business units for global banks through client acquisition, client retention and advisor growth within the wealth management, institutional and ultra-high net worth space. From April 2014 to July 2022 he was the Associate Complex Manager Americas Equities Management Reporting Business at Morgan Stanley's New York office. At Morgan Stanley, Mr. Aldavero co-managed its largest flagship Wealth Management Complex in the country, supervising and managing 245 Financial Advisors, with \$70 billion in AUM and \$500 million in revenues, including 25 Private Wealth Management Advisors (UHNW), 125 domestic advisors and 120 international advisors, covering individuals, single family offices, multi family offices, registered investment advisors and financial intermediaries. Prior to Morgan Stanley, Mr. Aldavero held leadership roles at Merrill Lynch, Deutsche Bank Securities Inc. Mr. Way started his career at Deloitte LLP and Bear Stearns, among other international financial institutions, was an audit manager in their asset management practice. Mr. Way holds series 7 & 24 securities licenses. He received his Bachelor's degree Bachelor of Science in Business Administration Major from Pace University and is a Certified Public Accountant in Finance, at Northeastern University School the State of Business in 1995, New York. Mr. Aldavero Way has his series 7, 9/10, 63, 66 securities licenses, no family relationship with any of the executive officers or directors of the Company. There are no arrangements or understandings between Mr. Way and any other person pursuant to which he was appointed as an officer of the Company. The Board of Directors believes that Mr. Aldavero's extensive wealth management experience Way's prior financial background qualifies him to serve as the President Chief Financial Officer of Dominari Financial Inc, the Company.

Christopher Devall

Mr. Christopher Devall has served as the Chief Operating Officer of the Company since January 1, 2023. Prior to that he was the Company's Vice President of Operations of the Company since from July 1, 2022, to January 1, 2023 and was a member of its advisory board from April 2022 to June 2022. Mr. Devall served as senior operations department head in the Department of Defense from February 2019 to June 2022, and as a senior operations department manager from April 2016 to January 2019. He Mr. Devall is a retired military veteran. Mr. Devall veteran and received his Masters of Business Administration from the University of Virginia Darden School of Business and holds a B.S. in Strategic Studies and Defense Analysis from Norwich University. Mr. Devall has no family relationship with any of the executive officers or directors of the Company. There are no arrangements or understandings between Mr. Devall and any other person pursuant to which he was appointed as an officer of the Company. The Board of Directors believes that Mr. Devall's prior operations background qualifies him to serve as the Vice President of Operations Chief Operating Officer of the Company.

Family Relationships

There are no arrangements between our directors, executive officers and any other person pursuant to which our directors were nominated or elected for their positions. Mr. Wool and Ms. Yu have been married since December 2010.

Section 16(a) Beneficial Ownership Reporting Compliance

Section 16(a) of the Exchange Act, requires our directors and executive officers, and anyone who beneficially owns ten percent (10%) or more of our Common Stock, common stock, to file with the SEC initial reports of beneficial ownership and reports of changes in beneficial ownership of Common Stock, common stock. Anyone required to file such reports also need needs to provide us with copies of all Section 16(a) forms they file.

Based solely upon a review of (i) copies of the Section 16(a) filings received during or with respect to 2022 2023 and (ii) certain written representations of our officers and directors, we believe that all filings required to be made pursuant to Section 16(a) of the Exchange Act during and with respect to 2022 2023 were filed in a timely manner.

Audit Committee

The Audit Committee has been established in accordance with Section 3(a)(58)(A) of the Securities Exchange Act of 1934, as amended, or the Exchange Act and is currently comprised of Timothy Mr. Tim Ledwick (Chairman), Paul LeMire, Mr. Robert Dudley and Robert J. Vander Zanden, Mr. Kyle Haug, each of whom the Board of Directors has determined satisfies the applicable SEC and Nasdaq independence requirements for audit committee members. The Board of Directors has also determined that Mr. Ledwick is an “audit committee financial expert,” as defined by the applicable rules of the SEC and Nasdaq.

The Audit Committee is responsible for, among other things:

- reviewing the independence, qualifications, services, fees and performance of our independent registered public accounting firm;
- appointing, replacing and discharging our independent registered public accounting firm;
- pre-approving the professional services provided by our independent registered public accounting firm;
- reviewing the scope of the annual audit and reports and recommendations submitted by our independent registered public accounting firm; and
- reviewing our financial reporting and accounting policies, including any significant changes, with our management and our independent registered public accounting firm.

Nominating Committee

The Nominating Committee currently consists of Mr. Gregory James Blattner (Chairman), Paul LeMire, and Mr. Robert Dudley, each of whom the Board of Directors has determined satisfies the applicable SEC and Nasdaq independence requirements.

The Nominating Committee reviews, evaluates and proposes candidates for election to our Board of Directors, and considers any nominees properly recommended by stockholders. The Nominating Committee promotes the proper constitution of our Board of Directors in order to meet its fiduciary obligations to our stockholders, and oversees the establishment of, and compliance with, appropriate governance standards.

Compensation Committee

The Compensation Committee currently consists of Kyle Wool (Chairman), Robert J. Vander Zanden, and Mr. Robert Dudley (Chairman) and Mr. Kyle Haug, each of whom the Board of Directors has determined satisfies the applicable SEC and Nasdaq independence requirements. In addition, each member of the Compensation Committee has been determined to be a non-employee director under Rule 16b-3 as promulgated under the Exchange Act. The Compensation Committee reviews and recommends to the Board of Directors the compensation for our executive officers and our non-employee directors for their services as members of the Board of Directors.

Compensation Committee Interlocks and Insider Participation

None of the members of our Compensation Committee is or has been an officer or employee of our company. None of our executive officers currently serves, or in the past year has served, other than Mr. Wool who previously served on our Compensation Committee until his appointment as President, as a member of the Compensation Committee of any entity that has one or more of its executive officers serving on our Board of Directors or Compensation Committee.

Compensation Recovery

Under the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act”), in the event of material noncompliance with the financial reporting requirements that results in a financial restatement that would have reduced a previously paid incentive amount, we can recoup those improper payments from our current and former executive officers. We plan to implement have adopted a clawback policy to address this, although we have not yet implemented such policy which is attached as an exhibit filed with this Annual Report.

Investment Committee

The Investment Committee currently consists of Mr. Kyle Wool (Chairman), Mr. Anthony Hayes and Mr. Kyle Haug. The Investment Committee recommends and oversees the Company’s investment transactions, management, policies, and guidelines, including reviews of investment manager selection, establishment of investment benchmarks, review of investment performance and oversight of investment risk management exposure policies and guidelines.

Code of Ethics and Code of Conduct

We are in the process of adopting have adopted a written code of business conduct and ethics that applies to our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. A copy of the code will be posted is available on our website, www.aikidopharma.com, www.dominari.com. The information on or accessed through our website is deemed not to be incorporated in this Annual Report or to be part of this Annual Report.

Item 11. EXECUTIVE COMPENSATION. COMPENSATION

Named Executive Officers

Our named executive officers (“NEOs”), which consist of (i) all individuals serving as our principal executive officers during fiscal year 2023, (ii) two other of our most highly compensated executive officers who were serving as executive officers at December 31, 2023, and (iii) up to two other of our most highly compensated executive officers for whom disclosure would have been provided pursuant to clause (ii) but for the fact that the individual was not serving as an executive officer at December 31, 2023, are:

- Anthony Hayes, our Chief Executive Officer, Director, Principal Accounting Officer, and Principal Financial Officer;
- Soo Yu, our Special Projects Manager; and
- Kyle Wool, our President.

The following Summary of Compensation table sets forth the compensation paid by our Company during the two fiscal years ended December 31, 2022 December 31, 2023 and 2021, 2022, to all Executive Officers earning in excess of \$100,000 during any such year, our NEOs.

Summary of Compensation Table

Name and Principal Position	Year	Salary (\$)	Bonus (\$)	Stock Awards \$(1)	Non-Equity Incentive Plan Compensation \$(2)	All Other Compensation \$(3)	Total (\$)
Anthony Hayes,	2023	500,000	500,000	-	-	-	1,000,000
Chief Executive Officer, Director, Principal Accounting Officer and Principal Financial Officer	2022	500,000	500,000	484,888	-	208,462	1,693,350
Soo Yu,	2023	106,875	-	5,266,666	2,916,124	16,250	8,305,915
Special Projects Manager	2022	-	-	-	-	-	-
Kyle Wool	2023	500,000	-	-	-	100,360	600,360
President	2022	-	-	-	-	-	-

- (1) The amount reported in this column represents the aggregate grant date fair value of stock granted to Ms. Yu during 2023, as calculated in accordance with FASB ASC Topic 718. The stock was earned pursuant to the attainment of certain assets under management goals, as set forth in Ms. Yu’s employment agreement (described below). The stock was fully vested on the grant date.
- (2) The amount reported in this column represents the cash payment earned by Ms. Yu pursuant to her employment agreement for attaining certain assets under management goals, as more fully discussed below. The amount also includes performance compensation based on sales production paid at a rate of 60%.
- (3) For Ms. Yu, the amounts reported in this column consist of director fees. For Mr. Wool, the amounts reported in this column consists of payments for reimbursement to support health and wellness and client development used exclusively for business.

Summary of Compensation

Name and Principal Position	Year	Salary (\$)	Bonus (\$)	Stock Awards (\$)	Option Awards (\$)	Non-Equity Incentive Plan Compensation \$(1)	Change in Pension Value and Non- Qualified Deferred Compensation Earnings (\$)	All Other Compensation (\$)	Total (\$)
Anthony Hayes, Chief Executive Officer, Director, Principal Accounting Officer and Principal Financial Officer	2022	500,000	500,000	484,888	-	-	-	208,462	1,693,350
	2021	460,000	500,000	-	-	-	-	-	960,000
Darrell Dotson, VP of Drug Development & General Counsel	2022	317,308	-	-	-	-	-	-	317,308
	2021	275,000	50,000	-	-	-	-	-	325,000
Christopher Devall, VP of Operations	2022	125,000	100,000	47,601	-	-	-	-	272,601
	2021	-	-	-	-	-	-	-	-
Carlos Aldovero, President	2022	198,750	213,000	146,250	-	-	-	71,589	629,589
	2021	-	-	-	-	-	-	-	-

(1) Awards pursuant to the Alkido Pharma, Inc. 2013 Incentive Compensation Plan, 2014 Plan and 2020 Plan.

Narrative Disclosure to Summary of Compensation Table

Employment Agreements

Anthony Hayes

On April 1, 2016 June 28, 2021, we entered into an employment agreement with Mr. Anthony Hayes (the “Hayes Agreement”), pursuant to which Mr. Hayes serves as the our Chief Executive Officer Officer. Under an amendment effective April 1, 2023, the term of the Hayes Agreement is for a period five years from the effective date of one year, subject to renewal. In consideration for his employment, we agreed to pay the amendment with automatic one-year extensions unless either the Company or Mr. Hayes a gives six months’ non-renewal notice.

Pursuant to an amendment effective December 6, 2023, the Hayes Agreement provides that Mr. Hayes shall receive an annual base salary of \$350,000 per annum, \$500,000 and an annual bonus. The annual bonus is paid in a combination of cash and shares of our common stock upon the Company’s achievement of certain annual revenue targets, as stated in the table below.

Annual Revenue	Annual Bonus
\$3,500,000 or more	\$150,000, plus 154,559 shares
Between \$7.5mm and \$15mm	\$250,000, plus 154,599 shares
\$15mm or more	\$500,000, plus 154,559 shares

Our Board of Directors may adopt different or additional performance criteria for future years after consultation with Mr. Hayes, provided that such criteria must be reasonably attainable. The bonus, to the extent earned, will be paid following the completion of our annual audit and public announcement of such results (and in all cases by July 31 of the year following the performance year), provided that Mr. Hayes is actively employed on April 15th of the year following the performance year.

The Hayes Agreement also provides that Mr. Hayes will be entitled to participate in pension, profit sharing, group insurance, hospitalization, group health and benefit plans, perquisites, and all other benefits and plans the Company provides to its senior officers. If at any time during the term, the Company does not provide its senior executives with health insurance, Mr. Hayes will be entitled to secure such insurance for himself and his immediate family and the Company will reimburse him for the cost of such insurance.

The Hayes Agreement provides that upon Mr. Hayes’ termination due to (A) his death, (B) disability, (C) by the Company without cause (as defined in the Hayes Agreement), or (D) due to the Company not renewing the Hayes Agreement term, he or his estate will be entitled to the following: (i) twelve months’ base salary paid in a lump sum, (ii) continued group health coverage (if validly elected) for 12 months at the same cost as applied prior to his termination, and (iii) the pro-rata portion of any earned annual bonus.

If Mr. Hayes’ employment is terminated (A) by Mr. Hayes for good reason (as defined in the Hayes Agreement) or (B) within 30 days of a change in control (as defined in the Hayes Agreement), then Mr. Hayes will be entitled to receive an annual bonus in an amount equal to up to 100% of his the following: (i) twelve months’ base salary if we meet or exceed certain criteria adopted by our Compensation Committee. We further agreed to grant executive restricted stock units, pursuant to the Corporation’s 2014 Equity Incentive Plan, with respect to 118,512 shares of the Company’s common stock. One-half of the grant shall vest if as of December 31, 2016, the Corporation has pro-forma cash of at least five million dollars (\$5,000,000) (cash plus any cash used for a Board-approved extraordinary acquisition or transaction reconstituting the Company’s core operations, less accrued bonuses) and one-half shall vest upon the Company meeting certain agreed upon criteria. As of June 30, 2020, 59,256 restricted stock units were vested and 59,256 restricted stock units were forfeited.

Under the April 1, 2016 employment agreement with Mr. Hayes, we have agreed to, in the event of termination by us without “cause” or pursuant to a change in control, grant Mr. Hayes, in addition to reimbursement of any documented, unreimbursed expenses incurred prior to such date, (i) any unpaid compensation and vacation pay accrued during the term of the Employment Agreement, and any other benefits accrued to him under any of our benefit plans outstanding at such time, (ii) twelve (12) months base salary at the then current rate to be paid in a single lump sum, within thirty (30) days of Mr. Hayes’ (ii) continued group health coverage (if validly elected) for 12 months at the same cost as applied prior to his termination, (iii) continuation for a period of twelve (12) months the pro-rata portion of any benefits as extended to our executive officers from time to time, including but not limited to group health care coverage earned annual bonus, and (iv) payment on a pro rata basis full vesting of any annual bonus or other payments earned in connection with any bonus plans to which Mr. Hayes was a participant as of the date of termination. In addition, any options or restricted stock shall be immediately vested upon termination of Mr. Hayes’s employment without “cause” or pursuant to a change in control.

On October 19, 2017, the Company entered into an amendment to the employment agreement of Mr. Hayes, pursuant to which, effective January 1, 2017, Mr. Hayes was entitled to receive an annual cash bonus in an amount equal to up to \$250,000 if the Company meets or exceeds certain criteria adopted by the Compensation Committee of the Company’s Board of Directors. In addition, Mr. Hayes was awarded a restricted stock unit grant for 30,000 shares of the Company’s common stock under the Company’s 2014 Equity Incentive Plan. Such grant shall vest in installments, in tandem with the satisfaction of the same criteria to which the cash bonus is subject. If all criteria are met, 100% of the grant of restricted stock units shall vest upon the determination of the Compensation Committee, which in any event shall not be later than March 15, 2018.

On June 28, 2021, the Company entered into an amendment to the employment agreement of Mr. Hayes, pursuant to which, effective on July 1, 2021 the term of the employment agreement shall be extended to June 28, 2024 outstanding and that Mr. Hayes’ executive compensation will be increased to \$500,000 annually. Mr. Hayes was entitled to receive an annual cash bonus in an amount equal to up to \$250,000 if the Company meets or exceeds certain criteria adopted by the Compensation Committee of the Company’s Board of Directors, then unvested equity awards.

All other terms of Mr. Hayes’ employment agreement, effective as of April 1, 2016, as amended on October 9, 2017 and June 28, 2021, remain in full force and effect.

Darrell Dotson Soo Yu

On January 1, 2017 April 3, 2023, we entered into an employment agreement with Mr. Darrell Dotson Soo Yu (the “Yu Agreement”), pursuant to which Mr. Dotson Ms. Yu serves as both the Vice President, for Special Projects Manager and a period registered representative of three months, the Company performing broker services. The Yu Agreement has a one-year term, which the Company may extend at its discretion. If the Company does not extend the term, Ms. Yu’s continued service with us will be limited to broker services, which will be provided on an at-will basis. The Yu Agreement provides that Ms. Yu shall automatically be extended for three months unless either party provides notice of non-renewal. In consideration for his employment, we agreed to pay Mr. Dotson receive a base salary of \$125,000 \$150,000 per annum. Mr. Dotson annum, which must be paid through the end of the term or any extension of the term unless Ms. Yu is terminated for cause (as defined in the Yu Agreement) or terminates voluntarily without Good Reason (as defined in the Yu Agreement). Additionally, the Yu Agreement provides that Ms. Yu will be entitled to receive an annual a performance bonus based on the gross revenue she generates over a trailing twelve-month period in an amount equal to up to 50% of his base salary if we meet or exceed certain criteria adopted accordance with the formula below.

Trailing 12 month Gross Revenue (\$)	Grid
1 to 999,999	50 %
1,000,000 to 1,999,999	55 %
2,000,000 and up	60 %

Any compensation earned by our Compensation Committee. We further agreed to grant executive restricted stock units, Ms. Yu pursuant to the Corporation's 2014 Equity Incentive Plan, table will be paid to Ms. Yu on a monthly basis on or about the 15th day following the end of each calendar month in which the underlying Gross Revenue was generated by Ms. Yu, with compensation earned being limited by the proceeds actually paid to the Company (rather than accrued). We agreed to commence Ms. Yu's performance at the \$2,000,000 level based on her most recent 12-month production with her prior employer. This level may only be adjusted after April 3, 2024. In addition to the gross revenue bonus, the Yu Agreement also provides for production payments ("Production Payments") of up to \$8,000,000, to be paid in equal payments of \$2,666,666, upon Ms. Yu's attainment of the following production goals:

- Completing all required registrations and providing binding commitments and opening accounts for clients with assets under management or account value of at least \$50,000,000;
- Providing binding commitments and opening accounts for clients with assets under management or account value of at least \$150,000,000 in the aggregate; and
- Providing binding commitments and opening accounts for clients with assets under management or account value of at least \$560,000,000 in the aggregate.

The account values are inclusive of prior account values. Each of the Production Payments will be paid as soon as administratively feasible after the date on which the conditions for a given payment are met but no later than 30 days, provided that the Company is in full compliance with its net capital and other regulatory requirements at that time. Production Payments will be made fifty percent (50%) in cash bonus, upon confirmation by and fifty percent (50%) in shares of the compensation committee, Company. The Production Payments are subject to pro rata clawback if Ms. Yu is terminated for cause or resigns without good reason during the seven (7) years following the payment date of any Production Payment.

On March 24, 2020, we entered into an amendment Pursuant to the employment agreement of Mr. Dotson pursuant to which Mr. Dotson was entitled to receive a base salary of \$250,000 per annum. On July 1, 2021, we entered into a second amendment to the employment agreement of Mr. Dotson pursuant to which Mr. Dotson was entitled to receive a base salary of \$300,000 per annum.

Under the January 1, 2017 employment agreement with Mr. Dotson, we have agreed to, in the event of termination by us without "cause" or pursuant Yu Agreement, Ms. Yu is subject to a change in control, grant Mr. Dotson, in addition to reimbursement perpetual confidentiality covenant, and for the duration of any documented, unreimbursed expenses incurred prior to such date, (i) a cash payment of \$250,000 Ms. Yu's employment and any unpaid compensation and vacation pay accrued during for the term of his employment agreement, and any other benefits accrued to him under any of our benefit plans outstanding at such time, (ii) continuation for a period of twelve (12) months of any benefits as extended to our executive officers from time to time, including but not limited to group health care coverage and (iii) payment on a pro rata basis of any annual bonus or other payments earned in connection with any bonus plans to which Mr. Dotson was a participant as of the date of termination. In addition, any options or restricted stock shall be immediately vested upon following her termination of Mr. Dotson employment without "cause" or pursuant with the Company, a covenant not to a change in control.

We provided timely notice of non-renewal of Mr. Dotson's contract ending December 31, 2022 solicit the Company's clients and Mr. Dotson's employment terminated without "cause" on December 31, 2022, service providers.

Christopher Devall Kyle Wool

On July 1, 2022 October 12, 2022, we our subsidiary Dominari Financial entered into an employment agreement with Mr. Christopher Devall Kyle Wool (the "Wool Agreement"), pursuant to which Mr. Devall Wool serves as the Vice President, for a period Chief Executive Officer of Dominari Financial. The term of the Wool Agreement is five years which shall automatically be extended for an additional year with automatic one-year extensions unless either party provides notice of non-renewal. In consideration for his employment, we agreed to pay Dominari Financial or Mr. Devall a base salary of \$250,000 per annum (which was prorated to \$125,000 during the first year). The employment agreement provides for an annual salary of \$300,000 in year two and \$350,000 in year three through five. Mr. Devall was paid a \$50,000 signing bonus in restricted stock that will fully vest on January 1, 2023. Mr. Devall's employment agreement also provides for an annual bonus of a minimum of \$50,000, to be paid in cash of restricted based on the determination of the Compensation Committee of the Board of Directors. We further agreed to grant executive restricted stock units (RSUs), pursuant to the Corporation's 2014 Equity Incentive Plan, in addition to the cash bonus, upon confirmation by the Compensation Committee in the amount of \$1,000,000. The RSUs vest on a pro rata basis on each of the twelve calendar quarters starting after the grant date. Mr. Devall is also entitled to the payment or reimbursement of up to \$10,000 per month for reasonable out-of-pocket expenses. Wool gives six months' non-renewal notice.

The employment agreement Wool Agreement provides that Mr. Wool shall receive an annual base salary of \$500,000 and an annual bonus. The annual bonus is paid in a combination of cash and shares of our common stock upon Dominari Financial's achievement of certain annual revenue targets, as stated in the table below.

Annual Revenue	Annual Bonus
\$3,500,000 or more	\$150,000, plus 154,559 shares
Between \$7.5mm and \$15mm	\$250,000, plus 154,599 shares
\$15mm or more	\$500,000, plus 154,559 shares

Our Board of Directors may adopt different or additional performance criteria for future years after consultation with Mr. Wool, provided that such criteria must be reasonably attainable. The bonus, to the extent earned, will be paid following the completion of our annual audit and public announcement of such results (and in all cases by July 31 of the year following the performance year), provided that Mr. Wool is actively employed on April 15th of the year following the performance year.

The Wool Agreement also provides that Mr. Wool will be entitled to participate in pension, profit sharing, group insurance, hospitalization, group health and benefit plans, perquisites, and all other benefits and plans Financial provides to its senior officers. If at any time during the term, Dominari Financial does not provide its senior executives with health insurance, Mr. Wool will be entitled to secure such insurance for customary events himself and his immediate family and Dominari Financial will reimburse him for the cost of termination of employment and provides that in such insurance.

Pursuant to the event of termination as a result of Wool Agreement, Mr. Devall's death or disability, Mr. Devall Wool is entitled to severance consisting receive the following: (i) the support of an administrative assistant, (ii) reimbursement for his personal cell phone expenses, (iii) a monthly expense account of up to \$20,000 for his business use, (iv) up to \$100,000 in reimbursement for health care and social club memberships, and (v) subject to Dominari Financial's consent, reimbursement for all other reasonable out-of-pocket expenses actually incurred or paid by Mr. Wool in the course of his employment.

The Wool Agreement provides that upon Mr. Wool's termination due to (A) his death, (B) his disability, (C) within 40 days of the consummation of change in control transaction (as defined in the Wool Agreement), or (D) due to Dominari Financial not renewing the Wool Agreement term, he or his estate will be entitled to the following: (i) twelve (12) months of his then current months' base salary payable paid in a lump sum, less withholding of applicable taxes, within thirty (30) days of the date of termination; (ii) if he elects continuation coverage for continued group health coverage pursuant (if validly elected) for 12 months at the same cost as applied prior to COBRA, then for a period of twelve (12) months following his termination, and (iii) the termination of Mr. Devall's employment the Company will pay such amount of the COBRA premiums so that Mr. Devall is only required to pay the pro-rata portion of the premiums that active employees are required to pay; and (iii) payment on a pro-rated basis of any earned annual bonus or other payments earned in connection with any bonus plan to which bonus.

If Mr. Devall was a participant as of the date of death or disability. In the event of termination of Mr. Devall's Wool's employment (i) as a result of the non-renewal of the employment agreement by the Company at the end of the then current term, (ii) is terminated (A) by Mr. Devall Wool for "good reason" good reason (as such term is defined in the employment agreement), (iii) Wool Agreement) or (B) by the Company, Dominari Financial without cause or (iv) by Mr. Devall, (as defined in the event of a change in control, Wool Agreement), then Mr. Devall is Wool will be entitled to receive the following: (i) twelve months' base salary paid in a lump sum, (ii) continued group health coverage (if validly elected) for 12 months at the same severance cost as provided above. Additionally, if applied prior to his termination, is by Mr. Devall for good reason or by (iii) the Company, without cause, pro-rata portion of any earned annual bonus, and (iv) full vesting of all outstanding and then all unvested equity grants held by Mr. Devall will immediately vest, awards.

Carlos Aldavero Retirement Benefits

On July 22, 2022, the Company entered into an employment agreement with Mr. Carlos Aldavero. Our NEOs are eligible to serve as the President participate in our 401(k) plan, which is a defined contribution plan offered to all of Dominari Financials Inc., a wholly owned subsidiary of the Company, for a period of three years, which shall automatically be extended for an additional year unless either party provides notice of non-renewal. In consideration for his employment, we agreed to pay Mr. Aldavero a base salary of \$450,000 per annum (which was prorated to \$198,750 during the first year). Following the initial three year term, the Compensation Committee of the Board of Directors has the right our full-time employees. There are no obligation make any adjustments to Mr. Aldavero's base salary as it deems fit. The employment agreement provides for a cash signing bonus other retirement benefit arrangements covering our NEOs.

Termination and Change in the amount of \$213,000 upon the effective date of the employment agreement. Mr. Aldavero's employment agreement also provides for an annual bonus at the discretion of the Board of Directors, to be paid in cash of restricted based on the determination of the Compensation Committee of the Board of Directors. We further agreed to grant executive restricted stock units (RSUs), pursuant to the Company's 2014 Equity Incentive Plan (the 2014 Plan), in addition to the cash bonus, upon confirmation by the Compensation Committee, in the amount of 50,000 shares. This grant has not been made prior to December 31, 2022 because the 2014 Plan has no shares available. The RSUs vest on a pro rata basis on each of the ten calendar months starting after the grant date. Mr. Aldavero is also entitled to RSUs in an amount equal to 2.5% of the Company's fair market value as determined by the Board of Directors in good faith. The RSUs vest on a pro rata basis on each of the twelve calendar quarters following the the grant date. This grant has not been made prior to December 31, 2022 because the 2014 Plan has no shares available. Control Benefits

The employment agreement also provides for customary events of termination of employment and provides that in the event of termination as a result of Mr. Aldavero's death or disability, Mr. Aldavero is entitled to severance consisting of (i) twelve (12) months of his then current base salary, payable in a lump sum, less withholding of applicable taxes, within thirty (30) days material terms of the date contracts with each termination; (ii) if he elects continuation coverage for group health coverage pursuant our NEOs are summarized above, including the payments to COBRA, then for a period of twelve (12) months NEOs at, following, the termination of Mr. Aldavero's employment the Company will pay such amount of the COBRA premiums so that Mr. Aldavero is only required to pay the portion of the premiums that active employees are required to pay; and (iii) payment on a pro-rated basis of any annual bonus or other payments earned in connection with any bonus plan to which Mr. Devall was a participant as of the date of death or disability. In the event of termination of Mr. Aldavero's employment (i) as a result of the non-renewal of the employment agreement by the Company at the end of the then current term, (ii) by Mr. Aldavero for Good Reason (as such term is defined in the Amended employment agreement), (iii) by the Company, without cause, or (iv) by Mr. Aldavero, in the event of a resignation, change in control, then Mr. Aldavero is entitled to the same severance as provided above. Additionally, if or other termination is by Mr. Aldavero for good reason or by the Company, without cause, then all equity grants held by Mr. Aldavero will immediately vest, of an NEO.

Outstanding Equity Awards at December 31, 2022 December 31, 2023

Name	Option Awards			
	Number of Securities Underlying Unexercised Options (#) Exercisable	Number of Securities Underlying Unexercised Options (#) Unexercisable	Option Exercise Price (\$)	Option Expiration Date
Anthony Hayes	2,941	-	\$ 10.88	12/23/2030
Darrell Dotson	72	-	\$ 1,839.49	8/1/2024

Name	Option Awards			
	Number of Securities Underlying Unexercised Options (#) Exercisable ⁽¹⁾	Number of Securities Underlying Unexercised Options (#) Unexercisable	Option Exercise Price (\$)	Option Expiration Date
Anthony Hayes	2,941	-	\$ 10.88	12/23/2030
Soo Yu	-	-	-	-
Kyle Wool	-	-	-	-

(1) These options are fully vested.

Pay versus Performance

Pursuant to Section 953(a) of the Dodd-Frank Wall Street Reform and Consumer Protection Act, and Item 402(v) of Regulation S-K, we are providing the following information regarding "compensation actually paid", as defined in Item 402(v). In accordance with SEC rules, the "compensation actually paid" amounts shown in the table below for each applicable year reflect certain adjustments to the values reported in the Summary of Compensation Table as described in the footnotes to the following table.

In accordance with the transitional relief under the SEC rules for smaller reporting companies, only three years of information is required as this is the Company's first year of disclosure under Item 402(v) of Regulation S-K.

Year	Summary Compensation Table Total for PEO ⁽¹⁾	Compensation Actually Paid to PEO ⁽²⁾	Average Summary Compensation Table Total for Non-PEO NEOs ⁽³⁾	Average Compensation Actually Paid to Non-PEO NEOs ⁽⁴⁾	Value of Initial Fixed \$100 Investment Based On TSR ⁽⁵⁾	Net Income (Loss) ⁽⁶⁾
(a)	(b)	(c)	(d)	(e)	(f)	(g)
2023	\$ 1,000,000	\$ 1,000,000	\$ 4,453,138	\$ 4,453,138	\$ (25.14)	\$ (22,882)
2022	\$ 1,693,350	\$ 1,693,350	\$ 406,499	\$ 406,499	\$ (66.73)	\$ (22,107)
2021	\$ 960,000	\$ 962,663	\$ 108,333	\$ 108,333	\$ (32.18)	\$ (7,171)

(1) For each year shown, the PEO was the Chief Executive Officer, Anthony Hayes. The values reflected in this column reflect the "Total Compensation" paid to Mr. Hayes, the Company's Principal Executive Officer, as set forth in the Summary of Compensation Table.

(2) The dollar amounts reported in this column represent the amount of “compensation actually paid” to Mr. Hayes, as computed in accordance with Item 402(v) of Regulation S-K. The dollar amounts do not reflect the actual amount of compensation earned by or paid to Mr. Hayes during the applicable year. In accordance with the requirements of Item 402(v) of Regulation S-K, the following adjustments were made to determine the “compensation actually paid” amounts reported above for Mr. Hayes:

Reconciliation of Summary of Compensation Table Total to Compensation Actually Paid for CEO	2023	2022	2021
Summary of Compensation Table Total	\$ 1,000,000	\$ 1,693,350	\$ 960,000
Less: Grant Date Fair Value of Option and Stock Awards Granted in Fiscal Year		\$ (484,888)	
Plus: Fair Value of Awards Granted during Applicable Fiscal Year that Remain Unvested as of Applicable Fiscal Year End, Determined as of Applicable Fiscal Year End			
Plus: Fair Value of Awards Granted During the Applicable Fiscal Year that Vested During the Applicable Fiscal Year, Determined as of the Vesting Date		\$ 484,888	
Plus (Less): Adjustment for Awards Granted During a Prior Fiscal Year that were Outstanding and Unvested as of the Applicable Fiscal Year End, Determined Based on the Change in ASC 718 Fair Value from Prior Fiscal year End to the Applicable Fiscal Year End			\$ 2,663
Plus (Less): Adjustment for Awards Granted During a Prior Fiscal Year that Vested During the Applicable Fiscal year, Determined based on the Change in ASC 718 Fair Value from the Prior Fiscal Year End to the Vesting Date			
Less: ASC 718 Fair Value of Awards Granted During a Prior Fiscal Year that were Forfeited During the Applicable Fiscal Year, determined as of the Prior Fiscal Year End			
Plus: Dividends or Other Earnings Paid During the Applicable Fiscal year Prior to the Vesting Date			
Plus: Incremental Fair Value of Options/SARs Modified During the Applicable Fiscal Year			
Compensation Actually Paid	\$ 1,000,000	\$ 1,693,350	\$ 962,663

(3) For 2021 and 2022, the non-PEO NEOs were Darrell Dotson, Carlos Aldavero and Christopher Devall. For 2023, the non-PEO NEOs were Soo Yu and Kyle Wool. The values reflected in this column reflect the average “Total Compensation” paid to each of the non-PEO NEOs in the applicable year, as set forth in the Summary of Compensation Table for the applicable year.

- (4) The dollar amounts reported in column (e) represent the average amount of “compensation actually paid” to the non-PEO NEOs, as a group, as computed in accordance with Item 402(v) of Regulation S-K. The dollar amounts do not necessarily reflect the actual average amount of compensation earned by or paid to such persons during the applicable year. In accordance with the requirements of Item 402(v) of Regulation S-K, the following adjustments were made to average total compensation for the non-PEO NEOs as a group for each year to determine the compensation actually paid:

Reconciliation of Average Summary of Compensation Table Totals for non-PEO NEOs to Average Compensation Actually Paid to non-PEO NEOs			
	2023	2022	2021
Average Summary of Compensation Table Total	\$ 4,453,138	\$ 406,499	\$ 108,333
Less: Grant Date Fair Value of Option and Stock Awards Granted in Fiscal Year	\$ (5,266,666)	\$ (193,851)	
Plus: Fair Value of Awards Granted during Applicable Fiscal Year that Remain Unvested as of Applicable Fiscal Year End, Determined as of Applicable Fiscal Year End			
Plus: Fair Value of Awards Granted During the Applicable Fiscal Year that Vested During the Applicable Fiscal Year, Determined as of the Vesting Date	\$ 5,266,666	\$ 193,851	
Plus (Less): Adjustment for Awards Granted During a Prior Fiscal Year that were Outstanding and Unvested as of the Applicable Fiscal Year End, Determined Based on the Change in ASC 718 Fair Value from Prior Fiscal year End to the Applicable Fiscal Year End			
Plus (Less): Adjustment for Awards Granted During a Prior Fiscal Year that Vested During the Applicable Fiscal year, Determined based on the Change in ASC 718 Fair Value from the Prior Fiscal Year End to the Vesting Date			
Less: ASC 718 Fair Value of Awards Granted During a Prior Fiscal Year that were Forfeited During the Applicable Fiscal Year, determined as of the Prior Fiscal Year End			
Plus: Dividends or Other Earnings Paid During the Applicable Fiscal year Prior to the Vesting Date			
Plus: Incremental Fair Value of Options/SARs Modified During the Applicable Fiscal Year			
Average Compensation Actually Paid	\$ 4,453,138	\$ 406,499	\$ 108,333

- (5) Cumulative Total Share Return (“TSR”) is calculated by dividing the sum of the cumulative amount of dividends for the measurement period, assuming dividend reinvestment, and the difference between the Company’s share price at the end and the beginning of the measurement period by the Company’s share price at the beginning of the measurement period.
- (6) The dollar amounts reported represent the amount of net income reflected in the Company’s audited financial statements for the applicable year.

Analysis of the Information Presented in the Pay versus Performance Table

The Company’s executive compensation program reflects a variable pay-for-performance philosophy. While the Company utilizes several performance measures to align executive compensation with Company performance, all of those Company measures are not presented in the Pay versus Performance table. Moreover, the Company generally seeks to incentivize long-term performance, and therefore does not specifically align the Company’s performance measures with compensation that is actually paid (as computed in accordance with Item 402(v) of Regulation S-K) for a particular year. In accordance with Item 402(v) of Regulation S-K, the Company is providing the following descriptions of the relationships between information presented in the Pay versus Performance table.

Compensation Actually Paid and Cumulative TSR

The following graph illustrates the amount of “compensation actually paid” (“CAP”) to Mr. Hayes and the average amount of CAP to the Company’s Named Executive Officers as a group (excluding Mr. Hayes) relative to the Company’s cumulative TSR over the three years presented in the table.



As demonstrated by the following table, the amount of CAP to Mr. Hayes and the average amount of CAP to the Company's Named Executive officers as a group (excluding Mr. Hayes) is not aligned with the Company's net loss over the three years presented in the table. The Company has not used net loss as a performance measure in the overall executive compensation program.

Our non-employee directors received the following annual compensation for service as a member of the Board of Directors for the fiscal year ended December 31, 2023:

Annual Retainer	\$ 65,000	To be paid in cash in four equal quarterly installments.
Additional Retainer	\$ 5,000	To be paid to the Chairman of the Board upon election annually.

The following table summarizes the compensation paid to non-employee directors during the year ended December 31, 2022 December 31, 2023.

	Fees earned or paid in cash (\$)	Stock Awards (\$)	Option Awards (\$)	Non-Equity Incentive Plan Compensation (\$)	Change in Pension Value and Non-Qualified Deferred Compensation Earnings (\$)	All Other Compensation (\$)	Total (\$)	Fees earned or paid in cash (\$)	Stock Awards (\$)(1) (2)	Option Awards (\$)	Non-Equity Incentive Plan Compensation (\$)	Non-Qualified Deferred Compensation Earnings (\$)	All Other Compensation (\$)	Total (\$)
Robert J. Vander Zanden (2) (3)	75,000	49,360	-	-	-	-	124,360	65,000	-	-	-	-	-	65,000
Tim Ledwick (3) (4)	82,500	49,360	-	-	-	-	131,860	65,000	-	-	-	-	-	65,000
Gregory Blattner (4) (5)	65,000	49,360	-	-	-	-	114,360	65,000	-	-	-	-	-	65,000
Paul LeMire (5)	65,000	49,360	-	-	-	-	114,360							
Robert Dudley (6)	70,000	49,360	-	-	-	-	119,360	65,000	-	-	-	-	-	65,000
Kyle Wool (7)	32,143	484,888	-	-	-	248,071	765,102							
Yu Soo (8)	36,607	49,360	-	-	-	-	85,967							
Kyle Haug (7)								10,833	-	-	-	-	-	10,833

(2) As of December 31, 2023, the aggregate number of stock and option awards held by each director was as follows:

- Robert J. Vander Zander holds 2,941 option awards;
- Tim Ledwick holds 2,941 option awards;
- Gregory Blattner holds 2,941 option awards; and
- Robert Dudley holds 2,941 option awards.

- (3) Mr. Vander Zanden was paid \$75,000 \$65,000 in cash compensation for his service as a director in 2022. In addition, in August 2022, Mr. Vander Zanden was granted 8,000 shares of restricted stock awards for a fair value of \$49,360. 2023.
- (3) (4) Mr. Ledwick was paid \$82,500 \$65,000 in cash compensation for his service as a director in 2022. In addition, in August 2022, Mr. Ledwick was granted 8,000 shares of restricted stock awards for a fair value of \$49,360. 2023.
- (4) (5) Mr. Blattner was paid \$65,000 in cash compensation for his service as a director in 2022. In addition, in August 2022, Mr. Blattner was granted 8,000 shares of restricted stock awards for a fair value of \$49,360. 2023.
- (5) (6) Mr. LeMire Dudley was paid \$65,000 in cash compensation for his service as a director in 2022. In addition, in August 2022, Mr. LeMire was granted 8,000 shares of restricted stock awards for a fair value of \$49,360. 2023.
- (6) (7) Mr. Dudley Haug was paid \$70,000 \$10,833 in cash compensation for his service as a director in 2022. In addition, in August 2022, Mr. Dudley was granted 8,000 shares of restricted stock awards for a fair value of \$49,360.
- (7) Mr. Wool was paid \$32,143 in cash compensation for his service as a director in 2022. In addition, in August 2022, Mr. Wool was granted 78,588 shares of restricted stock awards for a fair value of \$484,888. Mr. Wool was also granted \$248,071 stock awards tax withholding bonus.
- (8) Mr. Soo was paid \$36,607 in cash compensation for his service as a director in 2022. In addition, in August 2022, Mr. Soo was granted 8,000 shares of restricted stock awards for a fair value of \$49,360. 2023.

Non-employee directors received the following annual compensation for service as a member of the Board for the fiscal year ended December 31, 2022:

Annual Retainer	\$	65,000	To be paid in cash in four equal quarterly installments.
Additional Retainer	\$	5,000	To be paid to the Chairman of the Board upon election annually.

Item 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDERS STOCKHOLDER MATTERS

Securities Authorized for Issuance under Equity Compensation Plans

The following table provides information about our Common Stock common stock that may be issued upon the exercise of options, warrants and rights under all of our existing equity compensation plans as of December 31, 2022 December 31, 2023.

Plan Category	Number of securities to be issued upon exercise of outstanding options, warrants and rights (1)	Weighted average exercise price of outstanding options, warrants and rights	Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (1)) (2)	Number of securities to be issued upon exercise of outstanding options, warrants and rights (1)	Weighted average exercise price of outstanding options, warrants and rights	Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (1)) (2)
Equity compensation plans approved by security holder	31,193	\$ 302.97	26,726	556,477	\$ 4.94	839,686
Equity compensation plans not approved by security holder	-	-	-	-	-	-
	31,193		26,726	556,477		839,686

(1) Consists of options to acquire 1,182 24,454 shares of our common stock under the 2013 Equity Incentive Plan and 25,537 under the 2014 Equity Incentive Plan and 395,714 shares of common stock under the 2022 Equity Incentive Plan, and restricted stock awards to acquire 136,309 shares of common stock under the 2022 Equity Incentive Plan.

(2) Consists of shares of Common Stock common stock available for future issuance under our equity incentive plans.

Beneficial Ownership of our Capital Stock by Certain Beneficial Owners and Management

The following tables set forth certain information concerning the number of shares of our **Common Stock**, **common stock**, Series D **Convertible Preferred Stock** (the “**Series D Preferred Stock**”) and Series D-1 **Convertible Preferred Stock** (the “**Series D-1 Preferred Stock**”) owned beneficially as of **March 20, 2023** **March 26, 2024** by (i) our officers and directors as a group and (ii) each person (including any group) known to us to own more than 5% of our **Common Stock**, **common stock**, Series D Preferred Stock and Series D-1 Preferred Stock. As of **March 20, 2023** **March 26, 2024** there were **4,840,597** **5,934,917** shares of **Common Stock** **common stock** outstanding, 3,825 shares of Series D Preferred Stock outstanding and 834 shares of Series D-1 Preferred Stock outstanding. Unless otherwise indicated, it is our understanding and belief that the stockholders listed possess sole voting and investment power with respect to the shares shown.

Name of Beneficial Owner(1)	Common Stock Beneficially Owned		Series D Preferred Stock		Series D-1 Preferred Stock	
	Shares	Percentage	Shares	Percentage	Shares	Percentage
Robert J. Vander Zanden	12,702 (2)	*	—	—	—	—
Anthony Hayes	176,681 (3)	3.64 %	—	—	—	—
Tim S. Ledwick	12,826 (4)	*	—	—	—	—
Paul LeMire	12,411 (5)	*	—	—	—	—
Robert Dudley	12,411 (6)	*	—	—	—	—
Gregory James Blattner	12,411 (7)	*	—	—	—	—
Kyle Wool	197,080 (8)	4.07 %	—	—	—	—
Soo Yu	83,701 (9)	1.72 %	—	—	—	—
Christopher Devall	13,835 (10)	*	—	—	—	—
Carlos Aldavero	25,000 (11)	*	—	—	—	—
All Directors and Officers as a Group (10 persons)	436,522	9.43 %	—	—	—	—
Stockholders						
Daniel W. Armstrong 611 Loch Chalet Ct Arlington, TX 76012-3470	10 (12)	*	1,350	28.57 %	—	—
R. Douglas Armstrong 570 Ocean Dr. Apt 201 Juno Beach, FL 33408-1953	4 (13)	*	450	9.52 %	—	—
Thomas Curtis 4280 10 Oaks Road Dayton, MD 21036-1124	7 (14)	*	900	19.05 %	—	—
Francis Howard 376 Victoria Place London, SW1 V1AA United Kingdom	7 (15)	*	900	19.05 %	—	—
Charles Strogen 6 Winona Ln Sea Ranch Lakes, FL 33308-2913	9 (16)	*	1,125	23.81 %	—	—
Chai Lifeline Inc. 151 West 30th Street, Fl 3 New York, NY 10001-4027	7 (17)	*	—	—	834	100 %

Name of Beneficial Owner(1)	Common Stock Beneficially Owned		Series D Preferred Stock		Series D-1 Preferred Stock	
	Shares	Percentage	Shares	Percentage	Shares	Percentage
Anthony Hayes	317,310 (2)	5.35 %	—	—	—	—
Tim S. Ledwick	12,826 (3)	*	—	—	—	—
Robert Dudley	12,411 (4)	*	—	—	—	—
Gregory James Blattner	12,411 (5)	*	—	—	—	—
Kyle Wool	246,431 (6)	4.15 %	—	—	—	—
Soo Yu	1,243,466 (7)	20.95 %	—	—	—	—
Kyle Haug	—	*	—	—	—	—
George Way	32,103 (8)	*	—	—	—	—
Christopher Devall	77,651 (9)	1.31 %	—	—	—	—
All Directors and Officers as a Group (9 persons)	1,954,609	32.93 %	—	—	—	—
Stockholders						
Daniel W. Armstrong 611 Loch Chalet Ct Arlington, TX 76012-3470	10 (10)	*	1,350	35.29 %	—	—
R. Douglas Armstrong 570 Ocean Dr. Apt 201 Juno Beach, FL 33408-1953	4 (11)	*	450	11.76 %	—	—
Francis Howard 376 Victoria Place London, SW1 V1AA United Kingdom	7 (12)	*	900	23.53 %	—	—
Charles Strogen 6 Winona Ln Sea Ranch Lakes, FL 33308-2913	9 (13)	*	1,125	29.42 %	—	—
Chai Lifeline Inc. 151 West 30th Street, Fl 3 New York, NY 10001-4027	7 (14)	*	—	—	834	100 %

* Less than 1% of the outstanding shares of the **Company Common Stock**. **Company's common stock**.

- (1) Under Rule 13d-3 of the Exchange Act a beneficial owner of a security includes any person who, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise has or shares: (i) voting power, which includes the power to vote or to direct the voting of shares; and (ii) investment power, which includes the power to dispose or direct the disposition of shares. Certain shares may be deemed to be beneficially owned by more than one person (if, for example, persons share the power to vote or the power to dispose of the shares). In addition, shares are deemed to be beneficially owned by a person if the person has the right to acquire the shares (for example, upon exercise of an option) within 60 days of the date as of which the information is provided. In computing the percentage ownership of any person, the amount of shares outstanding is deemed to include the amount of shares beneficially owned by such person (and only such person) by reason of these acquisition rights.
- (2) Includes 9,761 314,369 shares of Common Stock common stock and 2,941 options for purchase of Common Stock, shares of common stock, which are exercisable within 60 days of March 20, 2023 March 26, 2024.
- (3) Includes 173,740 9,885 shares of Common Stock common stock and 2,941 options for purchase of Common Stock, shares of common stock, which are exercisable within 60 days of March 20, 2023 March 26, 2024.
- (4) Includes 9,885 9,470 shares of Common Stock common stock and 2,941 options for purchase of Common Stock, shares of common stock, which are exercisable within 60 days of March 20, 2023 March 26, 2024.
- (5) Includes 9,470 shares of Common Stock common stock and 2,941 options for purchase of Common Stock, shares of common stock, which are exercisable within 60 days of March 20, 2023 March 26, 2024.
- (6) Includes 9,470 246,431 shares of Common Stock and 2,941 options common stock.
- (7) Includes 1,243,466 shares of common stock.

- (8) Includes 32,103 restricted stock awards for purchase of Common Stock, shares of common stock, which are exercisable within 60 days of March 20, 2023 March 26, 2024.
- (7) (9) Includes 9,470 30,033 shares of Common Stock common stock and 2,941 47,618 options for purchase of Common Stock, shares of common stock, which are exercisable within 60 days of March 20, 2023 March 26, 2024.
- (8) Includes 197,080 shares of Common Stock.
- (9) Includes 83,701 shares of Common Stock.
- (10) Includes 13,835 shares of Common Stock.
- (11) Includes 25,000 shares of Common Stock.

- (12) (10) Represents 10 shares of Common Stock common stock issuable upon conversion of the Series D Preferred Stock, which are convertible within 60 days of March 20, 2023 March 26, 2024.
- (13) (11) Represents 4 shares of Common Stock common stock issuable upon conversion of the Series D Preferred Stock, which are convertible within 60 days of March 20, 2023 March 26, 2024.
- (14) (12) Represents 7 shares of Common Stock common stock issuable upon conversion of the Series D Preferred Stock, which are convertible within 60 days of March 20, 2023 March 26, 2024.
- (15) (13) Represents 79 shares of Common Stock common stock issuable upon conversion of the Series D Preferred Stock, which are convertible within 60 days of March 20, 2023 March 26, 2024.
- (16) (14) Represents 9 shares of Common Stock issuable upon conversion of the Series D Preferred, which are convertible within 60 days of March 20, 2023.
- (17) Represents 7 shares of Common Stock common stock issuable upon conversion of the Series D-1 Preferred Stock, which are convertible within 60 days of March 20, 2023 March 26, 2024.

Effective March 23, 2020, and as amended and restated on November 24, 2020 October 11, 2023, the Company and Continental Stock Transfer & Trust Co. entered into a certain rights agreement (the "Rights Agreement"). The Rights Agreement provides each stockholder of record a dividend distribution of one "right" for each outstanding share of Common Stock, common stock. Rights become exercisable at the earlier of ten days following: (1) a public announcement that an acquirer has purchased or has the right to acquire 4.99% or more of our Common Stock, common stock, in connection with, (x) the Company consolidating, or merging into any other person, (y) any person consolidates or merges with or into the Company or (z) the Company sells or otherwise transfers to any person or persons, in one or more transactions, assets or earning power aggregating 50% or more of the assets or earning power of the Company or (2) the commencement of a tender offer which would result in an offer or beneficially owning 10% or more of our outstanding Common Stock, common stock. All rights held by an acquirer or offer or expire on the announced acquisition date, and all rights expire at the earliest of: (i) the close of business on March 23, 2023 October 11, 2024, subject to further extension, extension; (ii) the time at which the Rights are redeemed; (iii) the time at which the rights are exchanged; (iv) the closing of any merger or other acquisition transaction involving the Company pursuant to a specified agreement; (vi) the close of business on the date the Board of Directors determines that the Rights Agreement is no longer necessary or desirable for the preservation of tax benefits; and (vii) the close of business on the first day of a taxable year of the Company to which the Board of Directors determines that no tax benefits are available to be carried forward. Each right entitles a stockholder to acquire, at a price of \$5.00 per one one-thousandth of a share of our Series A Q Preferred Stock, subject to adjustments, which carries voting and dividend rights similar to one share of our Common Stock, common stock. The purchase price of the preferred stock fractional amount is subject to adjustment for certain events as described in the Rights Agreement. At the discretion of a majority of the Board of Directors and within a specified time period, we may redeem all of the rights at a price of \$0.0001 per right. The Board of Directors may also amend any provisions of the Rights Agreement prior to exercise.

Item 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE

The current Board of Directors consists of: Mr. Anthony Hayes, Mr. Tim S. Ledwick, Mr. Anthony Hayes, Dr. Robert J. Vander Zanden, Mr. Robert Dudley, Mr. Paul LeMire, Mr. Kyle Wool, Mr. Gregory James Blattner, and Ms. Soo Yu, Yu and Mr. Kyle Haug. The Board of Directors has determined that Dr. Vander Zanden, Mr. Ledwick, Mr. Wool, Mr. Blattner, and Ms. Yu Mr. Haug are independent directors within the meaning of the applicable Nasdaq rules. Our Audit, Compensation, and Nominating Committees consist solely of independent directors.

There have been no transactions, since January 1, 2022, to which we have been a party, in which the amount involved exceeds or will exceed \$120,000 and in which any of our directors, executive officers, holders of more than 5% of our capital stock, or immediate family member thereof, had or will have a direct or indirect material interest.

We have not adopted written policies and procedures specifically for related person transactions. Our Board of Directors is responsible to approve for the approval of all related party transactions, and approved each of the transactions set forth above.

The Company has engaged the services of Revere Securities, LLC ("Revere") to strategically manage and build the Corporation's investment processes since 2021. Kyle Wool is the president of Revere. On March 14, 2022 the Board approved and consented to an affiliated transaction whereby Anthony Hayes will acquire an 8% ownership interest in Revere on the terms and subject to the conditions set forth in a Purchase Agreement.

Item 14. PRINCIPAL ACCOUNTING ACCOUNTANT FEES AND SERVICES

Audit Fees Paid to Auditor

The following table sets forth the fees paid for professional services rendered by our Company to Marcum LLP for audit and other services provided for the fiscal year years ended December 31, 2022. Marcum LLP did not provide any services in 2021.

	2022
Audit Fees	\$ 91,417
Audit Related Fees	-
Tax Fees	-
All Other Fees	-
Total	\$ 91,417

The following table sets forth the fees paid by our Company to WithumSmith+Brown, PC for audit December 31, 2023 and other services provided for the fiscal year ended December 31, 2021 December 31, 2022.

	2021	2023	2022
Audit Fees	\$ 41,200	\$ 419,360	\$ 60,517
Audit Related Fees	-	-	-
Tax Fees	-	-	-
All Other Fees	-	-	-
Total	\$ 41,200	\$ 419,360	\$ 60,517

Policy on Audit Committee Pre-Approval of Audit and Permissible Non-Audit Services of Independent Auditors
Consistent with SEC policies and guidelines regarding audit independence, the Audit Committee is responsible for the pre-approval of all audit and permissible non-audit services provided by our principal accountants. Our Audit Committee has established a policy regarding approval of all audit and permissible non-audit services provided by our principal accountants. No non-audit services were performed by our principal accountants during the fiscal years ended December 31, 2022 December 31, 2023 and 2021, 2022. Our Audit Committee pre-approves these services by category and service. Our Audit Committee has pre-approved all of the services provided by our principal accountants.

PART IV

Item 15. EXHIBITS, EXHIBIT AND CONSOLIDATED FINANCIAL STATEMENTS, STATEMENT SCHEDULES

Consolidated Financial Statements

The following consolidated financial statements are included in Item 8 herein:

2. Consolidated Financial Statement Schedules

None None.

Exhibits EXHIBITS

Exhibit No.	Description
3.1	Amended and Restated Certificate of Incorporation of Spherix Incorporated, dated April 24, 2014 (incorporated by reference to Form 8-K filed April 25, 2014)
3.2	Certificate of Amendment of the Amended and Restated Certificate of Incorporation of Spherix Incorporated, dated March 2, 2016 (incorporated by reference to Form 8-K filed March 18, 2016)
3.3	Amended and Restated Bylaws of Spherix Incorporated (incorporated by reference to Form 8-K filed October 15, 2013)
3.4	Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Spherix Incorporated, effective March 4, 2016 (incorporated by reference to Form 10-K filed March 29, 2016)
3.5	Second Amended and Restated Bylaws of Alkido Pharma Inc. (incorporated by reference from the Company's Proxy Statement on Form DEF 14A filed October 5, 2020)
3.6	Amendment No. 1 to the Second Amended and Restated Bylaws of Alkido Pharma Inc. (incorporated by reference to Form 8-K filed on November 9, 2021)
3.7	Certificate of Amendment to Amended and Restated Articles of Incorporation of Aikido Inc., effective on June 7, 2022 (incorporated by reference to Form 8-K filed on June 10, 2022)
3.8	Certificate of Amendment to Amended and Restated Articles of Incorporation of Aikido Inc., effective on December 22, 2022 (incorporated by reference to Form 8-K filed on December 22, 2022)
3.9	Certificate of Designation of Preferences, Rights and Limitations of Series D Convertible Preferred Stock (incorporated by reference to Form 8-K filed on April 4, 2013)
3.10	Certificate of Designation of Preferences, Rights and Limitations of Series D-1 Convertible Preferred Stock (incorporated by reference to Form 8-K filed on November 29, 2013)
3.11	Certificate of Designation of Preferences, Rights and Limitations of Series Q Preferred Stock (incorporated by reference to Form 8-K filed on October 17, 2023)
4.1	Specimen Certificate for common stock, par value \$0.0001 per share, of Spherix Incorporated (incorporated by reference to Form S-3/A filed April 17, 2014)
4.2	Certificate of Designation of Preferences, Rights and Limitations of Series J Convertible Preferred Stock (incorporated by reference to Form 8-K/A filed on June 2, 2014)
4.3	Certificate of Designation of Preferences, Rights and Limitations of Series K Convertible Preferred Stock (incorporated by reference to Form 8-K filed on December 3, 2015)
4.4	Certificate of Designation of Preferences, Rights and Limitations of Series O Redeemable Convertible Preferred Stock (incorporated by reference to Form 8-K filed on March 2, 2022)
4.5	Certificate of Designation of Preferences, Rights and Limitations of Series P Redeemable Convertible Preferred Stock (incorporated by reference to Form 8-K filed on March 2, 2022)
4.6*	Description of Securities Registered Under Section 12 of the Securities Exchange Act of 1934 (incorporated by reference to Form 10-K filed on March 31, 2023)
4.3	Rights Agreement, dated as of October 11, 2023, by and between Dominari Holdings Inc., as the Company, and Continental Stock Transfer & Trust Company, as Rights Agent (incorporated by reference to Form 8-K filed on October 17, 2023)

10.1	Agreement and Plan of Merger, dated April 2, 2013 (incorporated by reference to the Form 8-K filed on April 4, 2013)
10.2	First Amendment to Agreement and Plan of Merger, dated August 30, 2013 (incorporated by reference to the Form 8-K filed on September 4, 2013)
10.3	Spherix Incorporated 2014 Equity Incentive Plan (incorporated by reference from the Company's Proxy Statement on Form DEF 14A filed December 20, 2013)
10.4 10.2	Amendment to Spherix Incorporated 2014 Equity Incentive Plan (incorporated by reference from the Company's Proxy Statement on Form DEF 14A filed on March 28, 2014)
10.5 10.3	Form of Indemnification Agreement (incorporated by reference to the Form 8-K filed on September 10, 2013)
10.6	Employment Agreement, by and between Spherix Incorporated and Anthony Hayes (incorporated by reference to the Form 8-K filed on September 13, 2013)
10.7**	Patent Purchase Agreement, by and between Spherix Incorporated and Rockstar Consortium US LP, including Amendment No. 1 thereto (incorporated by reference to the Form 8-K/A filed on November 19, 2013)
10.8	Confidential Patent Purchase Agreement, dated December 31, 2013, by and between Spherix Incorporated and Rockstar Consortium US LP (incorporated by reference to the Form S-1/A filed January 21, 2014)
10.9	Settlement and License Agreement, dated October 13, 2015, by and between Spherix Incorporated and Huawei Technologies Co., Ltd. (incorporated by reference to Form 10-K filed March 29, 2016)
10.10	Patent License Agreement, dated as of November 23, 2015, by and between Spherix Incorporated and RPX Corporation (incorporated by reference to Form 8-K filed November 30, 2015)
10.11 10.4	Employment Agreement, effective as of April 1, 2016, by and between Spherix Incorporated and Anthony Hayes (incorporated by reference to Form 8-K filed May 26, 2016)
10.12 10.5	Amendment to Employment Agreement, by and between Spherix Incorporated and Anthony Hayes (incorporated by reference to the Form 8-K filed on October 25, 2017)
10.13	Patent License Agreement, dated as of May 23, 2016, by and between Spherix Incorporated and RPX Corporation (incorporated by reference to Form 10-Q filed August 15, 2016)
10.14 10.6	Technology Monetization Agreement, dated as of March 11, 2016, and amended as of April 22, 2016, April 27, 2016 and May 22, 2016, by and between Spherix Incorporated and Equitable IP Corporation (incorporated by reference to Form 8-K filed August 2, 2016)
10.15	Assignment and Assumption of Rights Agreement, dated as of June 16, 2016, by and between Spherix Incorporated and Transfer Online, Inc. (incorporated by reference to Form 8-K filed June 21, 2016)
10.16	Agreement and Plan of Merger, dated as of March 12, 2018, by and among Spherix Incorporated, Spherix Merger Subsidiary Inc., DatChat, Inc. and Darin Myman (incorporated by reference to Form 8-K filed March 14, 2018)
10.17	Assignment of Agreement, dated as of November 13, 2019, by and among The University of Texas in Austin, on behalf of the Board of Regents of the University of Texas, CBM BioPharma, Inc. and Spherix Incorporated (incorporated by reference to the Company's Annual Report on Form 10-K filed on February 3, 2020)
10.18	Assignment of Agreement, dated as of November 13, 2019, by and among Wake Forest University Health Sciences, CBM BioPharma, Inc. and Spherix Incorporated (incorporated by reference to the Company's Annual Report on Form 10-K filed on February 3, 2020)
10.19	First Amendment to Agreement and Plan of Merger, dated as of May 3, 2018, by and among Spherix Incorporated, Spherix Merger Subsidiary Inc., DatChat, Inc. and Darin Myman (incorporated by reference to Form 8-K filed May 7, 2018)

10.20	Agreement and Plan of Merger, dated as of October 10, 2018, by and among Spherix Incorporated, Spherix Delaware Merger Sub Inc., Scott Wilfong and CBM Biopharma, Inc. (incorporated by reference to Form 8-K filed October 16, 2018)
10.21 10.7	At The Market Offering Agreement, dated as of August 9, 2019, by and between Spherix Incorporated and H.C. Wainwright & Co., LLC (incorporated by reference to Form 8-K filed August 9, 2019)
10.22	Asset Purchase Agreement, dated as of May 15, 2019, by and between the Company and CBM BioPharma, Inc. (incorporated herein by reference to Form 10-Q filed on August 14, 2019)
10.23	Amendment No. 1 to Asset Purchase Agreement, dated as of May 30, 2019, by and between the Company and CBM BioPharma, Inc. (incorporated herein by reference to Form 10-Q filed on August 14, 2019)
10.24	Amendment No. 2 to Asset Purchase Agreement, dated as of December 5, 2019, by and between the Company and CBM BioPharma, Inc. (incorporated herein by reference to Form 8-K filed on December 10, 2019)
10.25 10.8	Amendment to Aikido Pharma Inc. 2014 Equity Incentive Plan (incorporated by reference from the Company's Proxy Statement on Form DEF 14A filed October 5, 2020)
10.26 10.9	Form of Securities Purchase Agreement Between Aikido Pharma Inc. and the Investors thereto, dated February 24, 2022 (incorporated by reference to Form 8-K filed on March 2, 2022)
10.27 10.10	Confirmation of Mutual Understanding Between Aikido Pharma Inc. and each of the Warrant Holders, dated as of March 24, 2022 (incorporated by reference from the Company's Annual Report on Form 10-K filed on March 28, 2022)
10.28 10.11	Aikido Pharma Inc. 2022 Equity Incentive Plan (incorporated by reference from the Company's Proxy Statement on Form DEF 14A filed October 21, 2022)
10.12	Employment Agreement, Made and Entered into as of July 1, 2022, By and Between Aikido Pharma Inc. and Christopher Devall (incorporated by reference to Form 8-K Filed on January 6, 2023)
10.29* 10.13	Employment Agreement, Made and Entered into as of July 22, 2022, By and Between Aikido Pharma Inc. and Carlos Aldavero (incorporated by reference to Form 10-K filed on March 31, 2023)
10.30 10.14	Amendment to Employment Agreement, Dated as of January 1, 2023, By and Between Dominari Holdings Inc. and Christopher Devall (incorporated by reference to Form 8-K filed on January 6, 2023)
10.31 10.15	Amended and Restated Membership Interest Purchase Agreement, Dated as of March 27, 2023, by and among Fieldpoint Private Securities, LLC, Fieldpoint Private Bank & Trust, and Dominari Financial Inc. (incorporated by reference to Form 8-K filed on March 28, 2023)
10.16	Employment Agreement, Made and Entered into as of March 29, 2023, By and Between Dominari Holdings Inc. and George M. Way (incorporated by reference to Form 8-K filed on April 3, 2023)
10.17	Employment Agreement, Made and Entered into as of April 3, 2023, By and Between Dominari Securities LLC and Soo Yu (incorporated by reference to Form 10-Q filed on May 11, 2023)

10.18	Amendment to Employment Agreement, Made and Entered into as of April 19, 2023, By and Between Dominari Securities LLC and Soo Yu (incorporated by reference to Form 10-Q filed on May 11, 2023)
21.1*	List of Subsidiaries
23.1*	Consent of Marcum LLP
23.2*	Consent of WithumSmith+Brown, PC
31.1*	Certification of Principal Executive Officer pursuant to Item 601(b)(31) of Regulation S-K, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*	Certification of Principal Financial Officer pursuant to Item 601(b)(31) of Regulation S-K, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1**	Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2**	Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
97.1*	Clawback Policy
101.INS*	Inline XBRL Instance Document
101.SCH*	Inline XBRL Taxonomy Extension Schema Document
101.CAL*	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*	Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*	Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE*	Inline XBRL Taxonomy Extension Presentation Linkbase Document
104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

* Filed herewith.

** [Furnished herewith.](#)

** Pursuant to a Confidential Treatment Request under Rule 24b-2 filed with and approved by the SEC, portions of this exhibit have been omitted

Item 16. [Form FORM](#) 10-K [Summary SUMMARY](#)

Not applicable.

Pursuant to the requirements of Section 13 or 15(d) of the Exchange Act of 1934, the Registrant registrant has duly caused this report Annual Report to be signed on its behalf by the undersigned, thereunto duly authorized.

By: /s/ Anthony Hayes
Anthony Hayes
Chief Executive Officer and Director
(Principal Executive Officer,
Principal Chairman
By: /s/ George Way
George Way
Chief Financial Officer and
Principal Accounting Officer)

Date: March 31, 2023 April 1, 2024

Date: April 1, 2024

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant **registrant** and in the capacities and on the dates indicated

/s/ Anthony Hayes	Chief Executive Officer and Director	Chairman	March 31, 2023	April 1, 2024
Anthony Hayes				
/s/ George Way	Chief Financial Officer			April 1, 2024
George Way				
/s/ Kyle Wool	President and Director			April 1, 2024
Kyle Wool				
/s/ Tim S. Ledwick	Director		March 31, 2023	April 1, 2024
Tim S. Ledwick				
/s/ Robert J. Vander Zanden	Chairman of the Board		March 31, 2023	
Robert J. Vander Zanden				
/s/ Paul LeMire	Director		March 31, 2023	
Paul LeMire				
/s/ Robert Dudley	Director		March 31, 2023	April 1, 2024
Robert Dudley				
/s/ Gregory James Blattner	Director		March 31, 2023	April 1, 2024
Gregory James Blattner				
/s/ Kyle Wool	Director		March 31, 2023	April 1, 2024
Kyle Wool				
/s/ Soo Yu	Director		March 31, 2023	April 1, 2024
Kyle Haug				
Soo Yu				

6847

Exhibit 4.6

**DESCRIPTION OF SECURITIES
REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES
EXCHANGE ACT OF 1934**

Common Stock

The following description is based on relevant portions of the Delaware General Corporation Law (the “DGCL”) and our Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”). This summary is a description of the material terms of, and is qualified in its entirety by, reference to our Certificate of Incorporation, a copy of which is filed as an exhibit to our previous filings with the SEC and incorporated by reference to the Annual Report on Form 10-K of which this Description of Securities is attached as an exhibit.

Authorization; Outstanding Shares. We are authorized to issue 100,000,000 shares of common stock, par value \$0.0001 per share, of which 4,840,597 shares were issued and outstanding as of March 20, 2022. We may amend from time to time our Certificate of Incorporation to increase the number of authorized shares of common stock. Any such amendment would require the approval of the holders of a majority of the voting power of the shares entitled to vote thereon.

Voting Rights. Holders of our common stock are entitled to one (1) vote for each share on all matters submitted to a stockholder vote. The common stock does not have cumulative voting rights. Therefore, holders of a majority of the shares of common stock voting for the election of directors can elect all of the directors. Holders of our common stock representing a majority of the voting power of our capital stock issued, outstanding and entitled to vote, represented in person or by proxy, are necessary to constitute a quorum at any meeting of stockholders.

Dividends. Subject to limitations under Delaware law and the rights of holders of any class of stock having preference over our common stock, holders of our common stock are entitled to share in all dividends that our board of directors, in its discretion, declares from legally available funds.

Liquidation; Dissolution. In the event of a liquidation, dissolution or winding up, each outstanding share entitles its holder to participate pro rata in all assets that remain after payment of liabilities and after providing for each class of stock, if any, having preference over the common stock.

Other Rights and Restrictions. Our common stock has no pre-emptive rights, no conversion rights and there are no redemption provisions or sinking fund provisions applicable to the common stock.

Listing. Our common stock is quoted on the Nasdaq Capital Market under the symbol “DOMH.” As of March 20, 2022, there were 135 record holders of our common stock.

Transfer Agent and Registrar. The transfer agent and registrar for our common stock is Continental Stock Transfer & Trust Company. The transfer agent and registrar’s address is 1 State Street, 30th Floor, New York, NY 10004 and its telephone number is (212) 509-4000.

Anti-Takeover Provisions

Provisions of our Certificate of Incorporation and Second Amended and Restated Bylaws (“Bylaws”) could make it more difficult to acquire us by means of a merger, tender offer, proxy contest, open market purchases, removal of incumbent directors and otherwise. These provisions, which are summarized below, are expected to discourage types of coercive takeover practices and inadequate takeover bids and to encourage persons seeking to acquire control of us to first negotiate with us. We believe that the benefits of increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging takeover or acquisition proposals because negotiation of these proposals could result in an improvement of their terms.

Vacancies. Newly created directorships resulting from any increase in the number of directors and any vacancies on the board of directors resulting from death, resignation, disqualification, removal or other cause shall be filled by a majority of the remaining directors on the board.

Bylaws. Our Certificate of Incorporation and Bylaws authorize the board of directors to adopt, repeal, rescind, alter or amend our bylaws without stockholder approval.

Removal. Except as otherwise provided, a director may be removed from office only by the affirmative vote of the holders of not less than a majority of the voting power of the issued and outstanding stock entitled to vote.

Cumulative Voting. Our Certificate of Incorporation does not provide for cumulative voting in the election of directors, which would allow holders of less than a majority of the stock to elect some directors.

Staggered Board. Our Bylaws provide for a board of directors divided into three classes with only one class of directors being elected in each year and each class serving a three-year term. As a result, only a minority of the board of directors will be considered for election at every annual meeting of stockholders, which may make the removal of management more difficult and may discourage transactions that otherwise could involve payment of a premium over prevailing market prices for our securities.

Exhibit 10.29

EMPLOYMENT AGREEMENT

THIS EMPLOYMENT AGREEMENT (the “**Agreement**”) is made and entered effective as of **July 22, 2022** (the “**Effective Date**”), by and between Aikido Pharma Inc., a Delaware with offices at One Rockefeller Plaza, 11th Floor, New York, NY (the “**Corporation**”), and Carlos Aldavero, an individual residing at 5 West 86th Street, Apt. 9E, New York, NY 10024 (the “**Executive**”), under the following circumstances:

RECITALS:

A. The Corporation desires to secure the services of the Executive upon the terms and conditions hereinafter set forth;

B. The Executive desires to render services to the Corporation upon the terms and conditions hereinafter set forth; and

C. The Corporation and the Executive desire for this Agreement to constitute and embody their full and complete understanding and agreement with respect to the Executive’s employment by the Corporation and supersede, as of the Effective Date, all prior understandings and agreements, whether oral or written, between them with respect to such employment.

NOW, THEREFORE, the parties mutually agree as follows:

1. **Employment.** The Corporation hereby employs the Executive and the Executive hereby accepts employment as an executive of the Corporation, subject to the terms and conditions set forth in this Agreement.

2. **Duties and Place of Employment.** The Executive shall serve as the President of Dominari Financial Inc., a wholly owned subsidiary of the Corporation, with such duties, responsibilities, and authority as are commensurate and consistent with his position, and such other duties, responsibilities and authority as may be, from time to time, reasonably assigned to him by the Chief Executive Officer of the Corporation (the “**CEO**”) or the Board of Directors of the Corporation (the “**Board**”). The Executive shall report directly to the CEO. During the Term (as defined in Section 3), the Executive shall devote his full business time and efforts to the performance of his duties hereunder unless otherwise authorized by the CEO. Notwithstanding the foregoing, the expenditure of reasonable amounts of time by the Executive for the making of passive personal investments, the conduct of private business affairs, and charitable and professional activities shall be allowed, provided such activities do not materially interfere with the services required to be rendered to the Corporation hereunder and do not violate the confidentiality provisions set forth in Section 8 below. The Executive shall be permitted to perform his services for the Corporation from his home in New York City or at Aikido’s offices at 755 5th Ave, New York City or such other location as mutually agreed to by the parties.

3. **Term of Employment.** The term of this Agreement shall be for three (3) years (the “Initial Term”) and automatically be extended for additional terms of one (1) year each (each a “Renewal Term”) unless either party gives prior written notice of non-renewal to the other party no later than three (3) months prior to the expiration of the Initial Term (“Non-Renewal Notice”), or the then current Renewal Term, as the case may be. For purposes of this Agreement, the Initial Term and any Renewal Term are hereinafter collectively referred to as the “Term.”

4. **Compensation of Executive.**

(a) The Corporation shall pay the Executive as compensation for his services hereunder, in equal semi-monthly or bi-weekly installments during the Term the sum of \$450,000 per annum (the “Base Salary”), less such deductions as shall be required to be withheld by applicable law and regulations. The Corporation, or the Compensation Committee of the Corporation (the “Compensation Committee”), shall review the Base Salary annually after the initial three year Term and shall have the right but not the obligation to make such adjustments to the Base Salary as it deems appropriate in its discretion.

(b) In addition to the Base Salary, on or about the Effective Date, the Corporation shall pay the Executive a signing bonus in cash equal to \$213,000, less such deductions as shall be required to be withheld by applicable law and regulations.

(c) In addition to the Base Salary, the Executive shall be entitled to receive an annual cash bonus (“Annual Bonus”) in an amount determined by the Board in its discretion if the Corporation meets or exceeds criteria adopted by the Board, which criteria shall be adopted by the Board annually after consultation with the Executive and which criteria must be reasonably likely to be attainable. Annual Bonuses shall be paid by the Corporation to the Executive promptly after the year end in cash or in restricted shares of the Corporation’s common stock, it being understood that the Board’s determinations concerning attainment of any financial targets associated with any bonus determination shall not be determined until following the completion of the Corporation’s annual audit and public announcement of such results and shall be paid promptly following the Corporation’s announcement of earnings, but in no event later than December 31 of the year following the year for which it is being paid (and if the Executive was employed on April 15th of year following the calendar year to which such Annual Bonus relates, then the Executive shall be entitled to the Annual Bonus for such year, even if he is not employed by the Corporation on the date the Annual Bonus is paid for such last year). For the avoidance of doubt, if Executive is employed upon expiration of the Term, he shall be entitled to the Annual Bonus for such last year on a pro-rata basis through the last date of employment provided such date is on or before the April 15th of year following the calendar year to which such Annual Bonus relates, even if he is not employed by the Corporation on the date such Annual Bonus is paid. In his sole discretion, the Executive may elect to receive such annual bonus in common stock of the Corporation on such basis as determined by the Board in good faith.

(d) The Board shall approve a restricted stock grant to the Executive (the “Restricted Stock Grant”) with respect to shares of common stock of Dominari Financial Inc. with a value on the grant date (the “Grant Date”) equal to 2.5% the fair market value of the Corporation, as determined by the Board in its good faith discretion. The Restricted Stock Grant shall be completed within twenty (20) days of the Effective Date. The Restricted Stock Grant shall vest on a pro rata basis on each of the twelve (12) calendar quarters starting after the Grant Date. Notwithstanding the foregoing, the Restricted Stock Grant shall immediately vest in full if during the Term if there is (i) a Change in Control Transaction during the term of the Executive’s employment, (ii) a termination of the Executive’s services hereunder by the Corporation other than for “Cause” (each as defined in Section 5 below), (iii) a termination by the Executive for Good Reason (as hereinafter defined), or (iv) as a result of the Executive’s death or Total Disability (as herein defined). In the event that the Executive makes an election under Section 83(b) of the Code, the Corporation will make a non-recourse loan to him on such reasonable terms as the parties shall determine in an amount sufficient to enable him to pay any income taxes resulting from such election.

(e) The Compensation Committee of the Corporation (the “Compensation Committee”) shall approve an equity grant to the Executive in stock options, restricted stock or restricted stock units as determined by the Compensation Committee (the “Equity Grant”) pursuant to the Corporation’s 2014 Equity Incentive Plan (the “Plan”) with respect to 50,000 shares of common stock of the Corporation. The Equity Grant shall be completed on the Grant Date and shall vest on a pro rata basis at the end of each of the ten (10) months starting after the Grant Date. Notwithstanding the foregoing, the Equity Grant shall immediately vest in full if during the Term if there is (i) a Change in Control Transaction during the term of the Executive’s employment, (ii) a termination of the Executive’s services hereunder by the Corporation other than for “Cause” (each as defined in Section 5 below), a termination by the Executive for Good Reason (as hereinafter defined), or (iv) as a result of the Executive’s death or Total Disability (as herein defined). In the event that the Executive makes an election under Section 83(b) of the Code, the Corporation will make a non-recourse loan to him on such reasonable terms as the parties shall determine in an amount sufficient to enable him to pay any income taxes resulting from such election. Notwithstanding the foregoing, the obligation of the Compensation Committee to issue shares of the common stock of the Corporation pursuant to the Equity Grant is contingent on the number of authorized shares under the Plan being sufficient to support such grant.

(f) The Corporation shall pay or reimburse the Executive for all reasonable out-of-pocket expenses actually incurred or paid by the Executive in the course of his employment, consistent with the Corporation’s policy for reimbursement of expenses from time to time.

(g) The Executive shall be entitled to participate in such pension, profit sharing, group insurance, hospitalization, and group health and benefit plans and all other benefits and plans, including perquisites (e.g., cell phone), if any, as the Corporation provides to its senior executives, including group family health insurance coverage, which shall be paid by the Corporation (the “Benefit Plans”). If at any time during the Term, the Corporation does not provide its senior executives with health insurance (including hospitalization) under a Benefit Plan, Executive shall be entitled to secure such health insurance for himself and his immediate family (i.e., spouse and natural born children) and the Corporation shall reimburse Executive for the cost of such insurance promptly after payment by the Executive for such insurance. If Executive secures such health insurance, such health insurance shall be deemed to be a Benefit Plan hereunder to maximum extent permitted under applicable law.

(h) The Corporation shall execute and deliver in favor of the Executive an indemnification agreement on the same terms and conditions entered into with the other officers and directors of the Corporation. Such agreement shall provide for the indemnification of the Executive for the term of his employment and for a period of at least six (6) years thereafter. The Corporation shall maintain directors’ and officers’ insurance during the Term and for a period of at least six (6) years thereafter.

5. **Termination.**

(a) This Agreement and the Executive’s employment hereunder shall terminate upon the happening of any of the following events:

(i) upon the Executive’s death;

(ii) upon the Executive’s Total Disability;

(iii) upon the expiration of the Initial Term of this Agreement or any Renewal Term thereof, if either party has provided a timely Non-Renewal Notice in accordance with

Section 3;

(iv) at the Executive’s option, upon ninety (90) days prior written notice to the Corporation (other than under the circumstances set forth in Section 5(b)(viii));

(v) at the Executive’s option, for Good Reason, as defined in Section 5(c);

(vi) at the Corporation’s option, for Cause, as defined in Section 5(e);

(vii) at the Corporation’s option, upon ninety (90) days prior written notice to the Executive, without Cause; and

(viii) at the Executive’s option, upon written notice to the Corporation at any time within forty (40) days of the consummation of a Change in Control Transaction.

(b) For purposes of this Agreement, the Executive shall be deemed to be suffering from a “Total Disability” if the Executive has failed to perform his regular and customary duties to the Corporation for a period of 180 days out of any 360-day period and if before the Executive has become “Rehabilitated” (as herein defined) a majority of the members of the Board, exclusive of the Executive, determine that the Executive is mentally or physically incapable or unable to continue to perform such regular and customary duties of employment. As used herein, the term “Rehabilitated” shall mean such time as the Executive is willing, able, and commences to devote his time and energies to the affairs of the Corporation to the extent and in the manner that he did so prior to his Total Disability.

(c) For purposes of this Agreement, the term “Good Reason” shall mean that the Executive has resigned due to: (i) a material diminution of duties inconsistent with Executive’s title, authority, duties, and responsibilities (including, without limitation, a change in the chain of reporting) prior to such diminution; or (ii) any material violation by the Corporation of its obligations (including, without limitation, its compensation obligations) under this Agreement; provided that the Executive has given written notice to the Corporation within ninety (90) days of Executive’s knowledge of the initial occurrence of such event, and the Corporation has failed to cure such acts within thirty (30) days of receipt of such notice, if curable, and the Executive must then terminate his employment within thirty (30) days following the expiration of such cure period for the termination to be on account of Good Reason.

(d) For purposes of this Agreement, the term “Change in Control Transaction” means the sale of the Corporation to an un-affiliated person or entity or group of un-affiliated persons or entities pursuant to which such party or parties acquire (i) shares of capital stock of the Corporation representing at least fifty percent (50%) of outstanding capital stock or sufficient to elect a majority of the Board or of the board of directors of the Corporation (whether by merger, consolidation, sale, or transfer of shares (other than a merger where the Corporation is the surviving corporation and the shareholders and directors of the Corporation prior to the merger constitute a majority of the shareholders and directors, respectively, of the surviving corporation (or its parent)) or (ii) all or substantially all of the Corporation’s assets determined on a consolidated basis.

(e) For purposes of this Agreement, the term “Cause” shall mean any material breach of this Agreement by Executive or material, gross, and willful misconduct on the part of the Executive in connection with his employment duties hereunder, in all cases that is not cured within fourteen (14) days after receipt of notice thereof (to the extent such breach is capable of

being cured), or the Executive's conviction of or entering of a guilty plea or a plea of no contest with respect to a felony or any crime involving fraud, larceny, or embezzlement resulting in material harm to the Corporation by the Executive.

6. Effects of Termination.

Upon termination of employment for any reason, whether by the Executive or the Corporation, the Executive shall be paid accrued but unpaid compensation and vacation pay through the date of termination and any other benefits accrued to him under any Benefit Plans outstanding at the date of termination and the reimbursement of documented, unreimbursed expenses incurred on or prior to such date, all paid as promptly as practicable and in accordance with applicable law (collectively, "**Base Benefits**"), and the Executive shall have any conversion rights available under the Corporation's Benefit Plans and as otherwise provided by law, including the Consolidated Omnibus Budget Reconciliation Act and any similar state law or regulation ("**COBRA**"). The following provisions apply to specified termination events. Any Annual Bonus (including any pro-rated Annual Bonus) payable pursuant to the following provisions shall be paid at the same time that it would have been paid if the Executive's employment had not terminated.

(a) Upon termination of the Executive's employment pursuant to Section 5(a)(i) or (ii), in addition to the Base Benefits, the Executive or his estate or beneficiaries, as applicable, shall be entitled to the following severance benefits: (i) twelve (12) months 'Base Salary at the then current rate, payable in a lump sum, less withholding of applicable taxes, within thirty (30) days of the date of termination; (ii) if the Executive elects continuation coverage for group health coverage pursuant to COBRA, then for a period of twelve (12) months following the Executive's termination he will be obligated to pay only the portion of the full COBRA cost of the coverage equal to an active employee's share of premiums (if any) for coverage for the respective plan year and, to the extent required by any applicable nondiscrimination rules, the Company's share of such premiums (the "**Employer-Provided COBRA Premium**") shall be treated as taxable income to the Executive; and (iii) payment on a pro-rated basis of any Annual Bonus or other payments earned in connection with any bonus plan to which the Executive was a participant as of the date of death or Total Disability. This Section 6(a) shall not terminate or otherwise interfere with any right to disability payments.

(b) Upon termination of the Executive's employment pursuant to Section 5(a)(iii) where the Corporation has offered to renew the term of the Executive's employment for an additional one (1) year period and the Executive chooses not to continue in the employ of the Corporation, the Executive shall be entitled to receive only the Base Benefits, and the payment on a pro-rated basis of any Annual Bonus, or other payments earned in connection with any bonus plan to which the Executive was a participant as of the date of the Executive's termination of employment. In the event the Corporation tenders a Non-Renewal Notice to the Executive, then the Executive shall be entitled to the same severance benefits as if the Executive's employment were terminated pursuant to Section 5(a)(v); provided, however, if such Non-Renewal Notice was triggered due to the Corporation's statement that the Executive's employment was terminated due to Section 5(a)(vi), then payment of severance benefits will be contingent upon a determination as to whether termination was properly for Cause.

(c) Upon termination of the Executive's employment pursuant to Section 5(a)(v), 5(a)(vii) or 5(a)(viii), in addition to the Base Benefits, the Executive shall be entitled to the following severance benefits: (i) twelve (12) months 'Base Salary at the then current rate, to be paid in a single lump sum payment not later than thirty (30) days following such termination, less withholding of all applicable taxes; (ii) if the Executive elects continuation coverage for group health coverage pursuant to COBRA, then for a period of twelve (12) months following the Executive's termination he will be obligated to pay only the portion of the full COBRA cost of the coverage equal to an active employee's share of premiums (if any) for coverage for the respective plan year and, to the extent required by any applicable nondiscrimination rules, the Employer-Provided COBRA Premium shall be treated as taxable income to the Executive; and (iii) payment on a pro-rated basis of any Annual Bonus or other payments earned in connection with any bonus plan to which the Executive was a participant as of the date of the Executive's termination of employment. In addition, any equity grants to Executive shall be immediately vested upon termination of Executive's employment pursuant to Section 5(a)(v) or 5(a)(vii).

(d) Upon termination of the Executive's employment pursuant to Section 5(a)(iv) or (vi), in addition to the Base Benefits, the Executive shall be entitled to the following severance benefits: (i) accrued and unpaid Base Salary and vacation pay through the date of termination, less withholding of applicable taxes; and (ii) if the Executive elects continuation coverage for group health coverage pursuant to COBRA, then, for a period of one (1) month following the Executive's termination, he will be obligated to pay only the portion of the full COBRA cost of the coverage equal to an active employee's share of premiums (if any) for coverage for one month of the respective plan year and, to the extent required by any applicable nondiscrimination rules, the Employer-Provided COBRA Premium shall be treated as taxable income to the Executive.

(e) Any payments required to be made hereunder by the Corporation to the Executive shall continue to the Executive's beneficiaries in the event of his death until paid in full.

7. Vacations. The Executive shall be entitled to three (3) weeks of paid vacation per year. The Executive shall take his vacation at such time or times as the Executive and the CEO shall determine is mutually convenient. Any vacation not taken in one (1) year shall accrue, up to a maximum of six (6) weeks of vacation and shall carry over to the subsequent year.

8. Disclosure of Confidential Information. The Executive recognizes, acknowledges and agrees that he will have access to secret and confidential information regarding the Corporation and its affiliates, including but not limited to, its products, formulae, patents, sources of supply, customer dealings, data, know-how, and business plans, provided such information is not in or does not hereafter become part of the public domain, or become known to others through no fault of the Executive. The Executive acknowledges that such information is of great value to the Corporation, is the sole property of the Corporation, and has been and will be acquired by him in confidence. In consideration of the obligations undertaken by the Corporation herein, the Executive will not, at any time, during or after his employment hereunder, reveal, divulge, or make known to any person any information acquired by the Executive during the course of his employment, which is treated as confidential by the Corporation, and not otherwise in the public domain. The provisions of this Section 8 shall survive the termination of the Executive's employment hereunder. All references to the Corporation in Sections 8 and 9 hereof shall include affiliates of the Corporation.

9. Clawback Rights. The Annual Bonus, and any and all stock-based compensation (such as options and equity awards) (collectively, the "**Clawback Benefits**") shall be subject to "**Clawback Rights**" as follows. During the period that the Executive is employed by the Corporation and upon the termination of the Executive's employment and for a period of three (3) years thereafter, if there is a restatement of any financial results from which any Clawback Benefits to Executive shall have been determined, the Executive agrees to repay any amounts that were determined by reference to any Corporation financial results that were later restated (as defined below), to the extent the Clawback Benefits paid exceed the Clawback Benefits that would have been paid, based on the restatement of the Corporation's financial information. All Clawback Benefits resulting from such restated financial results shall be retroactively adjusted by the Compensation Committee to take into account the restated results, and any excess portion of the Clawback Benefits resulting from such restated results shall be immediately surrendered to the Corporation and if not so surrendered within ninety (90) days of the revised calculation being provided to the Executive by the Compensation Committee following a publicly announced restatement, the Corporation shall have the right to take any and all action to effectuate such adjustment. The calculation of the revised Clawback Benefits shall be determined by the Compensation Committee in good faith and applicable laws, rules, and regulations. All determinations by the Compensation Committee with respect to the Clawback Rights shall be final and binding on the Corporation and Executive. The Clawback Rights shall terminate following a Change of Control Transaction, subject to applicable laws, rules, and regulations. For purposes of this Section 9, a restatement of financial results that requires a repayment of a portion of the Clawback Benefits shall mean a restatement resulting from material non-compliance of the Corporation with any financial reporting requirement under the federal securities laws and shall not include a restatement of financial results resulting from subsequent changes in accounting pronouncements or requirements that were not in effect on the date the financial statements were originally prepared ("**Restatements**"). The parties acknowledge that it is their intention that the foregoing Clawback Rights as relates to Restatements conform in all respects to the provisions of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 (the "**Dodd-Frank Act**") and requires recovery of all "incentive-based" compensation, pursuant to the provisions of the Dodd-Frank Act and any and all rules and regulations promulgated thereunder from time to time. Accordingly, the terms and conditions of this Agreement shall be deemed automatically amended from time to time to the extent required to assure compliance with the Dodd-Frank Act or any applicable rules or regulations enacted thereunder that may be adopted by the Securities and Exchange Commission or any stock exchange on which the securities of the Company are listed.

10. Section 409A.

(a) The provisions of this Agreement are intended to comply with or be exempt from Section 409A of the Internal Revenue Code of 1986, as amended (the "**Code**") and any final regulations and guidance promulgated thereunder ("**Section 409A**") and shall be construed in a manner consistent with the requirements for avoiding taxes or penalties under Section 409A. The Corporation and Executive agree to work together in good faith to consider amendments to this Agreement and to take such reasonable actions that are necessary, appropriate, or desirable to avoid imposition of any additional tax, penalties or income recognition prior to actual payment to the Executive under Section 409A.

(b) To the extent that the Executive will be reimbursed for costs and expenses or in-kind benefits, except as otherwise permitted by Section 409A, (i) the right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit; (ii) the amount of expenses eligible for reimbursement, or in-kind benefits, provided during any taxable year shall not affect the expenses eligible for reimbursement, or in-kind benefits to be provided, in any other taxable year; provided, that the foregoing clause (ii) shall not be violated with regard to expenses reimbursed under any arrangement covered by Section 105(b) of the Code solely because such expenses are subject to a limit related to the period the arrangement is in effect; and (iii) such payments shall be made on or before the last day of the taxable year following the taxable year in which Executive incurred the expense.

(c) A termination of employment shall not be deemed to have occurred for purposes of any provision of this Agreement providing for the payment of any amounts or benefits upon or following a termination of employment unless such termination constitutes a "Separation from Service" within the meaning of Section 409A and, for purposes of any such provision of this Agreement references to a "termination," "termination of employment," or like terms shall mean Separation from Service.

(d) Each payment that is made within the terms of the "short-term deferral" rule set forth in Treasury Regulation Section 1.409A-1(b)(4) is intended to meet the "short-term deferral" rule. Each other payment is intended to be a payment upon an involuntary termination from service and payable pursuant to Treasury Regulation Section 1.409A-1(b)(9)(iii), et seq., to the

maximum extent permitted by that regulation, with any amount that is not exempt from Code Section 409A being subject to Code Section 409A.

(e) Notwithstanding anything to the contrary in this Agreement, if the Executive is a “specified employee” within the meaning of Section 409A at the time of Executive’s termination, then only that portion of the severance and benefits payable to the Executive pursuant to this Agreement, if any, and any other severance payments or separation benefits that may be considered deferred compensation under Section 409A (together, the “Deferred Compensation Separation Benefits”), which (when considered together) do not exceed the Section 409A Limit (as defined herein) may be made within the first six (6) months following the Executive’s termination of employment in accordance with the payment schedule applicable to each payment or benefit. Any portion of the Deferred Compensation Separation Benefits in excess of the Section 409A Limit otherwise due to Executive on or within the six (6) month period following the Executive’s termination will accrue during such six (6) month period and will become payable in one lump sum cash payment on the date six (6) months and one (1) day following the date of the Executive’s termination of employment. All subsequent Deferred Compensation Separation Benefits, if any, will be payable in accordance with the payment schedule applicable to each payment or benefit. Notwithstanding anything herein to the contrary, if the Executive dies following termination but prior to the six (6) month anniversary of the Executive’s termination date, then any payments delayed in accordance with this paragraph will be payable in a lump sum as soon as administratively practicable after the date of the Executive’s death and all other Deferred Compensation Separation Benefits will be payable in accordance with the payment schedule applicable to each payment or benefit.

(f) For purposes of this Agreement, “Section 409A Limit” will mean a sum equal (x) to the amounts payable prior to March 15 following the year in which Executive terminations plus (y) the lesser of two (2) times: (i) Executive’s annualized compensation based upon the annual rate of pay paid to Executive during the Corporation’s taxable year preceding the Corporation’s taxable year of Executive’s termination of employment as determined under Treasury Regulation 1.409A-1(b)(9)(iii)(A)(1) and any IRS guidance issued with respect thereto; or (ii) the maximum amount that may be taken into account under a qualified plan pursuant to Section 401(a)(17) of the Code for the year in which Executive’s employment is terminated.

11. Miscellaneous.

(a) The Executive acknowledges that the services to be rendered by him under the provisions of this Agreement are of a special, unique, and extraordinary character and that it would be difficult or impossible to replace such services. Accordingly, the Executive agrees that any breach or threatened breach by him of Section 8 or 9 of this Agreement shall entitle the Corporation, in addition to all other legal remedies available to it, to apply to any court of competent jurisdiction to seek to enjoin such breach or threatened breach. The parties understand and intend that each restriction agreed to by the Executive hereinabove shall be construed as separable and divisible from every other restriction, that the unenforceability of any restriction shall not limit the enforceability, in whole or in part, of any other restriction, and that one or more or all of such restrictions may be enforced in whole or in part as the circumstances warrant. In the event that any restriction in this Agreement is more restrictive than permitted by law in the jurisdiction in which the Corporation seeks enforcement thereof, such restriction shall be limited to the extent permitted by law. The remedy of injunctive relief herein set forth shall be in addition to, and not in lieu of, any other rights or remedies that the Corporation may have at law or in equity.

(b) Neither the Executive nor the Corporation may assign or delegate any of their rights or duties under this Agreement without the express written consent of the other; provided however, that the Corporation shall have the right to delegate its obligation of payment of all sums due to the Executive hereunder, provided that such delegation shall not relieve the Corporation of any of its obligations hereunder.

(c) This Agreement constitutes and embodies the full and complete understanding and agreement of the parties with respect to the Executive’s employment by the Corporation, supersedes, as of the Effective Date, all prior understandings and agreements, whether oral or written, between the Executive and the Corporation with respect to such employment, and shall not be amended, modified, or changed except by an instrument in writing executed by the party to be charged. The invalidity or partial invalidity of one or more provisions of this Agreement shall not invalidate any other provision of this Agreement. No waiver by either party of any provision or condition to be performed shall be deemed a waiver of similar or dissimilar provisions or conditions at the same time or any prior or subsequent time.

(d) This Agreement shall inure to the benefit of, be binding upon and enforceable against, the parties hereto and their respective successors, heirs, beneficiaries, and permitted assigns.

(e) The headings contained in this Agreement are for convenience of reference only and shall not affect in any way the meaning or interpretation of this Agreement.

(f) All notices, requests, demands, and other communications required or permitted to be given hereunder shall be in writing and shall be deemed to have been duly given when personally delivered, sent by registered or certified mail, return receipt requested, postage prepaid, or by private overnight mail service (e.g. Federal Express) to the party at the address set forth above or to such other address as either party may hereafter give notice of in accordance with the provisions hereof. Notices shall be deemed given on the sooner of the date actually received or the third business day after sending.

(g) This Agreement shall be governed by and construed in accordance with the internal laws of the State of New York without reference to principles of conflicts of laws and each of the parties hereto irrevocably consents to the jurisdiction and venue of the federal and state courts located in the State of New York.

(h) This Agreement may be executed simultaneously in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one of the same instrument. The parties hereto have executed this Agreement as of the Effective Date.

AIKIDO PHARMA, INC

By: /s/ Anthony Hayes
Anthony Hayes, Chief Executive Officer

EXECUTIVE:
/s/ Carlos Aldavero
Carlos Aldavero

11

Exhibit EXHIBIT 21.1

List of Subsidiaries

Aikido Labs LLC

Dominari Financial Inc.

Dominari Securities LLC

Exhibit EXHIBIT 23.1

INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM’S CONSENTINDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM’S CONSENT

We consent to the incorporation by reference in the Registration Statement of Dominari Holdings Inc. (the “Company”) and Subsidiaries on Form S-8 (File No. 333-271179, File No. 333-267318, File No. 333-210627, File No. 333-197429, and File No. 333-185524) and Form S-3 (File No. 333-238172), of our report dated March 31, 2023April 1, 2024, with respect to our audits of the consolidated financial statements of Dominari Holdings Inc. and Subsidiaries as of December 31, 2022December 31, 2023 and 2022, and for year each of the two years ended December 31, 2022 December 31, 2023, which report is included in this Annual Report on Form 10-K of Dominari Holdings, Inc. for the year ended December 31, 2022December 31, 2023.

/s/ Marcum LLP
Marcum LLP
New York, NY
March 31, 2023April 1, 2024

Exhibit 23.2EXHIBIT 31.1

INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM’S CONSENT CERTIFICATION PURSUANT TO EXCHANGE ACT

RULE 13a-14(a)/15d-14(a), AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

We consent to the incorporation by reference in the Registration Statement of Dominari Holdings Inc. (the "Company") on Form S-8 (File No. 333-267318, File No. 333-210627, File No. 333-197429, and File No. 333-185524) and Form S-3 (File No. 333-238172), of our report dated March 28, 2022 with respect to our audit of the consolidated financial statements of Dominari Holdings Inc. (formerly Alkido Pharma, Inc.) as of December 31, 2021 and for year ended December 31, 2021, which report is included in I, Anthony Hayes, certify that:

1. I have reviewed this Annual Report on Form 10-K of Dominari Holdings Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:
 - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: April 1, 2024

/s/ Anthony Hayes

Anthony Hayes,
Chief Executive Officer and Chairman

EXHIBIT 31.2

CERTIFICATION PURSUANT TO EXCHANGE ACT
RULE 13a-14(a)/15d-14(a), AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, George Way, certify that:

1. I have reviewed this Annual Report on Form 10-K of Dominari Holdings Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:
 - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: April 1, 2024

/s/ George Way

George Way,
Chief Financial Officer

EXHIBIT 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES OXLEY ACT OF 2002
CERTIFICATION

In connection with the Annual Report of Dominari Holdings Inc. (the "Company") on Form 10-K for the year ended December 31, 2022.

/s/ WithumSmith+Brown, PC

New York, NY

March 31, 2023

Exhibit 31.1

Certification of Principal Executive, Financial December 31, 2023, as filed with the Securities and Accounting Officer
Pursuant to Section 302 of Exchange Commission on the Sarbanes-Oxley Act of 2002

date hereof (the "Report"), I, Anthony Hayes, Chief Executive Officer of the Company, certify, that:

1. I have reviewed this report on Form 10-K of Dominari Holdings Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the consolidated financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

- (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the consolidated financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's Board of Directors (or persons performing the equivalent functions):
- (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

/s/ Anthony Hayes

Anthony Hayes

Chief Executive Officer

(Principal Executive Officer,

Principal Financial Officer and Principal Accounting Officer)

March 31, 2023

Exhibit 32.1

Certification of Principal Executive, Financial and Accounting Officer

Pursuant pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

I, Anthony Hayes, Director, Chief Executive Officer, Principal Financial Accounting (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

/s/ Anthony Hayes

Anthony Hayes

Chief Executive Officer and Chairman

April 1, 2024

EXHIBIT 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES OXLEY ACT OF 2002 CERTIFICATION

In connection with the Annual Report of Dominari Holdings Inc. (the "Company") on Form 10-K for the year ended December 31, 2023, in compliance as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, George Way, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, hereby certify that to the best of my knowledge, the Company's Annual knowledge:

- (1) The Report on Form 10-K for the period ended December 31, 2022 (the "Report") filed fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and Exchange Commission; result of operations of the Company.

•

Fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

/s/ George Way

• George Way

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Anthony Hayes

Anthony Hayes

Chief Executive Officer

(Principal Executive Officer,

Principal Financial Officer and Principal Accounting Officer)

March 31, 2023

A signed copy April 1, 2024

EXHIBIT 97.1

DOMINARI HOLDINGS INC. EXECUTIVE COMPENSATION CLAWBACK POLICY

Effective as of this written statement required by Section 906 has been provided to, and will be retained by, December 1, 2023

The Board of Directors (the "Board") of Dominari Holdings Inc. (the "Company") has adopted the following executive compensation clawback policy (this "Policy"). This Policy shall supplement any other clawback or compensation recovery policy or policies adopted by the Company or included in any agreement between the Company, or any subsidiary of the Company, and furnished any person covered by this Policy. If any such other policy or agreement provides that a greater amount of compensation shall be subject to clawback, such other policy or agreement shall apply to the amount in excess of the amount subject to clawback under this Policy.

This Policy shall be interpreted to comply with United States Securities and Exchange Commission ("SEC") Rule 10D-1 and Listing Rule 5608 (the "Listing Rule") of The Nasdaq Stock Market, LLC ("Nasdaq"), as may be amended or supplemented and interpreted from time to time by Nasdaq. To the extent this Policy is in any manner deemed inconsistent with the Listing Rule, this Policy shall be treated as having been amended to be compliant with the Listing Rule.

1. Definitions. Unless the context otherwise the following definitions apply for purposes of this Policy:

(a) **Executive Officer.** An executive officer is the Company's chief executive officer and/or president, principal financial officer, principal accounting officer (or if there is no such accounting officer, the controller), any vice-president of the Company in charge of a principal business unit, division, or function (such as sales, administration, or finance), any other officer who performs a policy-making function, or any other person who performs similar policy-making functions for the Company. Executive officers of the Company's parent(s) or subsidiaries are deemed executive officers of the Company if they perform such policy making functions for the Company. Policy-making function is not intended to include policy-making functions that are not significant. Identification of an executive officer for purposes of the Listing Rule would include at a minimum executive officers identified in the Listing Rule.

(b) **Financial Reporting Measures.** Financial reporting measures are measures that are determined and presented in accordance with the accounting principles used in preparing the Company's financial statements, and any measures that are derived wholly or in part from such measures. Stock price and total shareholder return are also financial reporting measures. A financial

reporting measure need not be presented within the financial statements or included in a filing with the SEC and may be such financial measures as may be determined by the Board or the Compensation Committee thereof (the “**Compensation Committee**”).

(c) **Incentive-Based Compensation**. Incentive-based compensation is any compensation that is granted, earned or vested based wholly or in part upon the attainment of a financial reporting measure(collectively, “**Incentive-Based Compensation**”).

(d) **Received.** Incentive-Based Compensation is deemed “received” in the Company’s fiscal period during which the financial reporting measure specified in the Incentive- Based Compensation award is attained, even if the payment or grant of the Incentive-Based Compensation occurs after the end of that period.

2. Application of this Policy. This recovery of Incentive-Based Compensation from an executive officer as provided for in this Policy shall apply only in the event that the Company is required to prepare an accounting restatement due to the material noncompliance of Company with any financial reporting requirement under the United States securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period.

3. Recovery Period.

(a) The Incentive-Based Compensation subject to recovery is the Incentive- Based Compensation received during the three (3) completed fiscal years immediately preceding the date that the Company is required to prepare an accounting restatement as described in Section

2 above, provided that the person served as an Executive Officer at any time during the performance period applicable to the Incentive-Based Compensation in question. The date that the Company is required to prepare an accounting restatement shall be determined pursuant to the Listing Rule.

(b) Notwithstanding the foregoing, this Policy shall only apply if the Incentive- Based Compensation is received (i) while the Company has a class of securities listed on Nasdaq and (ii) on or after October 2, 2023.

(c) The provisions of the Listing Rule shall apply with respect to Incentive- Based Compensation received during a transition period arising due to a change in the Company’s fiscal year.

4. Erroneously Awarded Compensation. The amount of Incentive-Based Compensation subject to recovery from the applicable executive officers under this Policy (“**Erroneously Awarded Compensation**”) shall be equal to the amount of Incentive-Based Compensation received that exceeds the amount of Incentive Based-Compensation that otherwise would have been received had it been determined based on the restated amounts and shall be computed without regard to any taxes paid. For Incentive-Based Compensation based on stock price or total shareholder return, where the amount of Erroneously Awarded Compensation is not subject to mathematical recalculation directly from the information in an accounting restatement: (a) the amount shall be based on a reasonable estimate by the Company’s Chief Financial Officer (or principal accounting officer, if the office of Chief Financial Officer is not then filled) of the effect of the accounting restatement on the stock price or total shareholder return upon which the Incentive-Based Compensation was received, which estimate shall be subject to the review and approval of the Compensation Committee; and (b) the Company must maintain reasonable documentation of the determination of that reasonable estimate and provide such documentation to Nasdaq if requested. Notwithstanding the foregoing, if the proposed Incentive-Based Compensation recovery would affect compensation paid to the Company’s Chief Financial Officer, the determination shall be made by the Compensation Committee.

5. Timing of Recovery. The Company shall recover any Erroneously Awarded Compensation reasonably promptly except to the extent that the conditions of paragraphs (a), (b), or (c) below apply. The Compensation Committee shall determine the repayment schedule for each amount of Erroneously Awarded Compensation in a manner that complies with this “reasonably promptly” requirement. Such determination shall be consistent with any applicable legal guidance by the SEC, Nasdaq, judicial opinion, or otherwise. The determination of “reasonably promptly” may vary from case to case and the Compensation Committee is authorized to adopt additional rules or policies to further describe what repayment schedules satisfy this requirement.

(a) Erroneously Awarded Compensation need not be recovered if the direct expense paid to a third party to assist in enforcing (or making determinations in connection with the enforcement of) this Policy would exceed the amount to be recovered and the Compensation Committee has made a determination that recovery would be impracticable. Before concluding that it would be impracticable to recover any amount of Erroneously Awarded Compensation based on expense of enforcement, the Company shall (i) make a reasonable attempt to recover such Erroneously Awarded Compensation, (ii) document such reasonable attempt or attempts to recover, and (iii) provide appropriate documentation to the Compensation Committee or Nasdaq, if requested.

(b) Erroneously Awarded Compensation need not be recovered if recovery would violate home country law where that law was adopted prior to November 28, 2022. Before concluding that it would be impracticable to recover any amount of Erroneously Awarded Compensation based on a violation of home country law, the Company shall obtain an opinion of home country counsel, in form and substance that would be reasonably acceptable to Nasdaq, that recovery would result in such a violation and shall provide such opinion to Nasdaq, if requested.

(c) Erroneously Awarded Compensation need not be recovered if recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the requirements of 26 U.S.C. 401(a)(13) or 26 U.S.C. 411(a) and the regulations thereunder (as such provision may be amended, modified or supplemented).

6. Compensation Committee Decisions. Decisions of the Compensation Committee with respect to this Policy shall be final, conclusive, and binding on all executive officers subject to this Policy.

7. No Indemnification. Notwithstanding anything to the contrary in any other policy of the Company or any agreement between the Company and an executive officer, no executive officer shall be indemnified by the Company against the loss arising from the recovery of any Erroneously Awarded Compensation.

8. Agreement to Policy by Executive Officers. The Company shall take reasonable steps to inform executive officers of this Policy and obtain their express agreement to this Policy, which steps may constitute the inclusion of this Policy as an attachment to any award that is accepted by an executive officer. This Policy shall be deemed to apply to each employment or grant agreement between the Company or any of its **staff upon request**, subsidiaries and any executive officer subject to this Policy.

###

4

DISCLAIMER

THE INFORMATION CONTAINED IN THE REFINITIV CORPORATE DISCLOSURES DELTA REPORT™ IS A COMPARISON OF TWO FINANCIALS PERIODIC REPORTS. THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORT INCLUDING THE TEXT AND THE COMPARISON DATA AND TABLES. IN NO WAY DOES REFINITIV OR THE APPLICABLE COMPANY ASSUME ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED IN THIS REPORT. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY'S ACTUAL SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.

©2024, Refinitiv. All rights reserved. Patents Pending.